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Chapter 1 
Histone Deacetylase and Histone Deacetylase Inhibitors 
1.1 Histone deacetylase and histone acetyltransferase  
Recently, Cancer agent development has displaced from conventional cytotoxic 
chemotherapeutics to a more mechanism based targeted approach towards the common goal of 
tumour growth arrest. Histone deacetylase enzymes (HDACs) engaged attention as validated 
biological targets for the treatment of human cancer.[1,2]  
In eukaryotic cells, nucleosome is the basic unit of chromatin (Fig. 1.1), and is composed of a 
fragment of DNA wrapped around a histone octamer formed by four histone partners (H3, H4 
tetramer and two H2A, H2B dimers). DNA is maintained in a highly ordered and condensed 
form via its association with small histone. Histones are basic protein rich in lysine and arginine 
residues in N-terminal tail extending out of the nucleosome.[3] Histones take on extensive 
posttranslational modifications that affect gene expression. Reversible acetylation and 
deacetylation of ε-amino group of lysine residus on histone tails by histone acetyl transferase 
(HAT) and HDAC enzymes play a crucial role in the epigenetic regulation of gene expression 
by changing the chromatin architecture and transcriptional activity.[4-7] Aberrant gene 
  
 
Fig. 1.1 Organisation of the nucleosome and mechanism of action HDAC and HAT. 
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expression that results in functional inactivation of HAT or recruit of HDACs can induce tumor 
cell proliferation.[8] The level of histone acetylation and deacetylation controls the interaction of 
positively charged histones with the negatively charged DNA. Superdeacetylation of histone 
results in increasing positive charge density which will strengthen the interaction with the 
negatively charged DNA and thus inhibit the accessibility of regulators to DNA.[9] Therefore, in 
most case, histone acetylation enhances transcription while histone deacetylation represses 
transcription. Transcriptional deregulation of genes which caused by high histone deacetylation 
can lead to cancer developments which are involved in the control of cell cycle arrest, 
differentiation, and/or apoptosis.[10,11] 
1.2 Histone deacetylase family 
HDAC enzymes have emerged as validated biological targets for the treatment of human cancer. 
[12] HDAC enzymes family were found in animals, plants, fungi and bacterias. In 1996, HDAC1 
was first identified using the HDAC inhibitor Trapoxin as an affinity from nuclear extract.[13] It 
was found that HDAC1 shares high sequence homology with yeast Rpd3, a global gene 
regulator and transcriptional co-repressor with histone deacetylase activity.[14]  The human 
HDACs are classified into four different phylogenetic classes (class I, class II, class III and 
class IV, 18 subtype) according to their cellular localizations, structural, functional differences 
and on their sequence homology to their yeast orthologues Rpd3, HdaI and Sir2, respectively 
(Fig. 1.2)[15,16]: Class I includes HDAC1, 2, 3, and 8 that compounds are closely related to yeast 
 
 
Fig. 1.2 Classification of HDACs. 
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Rpd3 and shared homology in catalytic sites. Class II (HDAC4, 5, 6, 7, 9 and 10) shared 
domains yeast HDAC1. Class II HDAC is further subdivided into Class  IIa and Class IIb. Class 
IIa (HDAC4, 5, 7, 9) have homology in two regions: the C-terminal catalytic domain and the 
N-terminal regulatory domain. Class IIa are defined by a large, functionally important 
N-terminal domain regulating nuclear-cytoplasmic shuttling and specific DNA-binding. Class 
IIb (HDAC6, 10) are found in the cytoplasm and contain two deacetylase domains in catalytic 
site and C-terminal zinc finger.[17] HDAC6 has emerged as a major deacetylase functioning of 
α-tubulin deacetylase.[18] HDAC10 structurally relates to HDAC6, but contains one additional 
catalytically inactive domain. Its function is largely unknown.[19] Class IV, HDAC11 exhibits 
properties of class I and class II HDACs. HDACs class I and II are zinc-dependent enzymes that 
catalyze mechanism is similar for to remove the acetyl groups from the ε-amino group of lysine 
residues of histone amino terminal tail. Class III is a series of the NAD+-dependent Sir2 family 
of enzymes.[20] It was demonstrated that different HDACs have distinct biological functions and 
are recruited to specific regions of the genome.[21,22]  Overexpression of class I HDACs with 
concomitant down regulation and/or mutations of HATs are associated with a condensed 
chromatin structure preventing the access of transcription factors to DNA during gene 
expression causing cancer cells survival and progression. Selective inhibitors of class I HDACs 
has been shown to restore the acetylation of histones and the transcription of genes which 
induce cell cycle arrest and apoptosis of cancer cell lines.[23-25] 
Class I HDACs contain 350-500 amino acid residues, while class II enzymes are usually about 
1000 amino acid long. Due to the larger class II HDACs, they posses many additional structural 
features, including a lengthy N-terminal sequence. The class I and class II HDACs share a 320 
amino acid residues region of homology, corresponding to the section of the enzyme that forms 
the catalytic pocket.[26] The highly conserved catalytic pocket presents challenges to 
development of selective HDAC inhibitors. However, some structural differences have been 
found and have been useful in generating class selective and isoform selective inhibitors.[27] 
Crystal structures of the HDAC enzymes and their homologues provide essential information 
for rational drug design of selective HDAC inhibitors. For a long time, structural information on 
zinc-dependent HDAC catalytic domains has been limited to a bacterial HDAC-like protein (HDLP).[30] 
HDLP resemble a class I enzyme catalytic site. Up to now, the crystal structures of a human class I 
enzyme (HDAC8)[28] and a bacterial class IIb HDAC-like amidohydrolase (HDAH)[31] have 
been reported. However, the structure of human class II HDAC7[29] and HDAC4[162] catalytic 
domain were reported. 
‐ 4 ‐ 
 
Class I HDACs are highly expressed in gastric cancer, pancreatic cancer, colorectal cancer, 
prostate cancer, hepatocellular carcinoma and cervical carcinoma, and Class II HDACs are 
found mainly in breast cancer, colorectal cancer and oral squamous cell cancer.[32, 33] These 
isoforms HDACs have distinct cellular localizations and functions. Each HDAC gene occupies 
on a special chromosome site, and there are some differences in the genes of the amino acids on 
the surface of active pocket. The selectivity in binding to the amino acids at the rims of the 
pockets of different HDACs enabled the HDAC inhibitors to exhibit distinct inhibitory 
activities to different cancer cells, and even cytotoxicity. Design and synthesis of the isoform 
selective HDAC inhibitors with low adverse and toxic effects will be useful in special cancer 
therapy, and it will greatly influence the clinical treatment on cancers. 
In addition to regulating the acetylation state of histones, HDACs can bind to, deacetylate and 
regulate the activity of a number of other proteins, including transcription factors (p53, E2F 
transcription factor 1 (E2F1) and nuclear factor-κB (NF-κB)) and proteins with diverse 
biological functions (α-tubulin, Ku70 and heat-shock protein 90 (Hsp90)) (Fig. 1.3).[34] 
Therefore, HDAC inhibitors could have far reaching effects on multiple cellular processes. 
Two examples of non-histone acetylated proteins that might be affected by HDAC inhibition 
and involved in Huntington's disease and other polyglutamine repeat diseases are p53 and 
HSP90 (Fig. 1.4 and Table 1.1).[35] Thereby, a number of HDAC inhibitors are potent 
mediators of tumour cell death. 
 
 
Fi g. 1.3 Effects of HDACs inhibition on histone and non-histone proteins. 
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Fig. 1.4 The function of HDAC and HAT for non-histone proteins. 
Table 1.1 Non-histone substrates of HDAC enzymes 
Substrate Function
α-Tubulin Cytoskeletal
Importin- α Nuclear/cytoplasmic shuttling 
β catenin Cell adhesion/transcription 
TCF DNA binding 
p53 Tumour suppressor 
E2F Transcriptional cell cycle 
pRb Tumour suppressor 
Hmg1(y) Transcription 
Hsp90 Molecular chaperone 
YY1 Transcription 
Bcl6 Transcription 
UBF Transcription 
Cart-1 Structural organisation 
P50; relA Transcription/inflammation 
HIV-1 Tat Replication
Rb Cell cycle
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1.3 The effect mechanism of HDAC inhibitors and HDAC 
In 1999, Finnin et al. first elucidated the interactions machanism between Trichostatin A (TSA), 
suberoylanilide hydroxamic acid (SAHA) of the structural details of the class I/II HDAC 
inhibitors and histone deacetylase-like protein (HDLP).[30] The crystal structure of HDLP, 
which was isolated from a hyperthermophilic bacterium, Aquifex aeolicus; a homologue of 
mammalian class I/II HDAC with 35.2% sequence identity over 375 residues, was solved with 
the HDAC inhibitor TSA bound to the active site (Fig. 1.5). This structural information 
provided the first concrete evidence that this enzyme indeed contained an active site 
zinc-binding pocket, consistent with previous observations that HDAC activity was contingent 
upon the presence of a metal cofactor and strongly supported by the pronounced activity of 
certain hydroxamic acid-based inhibitors (TSA). The crystal structure shows that HDLP has a 
single-domain structure belonging to the open α/β class of folds and the catalytic domain is very 
closely related to that of HDACs. The enzyme contains two Asp-His charge-relay systems, a 
structural feature which is conserved across the HDAC family. The prominent architectural 
feature of the ligand binding site shows the presence of a gently curved tubular pocket 
approximately 11Å deep whose walls are lined with hydrophobic and aromatic residues and 
14Å cavity (Fig. 1.6). The cavity narrows to ~7.5Å near its center, constrained by the 
 
 
Fig. 1.5 Crystal structure of TSA bound to the HDLP. HDLP residues are labelled in red with their 
counterparts in HDAC1 indicated in black.
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parallel disposition of Phe 141 and Phe 198. In the crystal structure of the zinc-reconstituted 
enzyme, the zinc ion is positioned near the bottom of the pocket. It consists of His170, Asp258 
and a water molecule. In the crystal structure of HDLP-TSA complex, TSA binds by inserting 
its long aliphatic chain into the HDAC pocket, making multiple contacts to the tube-like 
hydrophobic portion of the pocket. The hydroxamic acid group at one end of the aliphatic chain 
reaches the polar bottom of the pocket where it coordinates the zinc in a bidentate fashion and 
also contacts active site residues. The aromatic dimethylamino-phenyl group at the other end of 
the TSA chain makes contacts at the pocket entrance and in an adjacent surface groove, capping 
the pocket. The length of the aliphatic chain is optimal for spanning the length of the pocket and 
allowing contacts at the bottom and at the entrance of the pocket. In conclusion, the structure 
characteristics of HDAC inhibitors include three portions: the zinc binging group (ZBG), which 
interacts the zinc ion and engages in multiple hydrogen bonds with the amino acid residue at the 
active site of HDAC, the linker domain, which occupies the channel of HDAC, and the surface 
recognition domain, which interacts with amino acid residues on the rim of active pocket 
entrance. Fig. 1.7 shows pharmacophore domains of SAHA and SAHA-HDLP hydrogen bond 
and chelation interactions in the active site.[36] 
   
 
Fig. 1.6 Surface representation of the channel and internal cavity of HDLP-TSA complex in the active 
site pocket. 
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1.4 Structure class of HDAC inhibitors 
Abnormal activities of HATs and recruitment HDACs have been related to the pathogenesis of 
cancer. Inhibition HDACs activity can induce tumour cell growth arrest, differentiation and/or 
apoptosis in vitro and in vivo (Fig. 1.8),[37] and so HDAC inhibitors are evoking interest 
anticancer agents.[38,39]  
In 1976,  one of the first HDAC inhibitor TSA was isolated by Tsuji et al. from Streptomyces 
hygrocopicus as an fungistatic antibiotic active against trichophytin,[40] and the very potent 
HDAC activity of TSA was found by Yoshida et al. in 1990 in inducing friend leukemia cell 
differentiation and inhibiting cell cycle of normal fibroblasts in both the G1 and G2 phases, 
respectively.[41] Although the structures of HDAC inhibitors were different, inhibitors had 
similar three portions (the zinc binging group, linker and surface recognition). The zinc binding 
domain is analogous to the acetyl group of the N-acetylated Lys substrate, and it 
H
N N
H
OH
O
O
Linker Zinc BindingSurface Recognition
hydroxamic acid groupaliphatic chaincapping group
 
 
 
Fig. 1.7 Pharmacophore domains of SAHA and SAHA-HDLP hydrogen bond and chelation interactions 
in the active site. 
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interacts with Zn2+ ion and many of the same residues of HDAC. The zinc binding groups are 
typically a thiol, hydroxamic acid, carboxylic acid, ketone or substituted aniline. The inhibitory 
activity is determined by the length of the spacer and interactions of the spacer, hydrophobic 
surface binding scaffolds, and the strength of bonding between the functional group and the 
active site. According to chemical structure of inhibitors, in general, HDAC inhibitors are 
divided into six structure classes. There is a brief discussion of different HDAC inhibitors 
classes. 
1.4.1 Carboxylates 
In 1978, Boffa et al. identified the HDAC inhibitors such as butyric acid,[42] sodium 
phenylacetate with butyric acid derivatives, phenyl butyrate that one of the first HDAC 
inhibitors to be tested in proteins. In 2001, valproic acid of anticonvulsant was identified as 
HDAC inhibitor (Fig. 1.9).[43] The carboxylic acid, the zinc binging group is less active than the 
hydroxamic acid; may be due to weak coordination with Zn2+ ions. Despite being much less 
 
 
Fig. 1.9 HDAC inhibitors of carboxylic acids class. 
 
 
Fig. 1.8 Biological effects of HDAC inhibitors. 
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potent, these are currently among the best studied HDAC inhibitors. Valproic acid and phenyl 
butyrate have already been widely approved as an anti-epileptic treatment and some cancers, 
respectively, and valproic acid is a key regulator of many pathways in the cell.[44] Butanoic acid 
and valproic acid are undergoing clinical trials phase I/II and phase I, respectively.  
1.4.2 Hydroxamic acids 
The HDAC inhibitors of Hydroxamic acid constitute the broadest family of HDAC inhibitors; 
hydroxamic acid is one of the well-studied ligand for the active site Zn2+ of HDACs. The 
feature of inhibitors contains a hydroxamic acid functional group, such as natural products TSA 
and selected SAHA in synthesized hybrid.[45,46] The general structure of these substances 
consists of a hydrophobic linker that allows the hydroxamic acid moiety to chelate the Zn2+ ion 
at the bottom of HDAC active pocket, while the aromatic ring (bulky part of the molecule), 
which is the surface recognition domain, acts as a cap group. The linker domain consists of 
linear either saturated or unsaturated as 5- or 6-methylene hydrophobic spacer.[45] TSA and 
SAHA inhibit class I and class II HDACs, and are potent inhibitors of histone deacetylase, are 
active at nanomolar concentrations. SAHA has recently entered phase II clinical trials.[47,48] 
Based on the structure a large number of hydroxamate-derived HDAC inhibitors (TSA 
analogues and SAHA analogues)  were designed and synthesized (Fig. 1.10).[49-64] These agents 
were evaluated as inhibitors of recombinant human HDAC, antiproliferative agents against a 
panel of human cell lines, and inducers of histone hyperacetylation and p21 expression.  
Structure activity relationship (SAR) study of these paradigmatic hydroxamate compounds 
were performed in a focused way by several research groups. Recently SAHA (Zolinza)  
approved by the FDA for the treatment of cutaneous T cell lymphoma (CTCL).[163,164] 
 
 
 
Fig. 1.10 HDAC inhibitors of hydroxamic acid class.
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1.4.3 Benzamides 
The HDAC inhibitors of benzamide derivatives were synthesized by Suzuki et al. in 1999.[65,66] 
These HDAC inhibitors are the class of compounds which inhibit HDACs by ligating the active 
site Zn2+ ion with a benzamide moiety, no structural similarity with the previous HDAC 
inhibitors. These compounds are generally less potent than the corresponding hydroxamate 
compounds and cyclic tetrapeptide classes. The most potent compound of the series is named as 
MS-275 (Fig. 1.11), induces hyperacetylation of nuclear histone in some tumor cell lines and 
overexpression of p21. It has HDAC inhibitory activity of 5 μM and shows significant 
anti-tumor activity in vivo. The evaluation of MS-275 demonstrated that it could inhibit 
partially purified human HDAC preparations and cause hyperacetylation of nuclear histones in 
various cell lines.[66,67]  The MS-275 has entered clinical trials phase II. The other HDAC 
inhibitors of benzamide derivatives, such as CI-994 which is a 4-acetylamino-N-(2’- 
aminophenyl) benzamide as effective against mouse, rat and human tumor cells,[68] and is a 
potential drug for human acute meylocytic leukemia, colorectal cancer  etc of a number of 
tumor diseases. The CI-994 is under clinical trials now.[69-71] 
 
1.4.4 Electrophilic ketones 
Electrophilic ketones form a new class of HDAC inhibitors. The mechanism of these HDAC 
inhibitors might be hydrated form of the ketone acts as a transition-state to chelate the Zn2+ ion 
at the bottom of HDAC active pocket resemble carboxypeptidase A.[73,74] The series include 
various trifluoromethyl ketones and α-ketoamide. In 2002, Frey et al. reported SAHA based 
straight chain trifluoromethyl ketones as HDAC inhibitors.[75] Wada synthesized α-ketoesters 
and α-ketoamides as HDAC inhibitors.[76] Several compounds in the series showed micromolar 
levels inhibitory activity, so they were developed by altering the aryl group, nanomolar 
 
 
Fig. 1.11 HDAC inhibitors of benzamides class. 
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α-ketoamide HDAC inhibitors (Fig. 1.12). The inhibitores of electrophilic ketone class 
represent a relatively new group of HDACs substrate that has not yet been fully explored. We 
should develop farther structural variants so as to assess optimal design parameters and 
tolerances. 
 
1.4.5 Cyclic peptide HDAC inhibitors 
Cyclic peptide-based HDAC inhibitor is a class of the most complicated compounds in HDAC 
inhibitors. The main structure of the HDAC inhibitors of cyclic peptide is composed of a 
macrocycle containing four amino acid residues (hydrophobic amino acids) in the surface 
recognition domain, an alkyl chain in the linker domain, and a functional group in the zinc ion 
binding domain (Fig. 1.13). Cyclic peptide-based HDAC inhibitors bind to the HDAC enzymes 
in a manner consistent with TSA. The aliphatic linker passes down the enzyme’s channel, 
positioning the binding moiety in proximity to the active site zinc, while the macrocyclic 
portion interacts with the rim of the active site. The macrocycle in naturally occurring cyclic 
tetrapeptide inhibitors is arranged with a D-amino acid and an imino acid (Pro or Pip) flanking 
the amino acid bearing the linker moiety, which generates a constrained 12-membered cyclic 
structure with extensive internal hydrogen bonding. It is postulated that the D-configuration of 
the amino acid is necessary for tight association with the rim of the active site, thereby allowing 
 
 
Fig. 1.13 Pharmacophore domains of cyclic peptide HDAC inhibitors. 
 
Fig. 1.12 HDAC inhibitors of electrophilic ketones class. 
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the linker to align and insert into the enzyme’s channel.[77] According to the chemical structure 
of zinc ion binding domain of inhibitors, cyclic peptide HDAC inhibitors were divided into the 
following different structure classes. 
(1)  Cyclic tetrapeptide containing epoxyketone  
The class of cyclic tetrapeptide HDAC inhibitors contains a unique amino acid, (S)-2-amino-8- 
oxo-9,10-epoxydecanoic acid (Aoe) in zinc ion binding domain. The Aoe side chain is 
approximately isosteric with an acetylated lysine, suggesting that it functions as a mimic of an 
acetylated histone. Reduction or hydrolysis of the epoxide can result loss of biological activity 
of inhibitors. The Aoe residue induces irreversibly inactivate its receptor through covalent bond 
formation. This series compounds have two more structural features in common: at least one 
amino acid with (R) configuration and a proline or pipecolic acid residue. In 1974, 
Chlamydocin and dihydro-Chlamydocin were first isolated and characterized from 
Diheterospora chlamydosporia by Closse et al. (Fig.1.14).[78] The structure of Chlamydocin 
contained an aromatic ring in its cyclic framework. Chlamydocin exhibited notable cytostatic 
activity in vitro. It is found to be a highly potent HDAC inhibitor, inhibiting HDAC activity in 
vitro with an IC50 of 1.3 nM. Whereas Chlamydocin, with reduced its C8-carbonyl, was inert. 
The epoxyketone group of Chlamydocin was replaced by -OH, -CH2=CH2, -CH2CH3 or 
-CH2CH2OH, the activity of HDAC inhibitors incoordinately reduced.[79] The prolyl- 
substituted Cyl-1 as well as its pipecolyl-variant Cyl-2 were produced by Cylindrocladium 
scoparium, were found as potent plant growth regulators.[80-82] The fungal metabolite 
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Fig. 1.14 Several HDAC inhibitors of cyclic tetrapeptid containing epoxyketone. 
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WF-3161 that was obtained from Petriella guttulata also exhibited better antitumor activity in 
vitro and in vivo.[83] 
HC-Toxin I that was isolated by Helminthosporium carbonum, was one of the first cyclic 
tetrapeptides in this structural class identified, and Liesch et al. characterized its chemical 
structure (Fig.1.15).[84] Later was revised structure by Knoche and co-workers.[85,86] HC-Toxins 
which are also cyclic tetrapeptide and have no aromatic ring in their cyclic framework are still 
inhibiting the HDACs. 9,10-2 hydroxy of HC-Toxin analogues is an inactivation.[87]  Further 
investigations led to the identification of HC-Toxin III,[88] bearing a trans-3-hydroxyproline. 
Moreove, HC-Toxin II was also discovered , an analog in which one Ala residue was replaced 
by a Gly.[89] While HC-Toxin III was found to be comparable in potency to HC-Toxin, 
HC-Toxin II have low activity (EC50 = 7 μg/mL in a maize root inhibition assay) relative to 
HC-Toxin (EC50 = 0.2 μg/mL). It is interesting to mention that this 35-fold decrease in efficacy 
originated from a relatively modest structural change. 
 
Trapoxins A and B which were producted in the fermentation broth of Helicoma ambiens,[90] 
can potentially inhibit cellular transformations. In their structure, they differ solely by the 
presence of either a cyclic imino acid D-Pip or D-Pro in the tetrapeptide scaffold (Fig. 1.16). 
Kijima et al. confirmed that inhibitory concentration of Trapoxin A was the same for in vivo 
and in vitro (<10 nM / L).[91] Taunton et al. synthesized Trapoxin B, [3H] Trapoxin B,  I-trap  
and K-trap etc. These analogues have inhibition, toxicity and instability.[92] 
HC-Toxin, Chlamydocin and Cyl-2 of three HDAC inhibitors were compared for phytotoxic 
efficacy to elucidate the relationship between cyclic tetrapeptide structure and biological 
activity.[93] The shifts in their respective biological activities correlated to overall cyclic peptide 
polarity. Consequently, it was postulated that these differences could be ascribed to a given 
 
 
Fig. 1.15 Several HDAC inhibitors of HC-Toxin analogues. 
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analogues’s potential ability to penetrate membranes, as increased hydrophobicity enhanced 
potency. HC-Toxin is 10-fold less potent than Chlamydocin against these sensitive maize 
hybrids.[94] This premise was further supported by the dramatically reduced efficacy of  the 
more polar glycine variant of HC-Toxin, HC-Toxin II (approximately 3% as active as 
HC-Toxin). Chlamydocin, Cyl-1, Cyl-2, Trapoxins, HC-Toxin and WF-3161 have irreversible 
HDAC inhibitory activity for epoxyketone. On the basis of the irreversible inhibition of 
trapoxin B with HDAC enzyme, Schreiber isolated HDAC1 using affinity chromatography.[95, 
96] Naturally occurring cyclic tetrapeptide based HDAC inhibitors containing epoxyketone 
functional group demonstrated the importance of the cyclic tetrapeptide moiety for the 
nanomolar inhibition of HDAC. Due to the irreversible nature of the epoxide based inhibitors; 
they did not receive much attention in the HDAC inhibitor research.  
(2)  Cyclic tetrapeptide containing hydroxamic acids 
The class HDAC inhibitors containing hydroxamic acids are all artificially synthsized as a 
series hybrid of TSA and cyclic tetrapeptide. These inhibitors contain a hydroxamic acid as the 
zinc binding group attached to a cyclic tetrapeptide scaffold (Cyl-1, Chlamydocin, Trapoxins, 
HC-Toxin etc.), and are reversible inhibitors of HDAC. The scaffold structure of cyclic 
hydroxamic-acid-containing peptide (CHAPs)[97] was constituted by varied changing the 
number of the amino acids, the pattern of amino acid chiral combinations, and the side chain 
 
 
Fig. 1.16 Several HDAC inhibitors of Trapoxin analogues. 
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structure of each amino acid. The activity of cyclic tetrapeptide revealed importance of the 
cyclic tetrapeptide scaffold for high HDAC inhibitory activity. The structures of CHAP 
derivatives are represented as cyclo(-Asu(NHOH)-AA2-AA3-Pro(Pip)-). CHAP 31 is one of 
the strongest the CHAPs with nanomolar activity (IC50 = 3.3 nM), having the cyclic tetrapeptide 
part of natural cyclic peptide Cyl-1 (Fig. 1.17). CHAP31 shows antitumor activity in C57BL x 
DBA/2 F1 (BD2F1) mice bearing B16/BL6 tumor cells. CHAP31 inhibits the growth in four of 
five human tumor lines implanted into nude mice. These results suggest CHAP31 to be 
promising as a novel therapeutic agent for cancer treatment. Yoshida and coworkers 
synthesized and carried out a SAR study using several CHAPs containing cyclic tetrapeptide 
and cyclic octapeptide.[98] A comparative study of the activity of cyclic tetrapeptide and cyclic 
octapeptide revealed the importance of the cyclic tetrapeptide scaffold for high HDAC 
inhibitory activity. 
 
Recently, Binoy et al. designed and synthesized a cyclic hexapeptide hydroxamic acid inhibitor 
(cyclo(-Ser-Asp-Asu(NHOH)-Thr-Ile-Gly-)) for HDAC6 that α-tubulin was the substrate  (Fig. 
1.18). But hexapeptide hydroxamic acid inhibitor showed very low HDAC inhibitory activity. 
To compare compouds conformation to the crystal structure of α-tubulin showed the acetylated 
lysine of the cyclic hexapeptide substrate or the Asu(NHOH) of cyclic hexapeptide inhibitor 
was different from that around α-tubulin’s lysine-40.[99] 
 
 
Fig. 1.17 Several HDAC inhibitors of synthetic cyclic tetrapeptide hydroxamic acids peptide (CHAPs). 
‐ 17 ‐ 
 
 
In 2004, Nishino et al. synthesized Chlamydocin hydroxamic acid analogues by replacing 
epoxy ketone moiety of Aoe by hydroxamic acid functional group (Fig. 1.19). In addition, they 
also have introduced several aromatic analogues in cyclic framework to study hydrophobic 
interaction of capping group, a number of amino-cycloalkanecarboxylic acids (Acc) were 
 
 
Fig. 1.19 Several HDAC inhibitors of synthetic Chlamydocin hydroxamic acid analogues. 
 
 
Fig. 1.18 Cyclic hexapeptide hydroxamic acid inhibitor. 
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introduced instead of the simple amino-isobutric acid (Aib) for a variety of the series of 
Chlamydocin analogues. The compounds synthesized were tested for HDAC inhibitory activity 
and the results showed that many of them were potent HDAC inhibitors. The replacement of 
Aib residue of Chlamydocin with an aromatic amino acid enhanced the in vivo and in vitro 
inhibitory activity. [100] 
In 2010, Nurul and coworkers synthesized a series of bicyclic tetrapeptide containing 
hydroxamic acids by changing the length of the aliphatic loop to explore the effect of the loop 
length on the activity of the inhibitors. The sequence and configuration of amino acids in 
CHAP31 are considered as the basis for designing the inhibitors. All the compounds as shown 
in Fig. 1.20 are active in nanomolar range and specific toward HDAC4 compared with HDAC1 
and HDAC6. They are about two times more active toward HDAC4 than HDAC1, and about 50 
times more active than HDAC6.[101] 
 
In addition, there is a series of HDAC inhibitors with retrohydroxamate (N-formyl 
hydroxylamine) and N-acetyl hydroxylamine as zinc binding ligands. Based on the assumption, 
that retrohydroxamates can also act as good HDAC inhibitors, Nishino et al. synthesized and 
evaluated  HDAC inhibitors of cyclic tetrapeptides with an optimum spacer length of five 
methylene units, as potent, long lived orally bioavailable matrix metalloproteinase’s (MMPs) 
inhibitors, which are zinc proteases (Fig. 1.21).[102] Eventhough they have ten times lower 
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Fig. 1.20 HDAC inhibitors of bicyclic tetrapeptide hydroxamic acid. 
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inhibitory activity than the corresponding hydroxamic acids, they are a novel class of inhibitors 
and have potential as anticancer agents.  
 
(3)  Cyclic tetrapeptide containing ketone 
Apicidin, is cyclopeptide HDACs inhibitor isolated from Fusarium Pallodoroseum, as a  potent 
and broad spectrum antiprotozoal agent that exerts its biological activity by reversibly 
inhibiting HDAC activity.[103] A group of Merck research laboratory extensively studied the 
HDAC inhibitory activity of Apicidin and its synthetic analogues (Fig. 1.22).[104-110] Apicidin 
contains an ethyl ketone moiety in its side chain, and so it is different from other natural cyclic 
peptides like Trapoxin or HC-Toxin with epoxyketone side chain. The high potency of HDAC 
inhibitory activity of Apicidin further confirmed the importance of the cyclic tetrapeptide 
scaffold for the inhibitor design. The experimental IC50 values of the HDACs inhibitors 
(Apicidin, Apicidin B, ApicidinC and analogue d) toward HDAC1 are 1, 10, 6 and 86 nM, 
respectively, while the IC50 of Apicidin toward HDAC8 is above 1000 nM. The shift of keto 
group from position C-8 to C-9 decreases potency, confirming that the exact location of the C-8 
keto group is critical for proper mimicking of acetylated histone lysine. On the other hand, if the 
ethyl ketone moiety is changed to hydroxamic acid, epoxyketone or methyl ester with a spacer 
of five methylene groups, the inhibitory activity is further enhanced.[111] Moreover, they found 
that the Trp residue of Apicidin was a key site and the replacement or modification of this 
moiety had great influence on the HDAC inhibitory activity which meaned that the amino acid 
present in the cyclic tetrapeptide inhibitor had some interactions with the rim of the HDACs 
active site pocket.[112] The introduction of a basic group at the Trp’s NH increased the HDAC 
activity and similar enhancement in activity was observed with the introduction of a bulky aryl 
substituent at the 2-position of Trp. 
 
 
Fig. 1.21 HDAC inhibitors containing retrohydroxamic acid. 
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Fig. 1.23 HDAC inhibitory activity of Chlamydocin analogues bearing carbonyl as functional group. 
 
 
Fig. 1.22 Apicidin and analogues with changing side chain. 
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Bhuiyan et al. have replaced the epoxy ketone moiety in Chlamydocin with several ketones and 
aldehyde to synthesize potent reversible and selective HDAC inhibitors.[113] They found most 
of them as potent inhibitors and some compounds have shown remarkable selectivity among 
HDAC subtypes (Fig. 1.23). 
Two new cyclic peptides possess the unusual amino acid Aoda ((S)-2-amino-8-oxodecanoic 
acid) and its hydroxyl derivative ((2S)-2-amino-8-hydroxydecanoic acid), respectively. 
Microsporins A and B (Fig. 1.24), were isolated from culture extracts of the marine-derived 
fungus Microsporum cf. gypseum by Wenxin Gu et al. in 2007.[114] Microsporins A and B are 
potent inhibitors of histone deacetylase. Microsporin A showed in vitro cytotoxicity against 
human colon adenocarcinoma HCT-116 (IC50 = 0.6 mg/mL) and a mean IC50 value of 2.7 mM 
in diverse 60-cell line panel. Microsporin B showed reduced in vitro cytotoxicity against 
HCT-116 (IC50 = 8.5 mg/ mL), which may indicate the importance of the Aoda ketone carbonyl 
group for biological activity.  
In 2009, Ana and coworker designed and synthesized a series of β-amino acid-containing 
HDAC inhibitors inspired by cyclic tetrapeptide natural products (Fig. 1.25). To survey a 
diverse ensemble of pharmacophoric configurations, they systematically varied the position of 
the β-amino acid, amino acid chirality, functionalization of the Zn2+ coordinating amino acid 
side chain, and alkylation of the backbone amide nitrogen atoms around the macrocycle. The 
ethylketone-containing compounds that were most active against HeLa cell nuclear extract 
exhibited significant cell-specific cytotoxicity. The hydroxamic-acid-containing peptide 
inhibited the growth of all the test cell lines, consistent with its high potency against HDAC 
activity in HeLa nuclear extract. The compounds exhibited potent activities against a number of 
HDAC isoforms as well as effective antiproliferative and cytotoxic activities against human 
tumor cells.[115] 
 
 
Fig. 1.24 Microsporins A and B as HDAC inhibitors. 
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Fig. 1.26. HDAC inhibitors of cyclic tetrapeptides containing hydroxymethyl ketone. 
 
 
Fig. 1.25 Cyclic tetrapeptide containing ketone and β-amino acid. 
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(4)  Cyclic tetrapeptide containing hydroxymethyl ketone  
In 1994, a phytotoxic cyclotetrapeptide containing an unusual amino acid, 2-amino-8-oxo-9- 
hydroxydecanoic acid, was isolated from the fungus Verticillium coccosporum. Structurally, 
the peptide is closely related to the known peptide Chlamydocin[116] and the tumorigenic 
TAN-1746s (Fig. 1.26).[117] Both new analogs, as noted, lack the 9,10-epoxide and instead bear 
a 9-hydroxyl. A published patent has described a desepoxy-Trapoxin analog (FR-225497, 
compound not shown) which had good activity against human tumor cell lines in vitro (IC50 = 
152 and 158 ng/mL against Jurkat and HT-29 cells, respectively).[118] A natural 
immunosuppressant FR235222, that potently inhibits mammalian HDACs has a Chlamydocin 
like cyclic tetrapeptide structure, inhibiting the HDACs (IC50 = 9.7 nM).[119] A number of 
synthetic FR235222 analogues that bearing a carboxylic or an hydroxamic acid functionality as 
Zn binding moiety replacement or modification of hydroxymethyl ketone moiety were reported 
(Fig. 1.26).[120] 
 (5)  Cyclic tetrapeptide containing electrophilic ketones 
Jose and coworker synthesized cyclictetrapeptides containing trifluoromethyl ketone and 
pentafluoroethyl ketone as the zinc binding functional group (Fig. 1.27).[121] HDAC inhibitory 
activity of these electrophilic ketones depends on the degree of hydration of the ketone, which 
can chelate with the zinc ion present in the deep pocket of HDAC binding site. Out of these 
compounds trifluoromethylketone are found to have excellent inhibitory activity. Changing 
from trifluoro to pentafluoro group did not increase the activity, probably because of the 
 
 
Fig. 1.27 Cyclic tetrapeptide containing electrophilic ketone. 
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balkiness of the pentafluromethyl group. Incorporation of a sulfur atom to the carbonyl 
increased the activity that may provide different mode of ligation with Zn2+ ions, using longer 
spacer length. 
 (6)  Cyclic peptides containing sulfur 
FK228 (FR901228, depsipeptide) as a natural product was obtained from the fermentation 
broth of  Chhromobacterium violaceum by Fujisawa Pharmaceutical Co. Ltd. in 1991 along 
with the closely related depsipeptide, FR901375 (Fig. 1. 28).[122,123] FK228 includes a 16- 
membered cyclic depsipeptide bridged by a 15-membered macrocyclic disulfide ring, and is 
composed of L-Val, L-2-amino-2-butylenoic acid, D-Cys, D-Val and Hm7 (3S,4R-3-hydroxy- 
7-mercapto-4-heptenoic acid). There is no visible functional group in FK228 that interacts with 
the zinc ion in the HDAC active site. Furumai et al. demonstrated that the zinc-binding site of 
FK228 was the sulfhydral functional group and converted to its active form by cellular reducing 
activity (Fig. 1. 29).[124]  
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Fig. 1.28 HDAC inhibitors of sulfur-containing cyclic tetrapeptide. 
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Fig. 1.29 FK228 and RedFK228 (reduced form). 
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In 2001, Spiruchostatins A and B (Fig. 1.28) were isolated from Pseudomonas sp. as gene 
expression-enhancing substances. The structure consists of D-cysteine, D-alanine, α-hydroxy 
acid and statine with potent HDAC inhibitory activity. They possess novel bicyclic 
depsipeptides involving 4-amino-3-hydroxy-5-methylhexanoic acid and 4-amino-3-hydroxy-5- 
methylheptanoic acid residues, respectively.[125] Recently, the total synthesis of Spiruchostatins 
was reported.[126,127]  
In 2008, Luesch and co-workers isolated Largazole that is a densely functionalized macrocyclic 
depsipeptide from the cyanobacterium Symploca sp. (Fig. 1.30).[128-130] This natural product 
exhibits exceptionally potent and selective biological activity, with 2- to 10-fold differential 
growth inhibition in a number of transformed and non-transformed human- and murine-derived 
cell lines. The remarkable selectivity of this agent against cancer cells prompts particular 
interest in its mode of action and its value as a potential cancer chemotherapeutic. Albert et al. 
synthesized and assayed fourteen analogs of Largazole with six variants of the side-chain 
zinc-binding domain.[131] 
 
FK228 showed a potent in vivo antitumor activity and HDAC inhibitory activity.[132-140]  FK228 
was conducted  in a phase I/II trial for patients with T-cell lymphoma, and these results 
suggested that inhibition of HDAC was a novel and potentially effective therapy.[141]  
FK228 (Romidepsin INN, trade name Istodax)  is an anticancer agent undergoing clinical trials 
as a treatment for cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma, and a 
variety of other cancers. Romidepsin is branded and owned by Gloucester Pharmaceuticals, 
now a part of Celgene. On November 5, 2009, it was approved by the U.S. Food and Drug 
Administration for the treatment of CTCL, after five years in the agency's fast track 
development program.[164,165] 
 
 
Fig. 1.30 Largazole as HDAC inhibitors of Sulfur-containing cyclic tetrapeptides. 
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In 1996, Khan et al. completed synthesis of FK228.[142] Recently, numerous improved synthesis 
methods were used for FK228 synthesis.[143-145] On the basis of this inhibitory activity of FK228, 
a series of HDAC inhibitors, sulfur-containing cyclic peptides (SCOPs), by replacing the 
L-Aoe[(2S,9S)-2-amino-8-oxo-9,10-epoxydecanoic acid] moiety of natural cyclic tetrapeptides 
with L-2-amino-7-mercaptoheptanoic acid (L-Am7) were synthesized by Nishino and 
coworkers.[146] These compounds were initially assayed for enzyme inhibition; they exhibited 
less activity in cell free condition. But in the p21 promoter assay most of the compounds 
showed good activity. Investigator considered that the disulfide bond was reduced  in cell 
medium to give a sulfhydryl group, to regulate the activity of promoter gene by inhibiting 
HDAC enzymes. Accordingly, the cell free enzyme inhibition assays were carried out, in 
presence of 0.1 mM of DTT. The results of HDAC inhibitory activity and the p21 promoter 
assay of the compounds are shown in Fig. 1. 31. 
 
 
 
Compound 
IC50 (nM) HDAC1/ 
HDAC4a 
P21 promoter assay 
EC1000 (nM) HDAC1 HDAC4 HDAC6 
TSA 1.9 2.0 2.8 1.0 190 
cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) 3.9 1.8 40 2.1 45 
cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) 2.0 1.6 8.8 1.2 140 
cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) 2.7 2.4 12 1.1 55 
cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) 36 25 33 1.4 2000 
cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) 170 70 71 2.4 25600 
cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) 3.7 2.2 56 1.6 550 
cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) 4.7 4.2 29 1.1 200 
cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) 88 56 86 1.5 7400 
cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) 6.2 3.2 36 1.9 320 
cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) 5.3 2.7 43 1.9 110 
cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) 3.2 1.6 24 2.0 72 
cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) 6.4 4.0 26 1.6 580 
cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) 9.4 5.2 43 1.8 750 
a Seletivity of the enzymes      
 
Fig. 1.31 Comparative activity of SCOPs.  
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Nishino et al. also synthesized some stable disulfide dimers and hybrids with thiols (Fig. 1.32). 
These compounds showed potent inhibitory activity.[147] To know the interaction of aliphatic 
cap groups with HDACs, bicyclic peptide disulphide hybrid was also synthesized without 
aromatic ring in their macrocyclic framework.[148] The bicyclic peptide was found to be active 
in both cell free and cell based condition, and it had some selectivity among HDAC1 and 
HDAC6.  
 
 (7)  Cyclic tetrapeptide containing carboxylic or amide group 
In 2006, Azumamide A-E were isolated from the marine sponge Mycale izuensis by Nakao et al. 
(Fig. 1.33),[149] and subsequently synthesized by Izzo et al.[150] Azumamides include three 
D-α-amino acids (D-Phe, D-Tyr, D-Ala, D-Val) and a unique α-amino acid assigned as (Z, 2S, 
3R)-3-amino-2-methyl-5-nonenedioic acid 9-amide (amnaa). The zinc-binding site of 
Azumamides is the carboxylic or amide functional group. To investigate the inhibitory activity 
of HDAC ligand, they performed Azumamides and the histone deacetylase-like protein (HDLP) 
model in the docking study. 
In 2010, Bruno group synthesized a series of FR235222 analogues bearing a carboxylic 
functionality as Zn binding moiety (Fig. 1.33).[151] The compounds displayed submicromolar 
inhibitory activity on class I HDACs 1, 2, and 3. Its potency was similar to that measured on 
deacetylation reactions catalyzed by HDACs present in the nuclear extract (NE) from HeLa 
cells. 
 
Fig. 1.32 HDAC inhibitors of Sulfur-containing cyclic tetrapeptide. 
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(8)  Cyclic tetrapeptide containing guanidine 
The derivatives based on HDAC inhibitor FR235222 were synthesized by Erinprit and 
coworker in 2008 (Fig. 1.34).[152] They first reported utilizing guanidine group as relating to 
zinc ion of HDAC. These compouds exhibited both inhibition of HDAC activity and 
cytotoxicity against the pancreatic cancer cell line BxPC3. 
(9)  Miscellaneous of HDAC inhibitors of cyclic tetrapeptide 
There are a number of HDAC inhibitors that can not be classified as a structural class. Meinke 
group synthesized HDAC inhibitors replacing the ketone side chain of Apicidins with 
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Fig. 1.33 HDAC inhibitors of cyclic peptides containing carboxylic or amide group. 
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phosphonate, showed very low HDAC inhibitory activity.[153] From all these phosphonate 
compounds studied for HDAC, it is clear that phosphonates are not good inhibitors for the 
HDAC inhibition, probably due to the highly acidic nature of phosphonate moiety, instead of 
the basic nature of the HDAC substrate. Jose et al. synthesized a phosphonate with a cap group 
of cyclic tetrapeptide and a spacer of five methylene units (Fig. 1.35).[154] The HDAC inhibitory 
activity study showed that the phosphonate cyclic tetrapeptide  was a very weak inhibitor of 
HDAC. 
 
 
 
Fig. 1.35 Miscellaneous HDAC inhibitors. 
 
 
Fig. 1.34 Cyclic tetrapeptide containing guanidine group. 
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Rich et al. synthesized a cytostatic Chlamydocin derivative having α-chloro ketone functional 
group as Zn2+ ligand of HDAC (Fig. 1.35). Though the new derivative exhibited somewhat 
decreased potencies in cell based antiproliferative assay (~3-4 fold) relative to the parent 
natural product, still it added a new variation to the zinc ligand library.[155] Bhuiyan et al. have 
replaced the epoxy ketone moiety in Chlamydocin with α-bromo ketone functional group to 
synthesize HDAC inhibitors.[113] 
1.5 Molecular simulation of interactions between HDAC and HDAC inhibitors 
Recently, the study of protein simulation in computer science, medicinal chemistry, molecular 
biology and computational chemistry, have become a powerful tool for biology experiments 
and drug design. Crystal structures of the HDAC enzymes and their homologues provide 
essential information for rational drug design of selective HDAC inhibitors. The first structural 
information on zinc-dependent HDACs was derived from the crystal structure of histone 
deacetylase-like protein (HDLP), a bacterial enzyme sharing high homology to the HDACs 
around the binding pocket and containing a Zn2+ in its active site, bounded with TSA or 
SAHA.[30] Currently, crystal structure of HDAC8 has been reported, and its active site is similar 
to HDLP[30,156] and FB188 HDAH[31]. The structure of human class II HDAC7[29] and 
HDAC4[162] catalytic domain were reported. 
Most of molecular simulation studies about the HDAC-inhibitor interactions are focused on 
small molecule inhibitors,[157,158] up to now only two contributions analyzing the binding 
contacts between HDLP and the tetracyclopeptide framework have been published: FR235222 
–HDLP[159,160] and Azumamide E-HDLP.[161] Cyclic peptides constitute the most structurally 
complex and diverse class of HDACs inhibitors. 
Simone and coworker used the HDLP as target model in the docking calculations.[160] They 
performed on the cis- and trans-isomers of FR235222 analogues with the HDLP binding pocket, 
using AutoDock 3.0.5 software. The DMSO solution-state structures were obtained by 
2D-NMR spectroscopy and were used as the initial conformations in the docking study. They 
analyzed the results obtained from docking to evaluate if one or both isomers interacted with 
the biological target (Fig. 1.36 a). It indicated that hydrophobic interactions contributed mostly 
to the stability of the complex. In particular, the indole ring (Trp) was able to interact efficiently  
with hydrophobic pockets located at the rim of zinc-containing tubular cavity. In addition, the 
change in C9 configuration caused a lowing in the binding affinities but didn’t lead to a 
complete loss of HDAC inhibition activities. 
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Nakia and coworker also performed on (+)-azumamide E and (-)-azumamide E, with the HDLP 
binding pocket (Fig. 1.36 b),[161] using the same AutoDock 3.0.5 software. The carboxylate 
moiety is of primary importance for its interactions network: it coordinates the zinc ion and 
establishes hydrogen bonds with Hε2 of H131 and H132, and OH of Y297. Moreover, the C3 
linked esenoic chain makes stabilizing hydrophobic interactions with the zinc-containing 
 
             
(a)                                                                                   (b) 
Fig. 1.36 Cyclic peptide superimposition in the zinc-binding site. (a) cis and trans of FR235222 
analogues. The Zn2+ is represented by a CPK sphere in dark orange. trans is depicted by sticks (yellow) 
and balls (by atom type: C, gray; polar H, sky blue; N, blue; O, red); cis is shown by sticks (green) and 
balls (by atom type: C, gray; polar H, sky blue; N, blue; O, red). (b) (+)-azumamide E and (-)-azumamide 
E. The Zn2+ is represented by a CPK sphere in dark green. (+)-azumamide E is depicted by sticks (yellow) 
and balls (by atom type: C, gray; polar H, sky blue; N, blue; O, red); (-)-azumamide E is shown by sticks 
(dark blue) and balls (by atom type: C, gray; polar H, sky blue; N, blue; O, red). The figure highlights the 
similar interactions with the 11 Å deep hydrophobic channel of the amnda side chains, whereas the phenyl 
groups of two compounds are located on opposite sides of the receptor surface hydrophobic pocket. 
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tubular pocket. The macrocyclic portion is accommodated in a shallow groove, establishing van 
der Waals interactions and hydrogen bonds with the receptor counterpart, and is formed by 
H170, Y196, A197, F198, and F200 residues. (+)-Azumamide E is a potent, selective inhibitor 
of class I HDACs 1-3.  
In conclusion, HDACs inhibitors are well known as a unique and promising class of anticancer 
agents. They induce growth arrest, cell differentiation and apoptosis in tumor cells. However, 
these inhibitors, especial the hydroxamates, do not exhibit isozyme specificity in HDAC 
inhibition. It is obvious that the selective inhibition of specific HDACs is highly desirable and 
more likely to yield specific and nontoxic drugs. 
After the X-ray structure determination of HDLP, the momentum of research on HDAC 
inhibitors increased and a large number of potent HDAC inhibitors are now available and most 
of them are in clinical trials. HDAC inhibitors which have been reported could provid 
information about the active site of HDACs. Cyclic peptides are of great helpful in finding the 
interactions of each HDAC in the rim region. The design of novel inhibitors based on the 
reported HDAC inhibitors and on the basis of the information on HDACs will lead to the 
synthesis of member selective inhibitors. HDAC research is currently focusing on the subtype 
selective inhibitors, which can be used as bioprobe to find the functions of each member of the 
HDAC family and also have potential as drugs for many specific diseases. 
1.6 Purpose of this study 
Since Finnin et al. reported the crystal structure of HDLP and the interactions machanism of 
HDLP-TSA complex, the structural information of HDAC inhibitors had been realized which is 
composed of three portion: the zinc binging group (ZBG), which interacts the zinc ion and 
engages in multiple hydrogen bonds with the amino acid residues at the active site of HDACs; 
The linker domain, which occupies the channel of HDACs; The surface recognition domain, 
which has cap group portion and interacts with amino acid residues on the rim of  active pocket 
entrance. The rim of active pocket of HDACs have multiple grooves that can selectively 
interact with the cap group of inhibitors. These grooves of HDACs can be well interacted by 
proper cap group. Therefore, the cap group of inhibitors can be the promising target for 
improving potency and selectivity. These inhibitors contain aromatic ring in their surface 
recognition domain and it is proved that the aryl group portion may act as a cap to bind the rim 
of HDAC enzymes active pocket. The sequence diversity of surface recognition domain of 
HDAC inhibitors may choose to bind the amino acid residues on the rim of active pocket of 
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HDAC subtypes. The modification at cap group portion in inhibitor can provide better 
specificity. The surface recognition domain of the pharmacophore affects not only inhibitory 
potency but also selectivity. Specificity is a necessary condition for a useful inhibitor as a drug 
with high pharmacokinetic properties and oral bioavailability. The potent HDAC inhibitors of 
cyclic tetrapeptide bearing hydroxamic acid or epoxy ketone have very low selectivity to 
HDAC subtype. Considering the facts described above, author intended to develop HDAC 
inhibitors of cyclic tetrapeptide bearing different sequences of scaffold (diversity non-natural 
amino acid replace at four residues position) and different zinc chelating functional groups 
(disulfide hybrid and hydroxamic acid). Author carried out arrangement of aromatic rings and 
non-aromatic ring on these scaffolds to develop inhibitors towards HDAC and to know the 
interaction of cap group with HDACs surface binding region. Moreover, author also examined 
the SAR of selective HDAC inhibitors. 
In Chapter 2 of this thesis, to explore the molecular details of the interactions between cyclic 
tetrapeptide and HDACs in the HDACs active site, author reported molecular dynamics (MD) 
study of Apicidin-HDAC1 and Apicidin-HDAC8. First, we constructed the 3D model of human 
HDAC1 structure using human HDAC8 as template and then validated using several evaluation 
programs. Subsequently docking studies were performed to analyze the binding modes between 
HDAC1 and Apicidin, its analogues. The selective inhibition of Apicidin was studied by 
comparing the binding modes of Apicidin and the two enzymes, followed by further molecular 
dynamics study of Apicidin-HDAC1 and Apicidin-HDAC8. 
In Chapter 3 of this thesis, author reported the design and synthesis of non-natural amino acid 
for the use of synthesizing novel HDACs inhibitors of cyclic tetrapeptide. H-Phe-OH 
derivatives were synthsized for aromatic ring modification at 3-position of cyclic tetrapeptide 
scaffold. According to two different starting material (tert-butoxycarbonyl-amino-malonic acid 
diethyl ester and diethyl acetamidomalonate), Boc-L-Phe(n-Me)-OH was synthesized by two 
methods. n-methyl- amino-cyclohexane-carboxylic acid (Anmc6c) were synthesized by the 
Strecker reaction methods that is one of the most efficient and straightforward for the synthesis 
of α-aminonitriles, which were very useful precursors for the synthesis of α-amino acids and 
various nitrogen- containing heterocycles. These n-methyl-amino-cyclohexane-carboxylic acid 
(A2mc6c, A3mc6c and A4mc6c)  were used for the synthesis of designed HDACs inhibitors of 
cyclic tetrapeptides at 2-position of scaffold to replace Aib residue. 2-amino-5-chloro- 
pentanoic acid (L-Ac5) and 2-amino-6-chloro-hexanoic acid (L-Ac6) were prepared for 
replacing aromatic ring at 3-position of cyclic tetrapeptide scaffold, because aromatic ring can 
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not  be metabolize in liver, moreover, the side chain containing chlorine of L-Ac5 or L-Ac6 
may be modified with oxygen or sulfur to chelating zinc ion of HDAC active pocket bottom. 
In Chapter 4 of this thesis, author reported design and synthesis of HDACs inhibitors having 
Chlamydocin scaffold bearing hydroxamic acid as the zinc binging group, and n-methyl- 
amino-cyclohexane-carboxylic acid (Anmc6c) replaced Aib residue to explore inhibitors 
interaction with HDAC enzymes. The replacement of Aib residue of Chlamydocin with an 
aliphatic ring (Anmc6c) enhanced the in vivo and in vitro inhibitory activity. These compounds 
were tested for HDACs inhibitory activity and the results showed potent inhibition of HDAC. 
We also tested for antiproliferative in vitro by MTT assay against MCF-7 (human breast 
cancer), Hela (human cervix cancer), 7721 (human liver cancer) and K562 (human leukemia) 
cell lines. All compounds exhibited nanomolar concentration antitumor activities. We have 
carried out molecular docking studies on Chlamydocin–hydroxamic acid analogues and HDLP, 
HDAC8 and HDAH, respectively. 
In Chapter 5 of this thesis, author reported design and synthesis of HDACs inhibitors having 
Chlamydocin scaffold bearing L-2-amino-7-(2-pyridyl)-disulphidyl heptanoyl (L-Am7(S2Py)), 
which equips thiol function group protected by disulfide hybrid. Chlamydocin is a naturally 
occurring cyclic tetrapeptide based HDAC inhibitor. Cyclic framework in Chlamydocin 
containing L-Phe is supposed to play an important role of cap group. To find out specific 
inhibitors for HDAC subtype, author focused on the benzene ring of L-Phe in Chlamydocin 
framework. Author here replaced the L-Phe residue of Chlamydocin with L-Phe(n-Me) to add 
exiguous hydrophobicity to study the role of aromatic ring in cap portion of cyclic tetrapeptide 
inhibitors. The synthesized compounds were tested for antiproliferative in vitro by MTT assay 
against MCF-7, Hela  and 7721 cell lines, and then docked and molecular dynamics simulated 
towards HDAC8. 
In Chapter 6 of this thesis, author reported design and synthesis of HDAC inhibitors of Phe 
replaced by aliphatic amino acid containing chlorine (L-Ac5 and L-Ac6) in Chlamydocin 
framework because the aromatic ring moiety of cyclic framework provide hydrophobic 
interaction with HDAC active pocket. but, HC-Toxins have no aromatic ring, which still inhibit 
the HDACs. In synthesis process, the L-Ac5 changed into L-Pro. Further investigation is 
needed to improve the activity. All compounds exhibited nanomolar concentration HDACs 
inhibitory activities. 
In summary, author designed and synthesized different classes of HDAC inhibitors with 
diversity non-natural amino acid at different positions of cyclic tetrapeptide scaffold and with 
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different HDAC subtypes of ligands. This aim is to exploit cyclic tetrapeptide HDAC inhibitors, 
especially for the design of selective and potent cyclic tetrapeptide HDAC inhibitors. 
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Chapter 2 
Molecular Simulation of Interactions between HDAC and Apicidin, 
Analogues  
2.1 Introduction 
Modulation of the acetylation state of lysine residues found in the accessible N-terminal of core 
histones plays a pivotal role in the regulation of gene expression.[1,2] Acetylation and 
deacetylation of histones are controlled by two corresponding enzymes, HDACs and HAT.[3] 
The HDACs strongly influence gene silencing as they are inappropriately recruited to key 
locations in nucleosomes through their interactions with transcription complexes.[4] Inhibition 
of HDACs represents a new strategy in human cancer therapy and the inhibitors are potent 
inducers of growth arrest, differentiation and 
apoptosis of tumor cells. A wide variety of 
HDAC inhibitors of both small molecule 
(Trichostatin A, TSA[5]) and cyclopeptides 
(Azumamide,[6] FR235222[7] and FK-228[8]) 
have been reported. Among them, Apicidin 
(cyclo(L-Trp(OMe)-L-Ile-D-Pip-L-Aode), Fig. 
2.1), isolated from Fusarium pallidoroseum, is 
a potent and broad-spectrum antiprotozoal 
agent which exerts its biological activity by 
reversibly inhibiting HDACs.[9,10] 
The first structural information on zinc-dependent HDACs was derived from the crystal 
structure of histone deacetylase-like protein (HDLP), a bacterial enzyme sharing high 
homology to the HDACs around the binding pocket and contains a Zn2+ in its active site, 
bounded with Trichostatin (TSA) or suberanilohydroxamic acid (SAHA).[11] Recently, the 
crystal structure of human HDAC8 was described by two independent groups, proposing a 
catalytic mechanism which is similar to the mechanism proposed from HDLP.[12,13] The 
crystallographic structure of human HDAC1 is not available yet. An alignment shows 41% 
Fig. 2.1 The structure of Apicidin and analogues.
‐ 46 ‐ 
 
sequence identity of human HDAC8 and HDAC1. The residues around the Zn2+ binding site of 
HDAC8 are completely conserved in all human class I HDACs. 
Most of molecular simulation studies about the HDAC-inhibitor interactions are focused on 
small molecule inhibitors,[14,15] up to now only two contributions analyzing the binding contacts 
between HDLP and the tetracyclopeptide framework have been published: FR235222-HDLP 
and Azumamide E-HDLP.[16,17] Cyclic peptides constitute the most structurally complex and 
diverse class of HDACs inhibitors. There is strong evidence that the three-dimensional 
appendage orientations of tetracyclopeptides Apicidin and its analogues significantly influence 
the inhibitor-enzyme recognition pattern.[18,19] However, the details of recognition between 
tetracyclopeptides and HDACs are only partly known. The scarce information on the role 
played by the cyclic tetrapeptide cap group in the HDACs recognition process prompted us to 
explore the molecular details of the interactions between HDACs and Apicidin and its 
analogues. Here, the 3D model of human HDAC1 structure was constructed using human 
HDAC8 as template and then validated by several evaluation programs. Subsequently docking 
studies were performed to analyze the binding modes between HDAC1 and the 
tetracyclopeptides. The selective inhibition of Apicidin was studied by comparing the binding 
modes of Apicidin and the two enzymes, followed by further molecular dynamics study of 
Apicidin-HDAC1 and Apicidin-HDAC8. 
2.2 Results and discussion 
2.2.1 Sequence alignment and homology model validation 
The sequence alignment of HDAC1 and HDAC8 is shown in Fig. 2.2, indicating 41% sequence 
identity between the two enzymes. It shows that the residues making up the active site and 
contacting the inhibitors were conserved these two HDACs, which was in agreement with the 
study of Somoza et al.[12] However, comparing with HDAC8, HDAC1 hads an additional 
segment in its C-terminal domain that is about 110 amino acids. Since the function of these 
residues was proposed to recruit the enzyme to large protein complexes that may modulate its 
enzymatic activity and localization,[20] they were omitted in further studies considering no 
similar sequences founded. 
The quality of the human HDAC1 model was then evaluated with three different validation 
tests. The φ/ψ distributions listed in Table. 2.1 showed that there were 91.4% of the residues in 
the HDAC1 model and 90.1% of HDAC8 template appeared in core regions, respectively. And 
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Fig. 2.3 The WHATIF packing quality scores calculated for the template HDAC8 and the homology 
model HDAC1. 
Table 2.1 The φ/ψ dihedral angle distribution of HDAC1 and HDAC8 
Value caculated 
Percentages of residues 
HDAC1 model HDAC8 template 
Core 91.4% 90.1% 
Allowed 7.6% 9.3% 
Generously allowed 0.9% 0.3% 
Disallowed 0 0.3% 
*The Phi, Psi region percentages were caculated by PROCHECK. 
 
 
Fig. 2.2 Sequence alignment between human HDAC 1 and HDAC8. The secondary structure assignment 
was derived from the HDAC8 structure. The residues forming active pocket are demarcated by red 
asterisk and those binding to zinc are demarcated by black dots. 
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none of the model residues was found in disallowed regions, while one template residue was 
found there. Summarizing the results of the PROCHECK analysis, the stereochemical quality 
of the model was better than that of the template. Packing quality of the model was analyzed by 
the  WHAT-IF Coarse Packing Quality Control test and depicted in Fig. 2.3. The key loops (L1: 
20-33, L2: 91-105, L3: 134-154, L4: 175-180, L5: 201-216, L6: 265-277 and L7: 299-304) 
which formed a part of the binding site were marked by frames. For a reliable structure, the 
WHATIF packing scores should be above -5.0. In general, the HDAC1 model had similar 
packing scores compared with the template X-ray structure. A few residues were poorly packed 
based upon scores lower than -5.0. However, these values were also similar to the ones in the 
HDAC8 template. When checking with ERRAT, the score for the model was 73.15, suggesting 
that the backbone conformation and non-bonded interactions of the model were all reasonable 
within a normal range. The results of three validation tests showed that the HDAC1 model was 
reliable for performing further docking studies. 
2.2.2 3D structure of the HDAC1 model 
In general, the overall structure of human HDAC1 model was similar to the X-ray structure of 
HDAC8. The structure comprises of a centrally located 8 β-sheets enclosed by 16 α-helixes. 
There were seven key loops L1-L7 forming the walls of the binding site (Fig. 2.4). The L3 and 
L4 located at the bottom of the active pocket nearing Zn2+ and house the catalytic machinery of 
the enzyme. L1, L2 and L6 formed rim of enzyme surface entrance. L5 and L7 located at 
channel. The superimposition of the HDAC1 homology model and the HDAC8 X-ray structure 
with the co-crystallized inhibitor TSA is shown in Fig. 2.4a, with RMSD 2.38 Å of the 
backbone atoms. The binding site was demarcated by the presence of TSA and Zn2+. The active 
pocket walls of HDAC1 model consisted of residues Phe150, Phe205, Asp181, Gly149, 
Leu271 and Tyr303. These residues were identical with that of HDAC8, with the exception of 
Leu271, which was a methionine in HDAC8.[12,13] The HDAC1 model gave a reasonable 
geometry of the zinc binding part (Fig. 2.4b). The distances of Zn2+-Asp176(Oδ1), 
Zn2+–Asp264(Oδ1) and Zn2+-His178(Nδ1) were 2.60, 2.59 and 2.67 Å in HDAC1 model while 
the counterparts in HDAC8 were 1.97, 1.94 and 2.15 Å. There were also two charge-relay 
systems formed by His140-Asp174 and His141-Asp181, respectively. 
At the entrance portion of the active pocket, there was a Glu98 (Fig. 2.5(1)a) in HDAC1 
insteaded of Tyr100 comparing with HDAC8 (Fig. 2.5(1)b). This change made the pocket 
entrance more open in HDAC1, indicating that the inhibitors with large cap groups can bind to 
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(1)     
                                           (a)  HDAC1                                            (b) HDAC8 
 
(2)  
 
 
                                         (a)  HDAC1                                            (b) HDAC8 
 
Fig. 2.5 (1) The surface representation of the active pocket of HDAC1 model and the HDAC8 template. 
The surface residues are color coded based on their nature: electropositive (red), electronegative (cyan), 
polar (green) and nonpolar (blue). The magenta circles demarcate the location of two residues, which are 
not conserved between human HDAC1 and HDAC8. (2) Surface representation of the internal cavity 
nearing the active pocket of HDAC1 (a) and HDAC8 (b) The TSA (yellow) is locating in the active 
pocket. 
(a)             (b)   
 
Fig. 2.4 (a) Superimposition of HDAC1 model (red: helices, yellow: sheets, green: loops) and HDAC8 
X-ray structure (grey: cartoon) with the co-crystallized inhibitor TSA (orange sticks). (b) The zinc 
geometry at the active site of HDAC1 (green) with HDAC8 counterpart (grey). (The cyan dashed lines 
represent hydrogen bonds while the red ones represent the two Asp-His charge delay systems in HDAC1).
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the active site in a more favorable manner. Another unconserved residue around the active 
pocket was Arg270, which was Met274 in HDAC8 (Fig. 2.5(1)b). These portions were 
different in electrostatic and hydrophobic properties between HDAC1 and HDAC8, which may 
influence the binding of inhibitors with large cap groups. There was a internal cavity near the 
active pocket in HDAC8 structure with accommodating acetic acid and two water molecule 
from deacetylation.  Compared to HDAC8, the one end of internal cavity of HDAC1 connected 
to active pocket (similar to HDAC8) and the other end swerved and formed entrance which 
moved the acetic acid and water out. So, It is likely to inhibit deacetylation for design molecule 
interact with the entrance of internal cavity (Fig. 2.5 (2)). 
2.2.3 Interactions between HDAC1 and inhibitors 
In order to validate the computation accuracy of AutoDock 4.0, HDLP-TSA and HDAC8-TSA 
crystal complexes were employed to perform redocking studies and the redocking results were 
compared with the original crystal structures. When redocking TSA to HDLP, two major poses 
appeared with two opposite orientation of the N, N-dimethylaminobenzyl group of TSA. In one 
case, the dimethylaminobenzyl group positions in the groove formed by Pro22, Tyr91 and 
Phe141. This kind of conformation took 18% of all with RMSD < 2.0 Å (compared with crystal 
TSA conformation). While in the other case, about 23% of all conformations interacted with the 
opposite groove formed by His170, Phe200, Leu265 and Ser266 with their 
dimethylaminobenzyl groups. The two grooves can be favorable binding positions for 
inhibitors with large caps, like cyclotetrapeptides. Interestingly, when redocking TSA to HDLP 
with several crystal waters remained, the percentage of the first conformation was dramatically 
increased to 63%, indicating that redocking studies with crystal waters involved were more 
accurate, as mentioned in former studies.[21] Similar results were obtained for HDAC8-TSA, 
indicating that AutoDock 4.0 program is capable of performing further docking studies. 
Four tetracyclopeptides, Apicidin (1), Apicidin B (2), Apicidin C (3) and Apicidin analogue 4 
(4), have been reported as HDACs inhibitors with IC50 values of 1, 10, 6 and 86 nM, 
respectively.[18] To understand how these inhibitors bind to the enzyme, docking studies were 
performed following the procedure described in the methodology section. As a result, the 
zinc-chelated conformation of Apicidin is rightly the lowest binding energy conformation 
(∆Gbinding = -9.67 kcal/mol), and the binding mode is shown in Fig. 2.6. The keto-carbonyl 
moiety was primary importance in coordinating with Zn2+ in a distance of 1.78 Å and 
establishing hydrogen bond with the O(H) of Tyr303. This hydrogen bond was very important 
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for stabilizing the binding of ligands to the enzyme.[22] Moreover, the long 8-oxo-decanoyl side 
chain made stabilizing hydrophobic interactions with the zinc-containing tubular pocket 
containing Tyr303, Gly301, Leu271, His178, Phe150, Gly149 and His141. The macrolactam 
portion was accommodated in a shallow groove at the rim of the active pocket formed by Glu98, 
Lys31, Tyr303 and Arg270, establishing van der Waals interactions and a hydrogen bond. The 
tetrapeptide core extended its hydrophobic interactions thanks to the N-O-methyl-Trp side 
chain, which interacted with the receptor counterpart involving Tyr303, Arg270, Phe150, 
Met30 and Pro32. The piperidinyl side chain purely established hydrophobic interactions with 
Asp99 and it is  mostly exposed to the environment. The isoleucyl side chain made hydrophobic 
 (a) 
(b) 
(c)
 
 
Fig. 2.6 3D model of the interactions between apicidin and the HDAC1 model binding site. Apicidin is 
shown as sticks with the carbon atoms colored yellow. (a) surface representation of the lowest binding 
energy conformation (top view); (b) important residues in close contact (green) with the inhibitor, cyan 
dashed lines represent hydrogen bonds (side view); (c) 2D representation of Apicidin and HDAC1 
showing hydrophobic contacts and hydrogen bonds. 
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interactions barely with Glu98 and Phe150. Three hydrogen bonds were formed between 
Apicidin and HDAC1, shown in both Fig. 2.6c and Table 2.2. 
 
The lowest binding energy conformation of Apicidin B (∆Gbinding = -8.94 kcal/mol) coordinates 
zinc ion in a similar manner of Apicidin, but no hydrogen bond was formed between its 
keto-carbonyl and Tyr303 (Fig. 2.7a and b). The long 8-oxo-decanoyl side chain made 
hydrophobic interactions with fewer residues involved in the tubular pocket than Apicidin, 
which may decrease the biological activities of the inhibitor. The cyclic backbone of Apicidin B 
was accommodated in the same position at the rim of the pocket, while it took a different 
orientation. Since the side chains of Ile and Pro pointed to the outside environment, no  
hydrophobic contact was established by them, which could be another reason for less biological 
activities. In contrast, the N-O-methyl-Trp side chain formed favorable π-π interaction with the 
Tyr303 side chain besides hydrophobic interactions mentioned above, which may slightly 
increase the biological activities. 
The binding mode of Apicidin C (∆Gbinding = -9.05 kcal/mol) was almost the same with Apicidin 
B, except the Val side chain (Fig. 2.7c and d). Although there were Val and piperidinyl instead 
of Ile and Pro, their side chains still pointed outside environment. The piperidinyl side chain 
formed no interaction, while the Val side chain established hydrophobic interactions with 
residues Glu98 and Phe150. 
The analogue 4 differed with Apicidin on the side chain, with the N-O-methyl-Trp side chain 
replaced by the group drawn in Fig. 2.1. Comparing with Apicidin, the zinc-chelated 
conformation of 4 (∆Gbinding = -8.54 kcal/mol) was not the lowest binding energy conformation, 
Table 2.2 The hydrogen bonds obtained from the docking results of the four tetracyclopeptides and 
HDAC1 model. 
Inhibitors 
Hydrogen Bonds 
Donor Acceptor Distance(Å) 
1 
Tyr303 : OH 1 : O6 2.72 
Arg270 : NE 1 : O4 3.13 
Lys31 : NZ 1 : O5 2.87 
2 
Arg270 : NE 2 : O3 3.32 
Lys31 : NZ 2 : O5 3.27 
3 Arg270 : NE 3 : O2 3.36 
4 No hydrogen bond founded 
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Fig. 2.7 3D model of the interactions between Apicidin analogues (yellow sticks) and the HDAC1 model 
binding site. Surface representation of the zinc-chelated conformation of Apicidin B (a), Apicidin C (c) 
and analogue 4 (e); Important residues in close contact (green) with Apicidin B (b), Apicidin C (d) and 
analogue 4 (f). The cyan sticks in (e) are the lowest binding energy conformation of 4. Cyan dashed lines 
represent hydrogen bonds. 
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 suggesting decrease of binding activity (Fig. 2.7e). The cyclic backbone of the lowest binding 
energy conformation blocked the entrance of the active pocket with the 8-oxo-decanoyl side 
chain pointing outside (∆Gbinding = -9.19 kcal/mol). The cyclic frame of the zinc-chelated 
conformation was quite the same with Apicidin, making similar interactions with the receptor 
counterparts (Fig. 2.7f). The only difference between the chemical structures of 1 and 4 was the 
side chain groups of the Trp-like residue. And a significant different orientation occured in this 
portion according to the docking results (Fig. 2.7e). The modified side chain of 4 established 
less hydrophobic interactions with HDAC1 and formed π-π interaction with the Tyr303 side 
chain. It can be concluded from the structure-energy analysis of 2 and 4 that, the π-π 
interactions between tetracyclopeptides and Tyr303 were positive but not leading factors for 
biological activities. 
The atomes of the zinc-chelated conformations which form hydrogen bonds with HDAC1 are 
summarized in Table 2.2. The calculated binding energy of the enzyme-inhibitor complexes 
were higher than the experimental data. Such an inconsistency in the docking results can 
happen in AutoDock docking studies, as few interactions between the inhibitors and enzyme 
may be missing since the side chains of the protein residues were not allowed to move during 
the docking process. But the semiempirical free energy functions[29] in AutoDock 4 enabled a 
reasonable good linear relationship between calculated binding energy from docking and 
experimental values, as shown in Fig. 2.8. 
 
 
Fig. 2.8 Correlation between the predicted binding energies (∆Gcalc) and the experimental values (∆Gexp).
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2.2.4 Selective inhibition of Apicidin on HDAC1 and HDAC8 
Apicidin is known as isoform selective inhibitor for class I HDACs, with IC50 value of 1 nM for 
HDAC1 while IC50 >1000 nM for HDAC8.[13] In the present study, Apicidin was also docked to 
HDAC8, gaining two main binding poses (Fig. 2.9). The lowest binding energy conformation 
was zinc-chelated, like the HDAC1-Apicidin achieved above, with its cyclic backbone 
accommodating in an opposite groove formed by Phe208, His180, Gly97 and 
Asp101. So the N-O-methyl-Trp side chain was far away from Tyr306 and it was impossible for 
forming any hydrophobic interactions or π-π interaction with this residue. Comparing with 
Apicidin-HDAC1 (Fig. 2.6b), there were less residues forming hydrophobic interactions and 
less hydrogen bonds in Apicidin-HDAC8 (Fig. 2.9b), which mean less stabilities and lower 
inhibitory activity. An important difference between the docking results of HDAC1-Apicidin 
and HDAC8-Apicidin was that, several clusters of conformations following the lowest binding 
energy conformation (ranked by binding energy scores) block the cavity adjacent to the 
HDAC8 active site with their cyclic backbones instead of coordinating Zn2+. While in the 
docking of Apicidin to HDAC1 model, the lowest binding energy conformation and several 
followings were all zinc-chelated structures. And the second binding mode mentioned above 
makes less hydrophobic interactions because of decreased contact area. It was mentioned in a 
a         b     
Fig. 2.9 3D model of the interactions between Apicidin and HDAC8 binding site. (a) surface 
representation of the zinc-chelated conformation (shown as sticks with the carbon atoms colored yellow) 
and the lowest binding energy conformation (cyan), top view; (b) important residues in close contacts 
(green) with the inhibitor, side view. Cyan dashed lines represent hydrogen bonds. 
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previous study that, large amount of non-zinc-chelated conformations in one docking related to 
less biologically activity of the cyclopeptide inhibitor.[17] 
The comparison of the two enzyme structures showed that, the Tyr100 and Met274 in HDAC8 
were replaced by the Glu98 and Arg270 in HDAC1 (Fig. 2.5) at the entrance portion of the 
active pocket. These changes made the pocket entrance more open in HDAC1, so the cyclic 
tetrapeptides can bind to the active site in a more favorable manner. Since the entrance of 
HDAC8 is less open and a second cavity adjacent the active pocket exists, inhibitors with large 
cap groups were apt to bind in the second cavity instead of coordinating Zn2+. The surrounding 
environment near the active pocket including the unconserved residues and the second cavity 
may be responsible for the selective inhibition of Apicidin between HDAC1 and HDAC8. 
To better understand the selective inhibition of Apicidin, a 3000 ps MD simulations were 
successfully performed on the complexes of Apicidin binding to HDAC1 and HDAC8. The 
root-mean-squared-fluctuation (RMSF) and potential energy remained stable after 
approximately the first 2200 ps of the simulation for the two systems studied (Fig.2.10). The 
RMSF value of residues at the active site of Apicidin-HDAC1 is smaller to Apicidin-HDAC8, 
（b） 
（a） 
 
 
Fig. 2.10 The average RMSF for amino acid residues of complexes during the last 800ps. (a) all residues; 
(b) residues in the active pocket (around Zn2+demarcated by asterisk). 
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that means Apicidin-HDAC1 complex structure is stable. The Glu98 and Arg270 residues 
locate at the entrance of HDAC1 active pocket, The Arg plays an important role in forming 
stable interactions with Apicidin. The hydrogen bonds between Apicidin and HDACs were 
examined on the basis of the trajectories of the MD simulation (Fig. 2.11). The hydrogen bond 
existence maps showed that, Apicidin mainly created two hydrogen bonds with Tyr303 (Donor: 
Tyr303 OH, hydrogen: Tyr303 HH, acceptor: Aode O=C8; Index 0) and with His178 (Donor: 
His178 NE2, hydrogen: His178 HE2, acceptor: Aode O=C; Index 11). In contrast, no hydrogen 
bond lasted through the simulation between Apicidin and HDAC8. This prominent difference 
in hydrogen existence maps gave another reason for the selective inhibitory activity of 
Apicidin.   
   
2.3 Summary 
The 3D model of HDAC1 has been constructed based on the X-ray structure of human HDAC8. 
And it was proved to be qualified for further studies by three independent validation tests. The 
interactions between the tetracyclopeptide inhibitors and the enzyme were described in details 
after docking. The keto-carbonyl moiety of tetracyclopeptides chelating with zinc ion is the 
basis of low binding energy. The tetracyclopeptide 4 contacted less residues of HDAC1 than 
Apicidin does, consistented with its lower inhibitory activity (∆Gbinding = -8.54 kcal/mol) than 
Apicidin (∆Gbinding = -9.67 kcal/mol). The Tyr100 and Met274 in HDAC8 were replaced by the 
Glu98 and Arg270 in HDAC1 at the entrance portion of the active pocket. These changes made 
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Fig. 2.11 Hydrogen bond existence maps during the 3000 ps on molecular dynamics simulation of 
Apicidin-HDAC1 (a) and Apicidin-HDAC8 (b). Shadow zone represents that the location of donor, 
receptor and hydrogen atom is suitable for the hydrogen bond while white zone represents unsuitable. 
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the pocket entrance more open in HDAC1, so that tetracyclopeptides bound to the active site in 
a more favorable manner. The docking of Apicidin to HDAC8 showed that, inhibitors with 
large cap groups were apt to bind in the second cavity near the active pocket instead of 
coordinating with Zn2+. The Apicidin binding to the second cavity decreased its inhibitory 
activity toward HDAC8. The fact that there were two hydrogen bonds retaining through the MD 
simulation in Apicidin-HDAC1 while none in Apicidin-HDAC8, it was another reason for the 
selective inhibition of Apicidin. This study will be helpful for the optimization of cyclic 
tetrapeptide HDAC inhibitors, especially for the design of selective HDACs inhibitors. 
2.4 Computational methodology 
2.4.1 Model building and validation of HDAC1 
The amino acid sequence of Human HDAC1 was obtained from the National Center for 
Biotechnology Information (NCBI) protein sequence database, Genbank Accession Number 
Q13547. The sequence extracted from one chain of human HDAC8 obtained from the Protein 
Data Bank (PDB ID: 1T64), was employed as template. Automated sequence alignment was 
carried out by ClustalW2 program[23] on the freely available automated web server of EBI 
(European Bioinformatics Institute; http://www.ebi.ac.uk). 
The homology modeling program MODELLER 9v4[24] was employed to build the human 
HDAC1 model using the crystal structure of human HDAC8 as template. Twenty models were 
built using the alignment file generated above. And geometry optimizations and molecular 
dynamics simulations were performed during the building processes. The methods involved in 
geometry optimizations and molecular dynamics simulations were Conjunctive Descent and 
Simulated Annealing, respectively. Among the 20 models, those with the lowest conditional 
probability density functions values (molpdf) or Discrete Optimized Protein Energy (DOPE) 
scores[25] were selected for further validation. 
The quality of the final HDAC1 model was checked by three independent tests, PROCHECK 
[26], WHATIF[27] and ERRAT[28]. The PROCHECK program was used to analyze the 
stereochemical quality of the model. The packing quality of the model was evaluated by another 
validation test, WHATIF Coarse Packing Quality Control value. The ERRAT program checked 
overall quality of the structure for non-bonded atomic interactions, and higher scores mean 
higher quality. The normally accepted range is >50 for a high quality model. All of the above 
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assessments were implemented on both HDAC1 model and HDAC8 crystal structure for 
comparison. 
2.4.2 Docking calculation 
To understand the binding modes between HDACs and the cyclic tetrapeptides, docking studies 
were conducted with AutoDock 4.0 program[29,30] using a Lamarckian genetic algorithm. We 
chose the AutoDock docking protocol and scoring function on the basis of the successful 
application in the interpretation of the inhibitory activity of several HDAC ligands[14,17]. The 
active site of HDAC protein was covered by a grid box size of 56×72×76 points with a spacing 
of 0.375 Å between the grid points. For TSA and the tetracyclopeptides Apicidin analogues, all 
the single bonds except the amide bonds and cyclic bonds were treated as active torsional bonds. 
For each inhibitor, two hundred independent dockings, i.e. 200 runs, were performed using 
genetic algorithm searches. A maximum number of 250 000 000 energy evaluations and a 
maximum number of 10 000 generations were implemented during each genetic algorithm run. 
The default nonbonded zinc parameters in Autodock 4.0[29] were employed after being 
validated by the redocking studies of two crystal enzyme-inhibitor complexes, HDLP-TSA 
(resolution 2.0 Å) and HDAC8-TSA (resolution 1.9 Å). The crystallographic structure of 
Apicidin was obtained from Cambridge Crystallographic Data Centre, and the deposition 
number is CCDC 274844.[31] The other Apicidin analogues were constructed manually based 
on Apicidin and minimized for further docking studies. The LigPlot program[32] was also 
employed to analyze the docking results focusing on hydrogen bonds and hydrophobic 
interactions. 
2.4.3 Molecular dynamics simulation 
MD simulations were performed using GROMACS program (version 3.3.3) with the 
GROMOS96 force field.[33] The starting geometries for the simulation were prepared from the 
docked conformation of Apicidin-HDAC1 and Apicidin-HDAC8 complexes. Before the 
simulation, the energy of the complexes was minimized using 5000 steps of a combined 
steepest-descent/conjugate gradient algorithms protocol. Each system was solvated by a layer 
of water molecules of 10 Å length in all directions. After a 50 ps position-restrained dynamics, 
each simulation preceded 3000 ps under periodic boundary conditions with NPT ensemble by 
using Berendsen’s coupling algorithm at 300 K. Simulation trajectory analyses were done by 
analysis tools in GROMACS. 
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Chapter 3  
Synthesis of Non-Natural Amino Acid 
3.1 Introduction  
Reversible ε-amino groups of lysine residues acetylation and deacetylation on histone tails by 
HAT and HDAC enzymes play an important role in the epigenetic regulation of gene 
expression via altering the chromatin architecture and controlling the accessibility of DNA and 
histones to transcriptional regulators.[1-2] More recently, HDACs have also been shown to 
deacetylate nonhistone proteins, predominantly transcription factors.[3-6] HDAC inhibitors are a 
promising series of anticancer agents that affect gene regulation. The sequence diversity of 
surface recognition domain of HDAC inhibitors may choose to bind the amino acid residues on 
the rim of active pocket of HDAC subtype.[7-9] The modification at cap group portion of 
inhibitor can provide better specificity. The surface recognition domain of the pharmacophore 
affects not only inhibitory potency but also selectivity. To find out specific inhibitors, author 
focused on the four amino acid residues in framework. Our aim was to synthesize potent and 
selective cyclic tetrapeptide HDAC inhibitors. A number of modifications are carried out to the 
cyclic tetrapeptide framework for replacing amino acid at four positions, respectively. 
Accordingly, we designed and synthsized several non-natural amino acids to replaced amino 
acid residues of Chlamydocin framework (Fig. 3.1). At first, we designed methyl 
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Fig. 3.1 Design  the site of non-natural amino acids in HDAC inhibitors framework. 
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phenylalanine (L-Phe(2-Me), L-Phe(4-Me) and L-Phe(3,5-2Me)) to replace phenylalanine at 
3-position of cyclic framework to investigate interaction between surface recognition domain 
of HDAC  inhibitors and HDACs, moreover, at 3-position of cyclic framework, we also 
designed two amino acids containing chlorine (Ac5 and Ac6) to discuss whether the aromatic 
ring of the HDAC inhibitors affects the potency of HDAC inhibitors or not. In addition, for 
chelating zinc ion of HDAC active site, the side chain containing chlorine of Ac5 or Ac6 can be 
modified by oxygen or sulfur. Author designed and synthesized three kinds of n-methyl- 
amino-cyclohexane-carboxylic acid (Anmc6c) (n=2; 3; 4) using the Strecker reaction method 
for replacing Aib at 2-position of scaffold to know the interaction of aliphatic cap group with 
the surface of HDAC enzymes.  
3.2 Synthesis of H-Phe-OH derivatives 
The non-natural amino acids of H-Phe-OH derivatives were designed and synthsized for 
aromatic ring modification at 3-position of cyclic tetrapeptide HDAC inhibitors. This has 
resulted in the development of vast number of methods for the synthesis of non-natural amino 
acids. They include at least 100 derivatives of phenylalanine, in which the phenyl group was 
widely modified, while aliphatic amino acids have been paid less attention. We are interested in 
the synthesis of optically pure non-natural aromatic amino acids containing methyl. According 
to different starting materials (diethyl (Boc-amino) malonate and diethyl acetamidomalonate), 
 
O
N
H
OEt
OEt
O
Boc
O
N
H
OEt
OEt
O
Boc
a, b c, d
N
H
OEt
O
Boc
e
N
H
OH
O
Boc
+
N
H
OEt
O
Boc
CH3 CH3 CH3 CH3(1)
 
 
Scheme 3.1  Synthesis of methyl-phenyalanine (H-Phe(n-Me)-OH). 
Reagents and conditions (1): (a) Na, anhyd EtOH, reflux, 30 min; (b) BrCH2C6H4CH3, reflux, 6 h; (c) 
NaOH aq., EtOH, 4 h; (d) toluene, reflux, 3 h; (e) subtilisin Carlsberg, DMF/H2O (1/3), 4 h. (2): (a) Na, 
anhydrous EtOH, reflux, 30 min; (b) BrCH2C6H4CH3, reflux, 6 h; (c) NaOH aq., EtOH, 4 h; (d) toluene, 
reflux, 3 h; (e) NaOH aq., EtOH, 4 h; (f) acylase CoCl3 6H2O, H2O, pH 8, 24 h. 
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Methyl Boc-L-Phe-OH derivatives were synthesized by the reported procedure[10] as illustrated 
in Scheme 3.1. L-Phe(n-Me) (n = 2; 4; 3,5) were used for the synthesis of designed cyclic 
tetrapeptides in Chapter 5. N-methylbenzyl bromides were separately coupled with diethyl 
Boc-amino- malonate by using NaOEt in ethanol. One of the ethyl ester groups of adduct was 
hydrolyzed by two equivalent of 2 M NaOH at room temperature. The oily monoacid 
monoester after work-up was then subjected to the decarboxylation by refluxing in toluene. 
Finally, Boc-DL-Phe(n-Me)-OEt was subjected to the action of subtilisin Carlsberg from 
Bacillus licheniformis (Sigma) in a mixture of DMF and water (1:3, v/v). Boc-L-Phe(n-Me) 
-OH was isolated as colorless oil with excellent purity in quantitative yield. 
3.2.1 Synthesis of Boc-L-Phe(2-Me)-OH 
3.2.1.1 Synthesis of Boc-L-Phe(2-Me)-OH from diethyl (Boc-amino) malonate (MW = 
279.33): 
Metallic sodium (1.24 g, 54 mmol) was dissolved in anhydrous EtOH (54 mL) and diethyl 
(Boc-amino) malonate (17.84 g, 64.8mmol) was added to the solution. After refluxing for 30 
minutes, the mixture was cooled to room temperature and then 2-methylbenzyl bromide (10 g, 
54 mmol) was added and refluxed for 5 hours. The reaction mixture was carried out by the 
addition of 2N NaOH aq (5 mL) for Hydrolysis. After 5 hours, ethanol was evaporated and the 
unreacted 2-methylbenzyl bromide was removed by extraction with ether. Then the aqueous 
solution was extracted with ethyl acetate at pH 2~3 by citric acid and washed with brine. After 
drying over MgSO4 and concentrating, the resulting Boc-DL-Phe(2-Me)-OEt(OH) was 
obtained(90%). The residue was dissolved in toluene (100 mL) and refluxed for 5 hours and 
toluene was evaporated and then was purified by silica gel chromatography to obtain 
Boc-DL-Phe(2-Me)-OEt (81%). Finally Boc-DL-Phe(2-Me)-OEt was subjected to the action of 
subtilisin Carlsberg from Bacillus licheniformis (Sigma) in a mixture of DMF and H2O (1:3, 
v/v) at 37 0C. The aqueous solution was extracted with ethyl acetate at pH 3 to obtained 
Boc-L-Phe(2-Me)-OH was isolated as colorless oil (85%). Characterization data for: HPLC: r.t. 
6.853 min, 100%. [α]D26 = +11.18° (C, 2.3, CH3OH); ESI-MS: [M-H]+ 278.0, [M+Cl]- 314.0 for 
C15H21NO4 (calcd 279.33). IR(Neat): 3333(NH), 3023, 2980(CH), 1707 (C=O,COOH), 
1659(C=O, -CONH), 1591, 1494(C=C, Ar), 1169, 1049(CN).  1H-NMR (400 MHz, DMSO): δ 
1.33(s, 9H), 2.26(s, 3H), 3.18(m, 1H), 3.60(s, 1H), 4.12 (s, 1H), 7.04(m, 4H). 
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3.2.1.2 Synthesis of Boc-L-Phe(2-Me)-OH from diethyl acetamidomalonate 
Metallic sodium (1.24 g, 54 mmol) was dissolved in anhydrous EtOH (54 mL) and diethyl 
acetamidomalonate (14.08 g, 64.8mmol) was added to the solution. After refluxing for 30 
minutes, the mixture was cooled to room temperature and then 2-methylbenzyl bromide (10 g, 
54 mmol) was added and refluxed for 5 hours. The reaction mixture was carried out by the 
addition of 3N NaOH aq ( 20 mL) for Hydrolysis. Ethanol was evaporated and the unreacted 
2-methylbenzyl bromide was removed by extraction with ether. Then the aqueous solution was 
extracted with ethyl acetate at pH 2~3 by HCl and washed with brine. After drying over MgSO4 
and concentrating, the resulting Ac-DL-Phe(2-Me)-OEt(OH) was obtained (60–80%). The 
residue was dissolved in toluene (100 mL) and refluxed for 5 hours and toluene was evaporated 
and then was purified by silica gel chromatography to obtain Ac-DL-Phe(2-Me)-OEt (9.58 g, 
43.3 mmol, 80%). The residue was dissolved in ethanol (50 mL) and hydrolysis and work up 
was carried out as described above to get Ac-DL-Phe(2-Me)-OH (75%). The Ac-DL-Phe(2-Me) 
-OH (43.3 mol) was dissolved in water (170 mL) at pH 7 by the addition of 1N NaOH aq.(43 
mL, 43 mmol). Then CoCl2·6H2O (51.5 mg, 1 mM) and acylase (2.2 g) were added and 
incubated at 380C for 24 hours. H-L-Phe(2-Me)-OH (2.1 g, 11.7 mmol) was solidified from the 
aqueous solution and was filtered after cooling the reaction mixture and washed with water and 
ethanol. The aqueous solution was extracted with ethyl acetate at pH 3 to recover 
Ac-D-Phe(2-Me)-OH(59%). The Boc protection of H-L-Phe(2-Me)-OH yielded Boc-L- 
Phe(2-Me)-OH as colourless oil in quantitative yield (95%).  
3.2.2 Synthesis of Boc-L-Phe(3-Me)-OH 
Boc-L-Phe(3-Me)-OH was synthesized in the same manner as 3.2.1.1 described reaction to 
obtain as white foam (43%). Characterization data for: HPLC: r.t. 6.987 min. [α]D26 = 
+11.33°(C, 2.6, CH3OH); ESI-MS: [M-H]+ 278.0, [M+Cl]- 314.0 for C15H21NO4 (calcd 279.33). 
IR(Neat): 3342(NH), 2978, 2934(CH), 1716(C=O, COOH), 1610(NH, -CONH), 1591, 
1506(C=C, Ar), 1166, 1057(CN); 1H-NMR (400 MHz, DMSO): δ 1.31(s, 9H), 2.29(s, 3H), 
2.89(m, 1H), 3.36(s, 1H), 4.09 (s, 1H), 7.15(m, 4H). 
3.2.3 Synthesis of Boc-L-Phe(4-Me)-OH 
Boc-L-Phe(4-Me)-OH was synthesized in the same manner as 3.2.1.1 described reaction to 
obtain as white foam (48%). Characterization data for: HPLC: r.t. 7.024 min. [α]D30 = 
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+12.39°(C, 1.7, CH3OH); ESI-MS: [M-H]+ 278.0, [M+Cl]- 314.0 for C15H21NO4 (calcd 279.33). 
IR(Neat): 3331(NH), 2978, 2930(CH), 1716(C=O,COOH), 1515, 1484 (C=C, Ar), 1166, 
1056(CN); 1H-NMR (400 MHz, DMSO): δ 1.27(s, 9H), 2.20(s, 3H), 2.78 (s, 1H), 3.52(m, 1H), 
4.02 (m, 1H), 7.06(m, 4H). 
3.2.4 Synthesis of Boc-L-Phe(3,5-2Me)-OH 
Boc-L-Phe(3,5-2Me)-OH was synthesized in the same manner as 3.2.1.1 described reaction to 
obtain as white foam (2.06 g, 7.8 mmol, 33%). HPLC: r.t. 7.136 min. ESI-MS: [M-H]+ 292.0, 
[M+Cl]- 328.0 for C16H23NO4 (calcd 293.36). 
3.3 Synthesis of n-methyl-amino-cyclohexane-carboxylic acid 
In the field of organic chemistry for the synthesis of α-aminonitriles, the Strecker reaction is one 
of the most efficient and straightforward method,[10] which is very useful precursors for the 
synthesis of α-amino acids or various nitrogen-containing heterocycles.[11,12] α-Amino acids are 
also of great biological and economical importance due to their significance in chemistry and 
biology. Herein, author designed and synthesized three kinds of n-methyl-amino-cyclohexane- 
carboxylic acids: (±)2-methyl-amino-cyclohexane-carboxylic acid (A2mc6c), 3-methyl- 
amino-cyclohexane-carboxylic acid (A3mc6c) and 4-methyl-amino-cyclohexane-carboxylic 
acid (A4mc6c)  based on  the reported procedure as illustrated in Scheme 3.2. These amino 
acids were used for the synthesis of designed HDAC inhibitors of cyclic tetrapeptides in 
Chapter 4. This reaction conditions was crucial for using NaCN for conversion the starting 
material methylcyclohexanone to methylcyclohexane amino nitrile. The use of an excess of 
ketone ensured that complete consumption of NaCN occurred. The optimal conditions involved 
concentration of nearly all the NH3/MeOH from the reaction mixture under reduced pressure 
and temperature, dilution with MTBE, and filtration of the inorganic solids.[13] Hydrolysis of 
methylcyclohexane amino nitrile in 50% H2SO4 was refluxed for 24 hours to provide a crude 
 
 
Scheme 3.2 Synthesis of n-methyl-amino-cyclohexane-carboxylic acids (H-Anmc6c-OH). 
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aqueous solution of  n-methyl-amino-cyclohexane-carboxylic acids followed by adjusting the 
pH to 5 ~ 6 by the addition of 10 N NaOH to separate out products.  
3.3.1 Synthesis of H-(±)A2mc6c-OH 
3.3.1.1 Preparation of (±)2-methyl-cyclohexane amino nitrile (MW=138.21): 
MgSO4 (6.14 g, 51.0 mmol), NH4Cl (2.73 g, 51.0 mmol), NaCN (4.75 g, 96.9 mmol) was 
dissolved into 7 M NH3 in MeOH (58 mL) in a round-bottom flask. The solution was stirred and 
cooled to -5 0C to -10 0C. The internal temperature of the slurry was -5 0C and rose to 8  0C after 
stirring for 10 minutes as some of the solids dissolved. To the solution was added 
(±)2-methylcyclohexanone (13 mL, 102.0 mmol). The internal temperature slowly rose from 8 
0C to 35 0C over the course of 1 hour, at which point it slowly decreased to 30 0C and was held 
at this temperature for 15 hours. The reaction was monitored by TLC. The solvent was then 
removed under reduced pressure (~30 mmHg) while maintaining the internal temperature < 30 
0C until nearly all of the MeOH and ammonia were removed. The resulting slurry of inorganic 
salts and the product was diluted with 66 mL of MTBE, stirred at room temperature for 30 min, 
and filtered. The inorganic wet cake was washed with MTBE (10 mL). The solvent was 
concentrated under reduced pressure (~30 mmHg) while maintaining the internal temperature < 
20 0C. The amino nitrile as oily compound was obtained (14.1 g, 102.0 mmol). TLC: Rf 0.8 
(CHCl3/MeOH/CH3COOH = 90/10/2).  
3.3.1.2 Synthesis of (±)2-methyl-amino-cyclohexane-carboxylic acid (MW= 157.1103): 
To the oily compound was added 64 mL (6 eq) of 50% v/v of H2SO4, and subjected to the 
carboxylation by refluxing. The reaction mixture was then heated to 100 0C for 24 hours. The 
reaction mixture was allowed to cool to room temperature, and the pH was adjusted to 5 ~ 6 by 
the portion addition of 10 N NaOH. The amino acid was separated out and filtered. The wet 
cake was washed with water and dried under air-dry for 24 hours to give 6.1 g (38.8 mmol, 39%) 
of  H-(±)A2mc6c-OH as an analytically pure colorless solid. HR-FAB-MS: [M+H]+ 158.1196, 
for C8H16NO2 (calcd 157.1103). 
3.3.2 Synthesis of H-A3mc6c-OH 
3.3.2.1 Preparation of 3- methyl-cyclohexane amino nitrile (MW=138.21): 
NH4Cl (11.50 g, 214 mmol), NaCN (10.04 g, 210 mmol) was dissolved into NH3(aq. conc.) (37 
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mL) and H2O (53 mL). To the solution was added 3-methylcyclohexanone (25 mL, 200 mmol) 
in ether (17 mL). After stirring for 68 hours at room temperature. The reaction was monitored 
by TLC. The solution was dissolved in ether, and then washed with water. The 
superfluous NaCN was removed by water layer. After concentrating ether, the resulting oily 
substance was obtained 3-methylcyclo hexanone amino nitrile (27.65 g, 200 mmol, 100%). 
TLC: Rf 0.65 (CHCl3/MeOH/ CH3COOH = 90/10/2).  
3.3.2.2 Synthesis of 3-methyl-amino-cyclohexane-carboxylic acid (MW= 157.1103): 
To the oily compound was added 6 N HCl (58 mL), CH3COOH (58 mL) and subjected to the 
carboxylation by refluxing. The reaction mixture was then heated to 100 0C for 96 hours. The 
reaction mixture was allowed to cool to room temperature, and the pH was adjusted to 5 ~ 6 by 
the portionwise addition of 10 N NaOH. The amino acid was separated out and filtered. The wet 
cake was washed with water and dried under air-dry for 24 hours to give 1.2 g (7.8 mmol, 3.9%) 
of 3-methyl-cyclohexane amino acid as white foam. HR-FAB-MS: [M+H]+ 158.1121, for 
C8H16NO2 (calcd 157.1103). 
3.3.3 Synthesis of H-A4mc6c-OH 
3.3.3.1 Preparation of 4-methyl-cyclohexane amino nitrile (MW=138.21): 
NH4Cl (8.94 g, 167 mmol), NaCN (7.79 g, 159 mmol) was dissolved into NH3 (aq. conc.) (28 
mL) and H2O (40 mL). To the solution was added 4-methylcyclohexanone (17 mL, 152 mmol) 
in ether (17 mL). After stirring for 68 hours at room temperature. The reaction was monitored 
by TLC. The solution was dissolved in ether, and then washed with water. The 
superfluous NaCN was removed by water layer. After concentrating ether, the resulting oily 
substance was obtained 4-methylcyclo hexanone amino nitrile (22.00 g, 152 mmol, 100%). 
TLC: Rf 0.65 (CHCl3/MeOH/ CH3COOH = 90/10/2).  
3.3.3.2 Synthesis of 4-methyl-amino-cyclohexane-carboxylic acid (MW= 157.1103): 
To the oily compound was added 6 N HCl (58 mL), CH3COOH(58 mL) and subjected to the 
carboxylation by refluxing. The reaction mixture was then heated to 100 0C for 96 hours. The 
reaction mixture was allowed to cool to room temperature, and the pH was adjusted to 5 ~ 6 by 
the portionwise addition of 10 N NaOH. The amino acid was separated out and filtered. The wet 
cake was washed with water and dried under air-dry for 24 hours to give 0.16 g (0.76 mmol, 
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0.5%) of H-A4mc6c-OH as white foam. HR-FAB-MS: [M+H]+ 158.1152, for C8H16NO2 (calcd 
157.1103). 
3.3.4 Synthesis of Z-Anmc6c-OH 
To a suspension of n-methyl-amino-cyclohexane-carboxylic acid (5 mmol) in acetone (5 mL) 
and water (5 mL) were added Z-Osu (5 mmol) and triethyl amine (15 mmol). After stirring for 
overnight, acetone was removed by evaporation; residue was extracted by ether, the water layer 
was added ethyl acetate, and then washed with an aqueous 10% citric acid solution and brine. 
After drying over MgSO4 and concentrating, the resulting crude product was purified by 
crystallization in diethyl ether/petroleum ether (1:9 v/v) to yield ( 85-90%). 
3.4 Synthesis of amino acid containing chlorine 
Boc-2- amino-chloro-pentanoic acid (Boc-L-Ac5-OH) and Boc-2-amino-chloro-hexanoic acid 
(Boc-L-Ac6-OH) were synthesized using the same manner as 3.2.1 described reaction to obtain 
(Scheme 3.3). The two amino acid were used for the synthesis of designed HDAC inhibitors of 
cyclic tetrapeptides in Chapter 6. The two reason of synthesis (Ac5) and (Ac6):  hydrophobic 
L-Ac5 and L-Ac6 replaced L-Phe at 3-position of cyclic tetrapeptide scaffold, to compare their 
inhibit HDAC activity with reported HDAC inhibitors and probe deeply into essential of 
aromatic ring in cyclic framework;  the side chain containing chlorine of L-Ac5 or L-Ac6 may 
be modified with oxygen or sulfur to chelate zinc ion of HDAC active pocket bottom.  
 
3.4.1 Synthesis of Boc-L-2-amino-5-chloropentanoic acid   
3.4.1.1 Synthesis of Boc-DL-Ac5-OEt(OH) (MW=323.77): 
 
Scheme 3.3 Synthesis of amino acid containing chlorine. 
Reagents and conditions: (a) Na, anhyd EtOH, reflux, 30 min; (b) Br(CH2)3 or 4Cl, reflux, 6 h; (c) NaOH 
aq., EtOH, 4 h; (d) toluene, reflux, 3 h; (e) subtilisin Carlsberg, DMF/H2O (1/3), 4 h. 
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Metallic sodium (2.3 g, 100 mmol) was dissolved in anhydrous EtOH (100 mL) and diethyl 
(Boc-amino)malonate (27.5 g, 140 mmol) was added to the solution. After refluxing for 30 
minutes, the mixture was cooled to room temperature and then 1-bromo-3-chloro-propane (17.3 
g, 110 mmol) was added and refluxed for 5 hours. Ethanol was evaporated, and then the 
aqueous solution was extracted with ethyl acetate and washed with water and brine. After 
drying over MgSO4 and concentrating, the resulting 2-tert-butoxycarbonylamino-2-(3-chloro- 
propyl)-malonic acid diethyl ester (Boc-DL-Ac5-OEt(OEt)) was obtained (32.1 g, 91.2 mmol, 
91%). The reaction mixture was carried out by the addition of one equivalent of 1 M NaOH 
(150 mL) at low temperature (00C) for hydrolysis in three aliquots with 30 minutes time interval. 
The reaction product was checked by TLC (Rf 0.20, CHCl3/MeOH=9/1). After 4 hours, ethanol 
was evaporated and the unreacted 1-bromo-3-chloro-propane was removed by extraction with 
4% NaHCO3 and ether. Then the aqueous solution was extracted with ethyl acetate at pH 2~3 by 
citric acid and washed with brine. After drying over MgSO4 and concentrating, the resulting 
2-tert-butoxycarbonylamino-2-(3-chloro-propyl)-malonic acid monoethyl ester (Boc-DL-Ac5- 
OEt(OH)) was obtained(20.1 g, 62.1 mmol, 68%).  
3.4.1.2 Synthesis of Boc-L-Ac5-OH (MW=251.71): 
The residue was dissolved in toluene (100 mL) and refluxed for 5 hours and checked by TLC 
(Rf  0.8, CHCl3/MeOH=9/1) and toluene was evaporated and then was purified by silica gel 
chromatography (φ5.0 x 20 cm, 1% methanol/chloroform) to obtain 2-tert-butoxycarbonyl-5- 
chloro pentanoic acid ethyl ester (11.0 g, 39.3 mmol, 63%, HPLC: r.t. 5:30 min, B: 0-100%). 
Finally Boc-DL-Ac5-OEt (11.0 g, 39.2 mmol) was subjected to the action of subtilisin (40 mg) 
Carlsberg from Bacillus licheniformis (Sigma) in a mixture of DMF (40 mL) and H2O (120 mL) 
at pH 7, 37 0C for 4 hours. The aqueous solution was extracted with ethyl acetate at pH 3 to 
obtained 2-tert-butoxycarbonyl-5-chloro-pentanoic acid (Boc-L-Ac5-OH) was isolated as 
colorless oil (4.9 g, 19.4 mmol, 50%, HPLC:  r.t. 5.36 min, B: 0-100%).  
3.4.2 Synthesis of Boc- L-2-amino-6-chlorohexanoic acid 
3.4.2.1 Synthesis of Boc-DL-Ac6-OEt(OH) (MW=337.80): 
Metallic sodium (2.3 g, 100 mmol) was dissolved in anhydrous EtOH (100 mL) and diethyl 
(Boc-amino) malonate (27.5 g, 140 mmol) was added to the solution. After refluxing for 30 
minutes, the mixture was cooled to room temperature and then 1-bromo-4-chloro-butane (18.9 
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g, 110 mmol) was added and refluxed for 5 hours. Ethanol was evaporated, and then the 
aqueous solution was extracted with ethyl acetate and washed with water and brine. After 
drying over MgSO4 and concentrating, the resulting 2-tert-butoxycarbonylamino-2-(4-chloro- 
butyl)-malonic acid diethyl ester (Boc-DL-Ac6-OEt(OEt)) was obtained (32.1 g, 87.7 mmol, 
88%). The reaction mixture was carried out by the addition of one equivalent of 1 M NaOH 
(150 mL) at low temperature (00C) for hydrolysis in three aliquots with 30 minutes time interval. 
The reaction product was checked by TLC (Rf 0.30, CHCl3/MeOH=9/1). After 4 hours, ethanol 
was evaporated and the unreacted 1-bromo-3-chloro-propane was removed by extraction with 
4% NaHCO3 and ether. Then the aqueous solution was extracted with ethyl acetate at pH 2~3 by 
citric acid and washed with brine. After drying over MgSO4 and concentrating, the resulting 
2-tert-butoxycarbonylamino-2-(4-chloro-butyl)-malonic acid monoethyl ester (Boc-DL-Ac6- 
OEt (OH)) was obtained (20.1 g, 59.5 mmol, 68%).  
3.4.2.2 Synthesis of Boc-L-Ac6-OH (MW=293.79): 
The residue was dissolved in toluene (100 mL) and refluxed for 5 hours and checked by TLC 
(Rf 0.8, CHCl3/MeOH=9/1) and toluene was evaporated and then was purified by silica gel 
chromatography(φ5.0 x 20 cm, 1% methanol/chloroform) to obtain 2-tert-butoxycarbonyl- 
6-chloro-hexanoic acid ethyl ester (15.6 g, 53.1 mmol, 89%, HPLC: r.t. 5:30 min, B: 0-100%). 
Finally Boc-DL-Ac6-OEt (15.6 g, 53.1 mmol) was subjected to the action of subtilisin (40 mg) 
Carlsberg from Bacillus licheniformis (Sigma) in a mixture of DMF (40 mL) and H2O (100 mL) 
at pH 7, 37 0C for 4 hours. The aqueous solution was extracted with ethyl acetate at pH 3 to 
obtained 2-tert-butoxycarbonyl-6-chloro-hexanoic acid (Boc-L-Ac6-OH) was isolated as 
colorless oil (10.8 g, 40.6 mmol, 76%, HPLC:  r.t. 5.97 min, B: 0-100%).  
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Chapter 4  
Molecular Design of Cyclic Tetrapeptide HDAC Inhibitors by 
Replacement of Aib in Chlamydocin Framework 
4.1 Introduction 
Deregulation of HAT and HDAC has been implicated in the formation and development of 
certain human cancers by changing the expression pattern of various genes. It is therefore 
proposed that HDACs are a potential target for the development of anticancer agent. As a result, 
design and synthesis of novel HDAC inhibitors is a promising field for research. The search for 
compounds with antitumor activities to develop novel HDAC inhibitors with potency and 
safety has been still going on. Recently, scientists have been reported HDAC inhibitors as 
naturally occurring HDAC inhibitors, Trichostatin A (TSA),[1] depsipeptide FK228,[2-4] 
Chlamydocin,[5] Trapoxin,[6] Cyl-1,[7] Cyl-2,[8] HC-toxins,[9] Apicidin.[10,11] Synthetic 
TSA-related, SAHA-related,[12-14] CHAPs,[15,16] SCOPs,[17] and Chlamydocin analogs with 
various binding functional groups[18,19] inhibitors have been also reported. All these inhibitors 
exhibit the inhibitory activity for zinc-dependent HDAC classes I and II. Several of these 
HDAC inhibitors inhibit tumor growth and many of them are under clinical trials. Base on 
X-ray crystallography, inhibition model of HDLP is proposed and it consists of three domains: 
a zinc binding site; a surface recognition with capping group; a linker connecting the zinc 
binding and surface recognition.[20] It is plausible that the active site and linker unit are essential 
but only bind to the pocket in enzyme, a capping site covering the rim surrounding binding 
pocket determine the selectivity of HDAC inhibitors. As the rim of the opening to the binding 
pocket has less homology between HDAC isoforms at the active site, the modification of cap 
group allows having a significant impact upon isoform selectivity.[21] The surface of the HDAC 
enzymes that surrounds the binding pocket has multiple grooves,[22] which could be exploited 
by inhibitors with appropriate cap groups to improve potency and selectivity of inhibitors. 
Modification of the cap group of HDAC inhibitors can lead to increase significantly the 
selectivity aim at HDAC isoforms.[23] 
In this Chapter of thesis, based on naturally occurring HDAC inhibitors, trichostatin A (TSA) 
and Chlamydocin, we designed and synthesized a series of HDAC inhibitors bearing surface 
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recognition of Chlamydocin framework and zinc binding site of TSA. Chlamydocin is a cyclic 
tetrapeptide containing an epoxyketone moiety in the side chain so that it is an irreversible 
inhibitor of HDAC. Author replaced the epoxyketone moiety of Chlamydocin with hydroxamic 
acid to design potent and reversible inhibitors of HDAC. In addition, a series of methyl- 
amino-cyclohexane-carboxylic acids (Anmc6c) were introduced instead of the amino-isobutric 
acid (Aib) for a variety of Chlamydocin analogues (Fig. 4.1). The replacement of Aib residue of 
Chlamydocin with an aliphatic ring (Anmc6c) enhanced the in vivo and in vitro inhibitory 
activity. These compounds were tested for HDAC inhibitory activity and the results showed 
that they were potent inhibitors of HDACs. We also tested for antiproliferative in vitro by MTT 
assay against MCF-7 (human breast cancer), Hela (human cervix cancer), K-562 (human 
leukemia) and 7721 (human liver cancer) cell lines. All compounds exhibited nanomolar 
 
 
 
Fig. 4.1 Design and synthsis Chlamydocin–hydroxamic acid analogues. 
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concentration antitumor activities. We have carried out circular dichroism and molecular 
docking studies on Chlamydocin–hydroxamic acid analogue and HDLP, HDAC8 and HDAH, 
respectively.  
4.2 Results and discussion 
4.2.1 Chemistry 
Herein we synthesized potent HDAC inhibitors based on the natural product Chlamydocin and 
TSA. Author proposed to synthesize Chlamydocin–hydroxamic acid analogue for replacing the 
epoxyketone moiety of Chlamydocin by hydroxamic acid of TSA as the zinc binding group, 
Ky-2 was synthesized. we prepared non-natural amino acids (methyl-amino-cyclohexane- 
carboxylic acids (Anmc6c)) described in 3.3 of Chapter 3 to replace Aib residue at 2-position of 
Ky-2. For this, we initially synthesized Chlamydocin–hydroxamic acid analogue using 
solution-phase peptide coupling method as show in Scheme 4.1. tert-Butyl protected D-Pro 
was coupled with Z-L-Phe to give the dipeptide Z-L-Phe-D-Pro-OtBu. The Z group of dipeptide 
was deprotected by catalytic hydrogenation and coupled with Z-Aib using DCC/HOBt orderly. 
The Z group of the resulted tripeptide Z-Anmc6c-L-Phe-D-Pro-OtBu was deprotected by 
catalytic hydrogenation. It was then coupled with Boc protected amino suberic acid benzyl ester 
(Boc-L-Asu(OBzl)) to give  linear tetrapeptide Boc-L-Asu(OBzl)-Anmc6c-L-Phe-D-Pro-OtBu. 
 
 
 
Scheme 4.1  Synthetic strategy of Chlamydocin–hydroxamic acid analogue. 
Reagents: (a) H2, Pd/C, MeOH; (b) HCl·NH2-OBzl, DCC/HOBt, DMF; (c) Pd-BaSO4, CH3COOH.  AA:  
A2mc6c, A3mc6c, A4mc6c. 
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The C-terminal and N-terminal protections of the tetrapeptide were removed by treatment with 
trifluoroacetic acid (TFA) and the resulted linear peptide was cyclized in DMF under high 
dilution condition using HATU as a coupling reagent to give cyclo(-L-Asu(OBzl)-Anmc6c- 
L-Phe-D-Pro-) in 60~70% yield. The OBzl of side chain of cyclic peptide was deprotected by 
catalytic hydrogenation and then coupled with hydroxylamine hydrochloride and the resulted 
product was deprotected by catalytic hydrogenation to yield the desired compounds and finally 
purified using gel filtration. We replaced Aib residue with non-natural amino acids to study the 
effect on the HDACs inhibitory activity. All the synthesized compounds were characterized by 
1H NMR and high resolution FAB-MS (HR-FAB-MS). The purity of the compounds was 
determined by HPLC analysis and all the synthesized cyclic tetrapeptides showed purity above 
97%. 
4.2.2 Enzyme inhibition and biological activity 
We  assayed these synthesized compounds for HDACs inhibitory activity using HDAC1, 
HDAC4 and HDAC6 enzymes prepared by 293T cells. In addition, to know the inhibitory 
activity of these compounds in cell based condition, we carried out p21 promoter assay. The 
results of HDAC inhibitory activity and the p21 promoter assay of compounds are shown in 
Table 4.1.  
Inhibitory activity of Trichostatin A and Ky-2 are also shown in Table 4.1 for comparison with 
synthesized compounds. These compounds showed good activity in both cell free and cell 
based conditions in nanomolar range. Further, these compounds were poorly inhibited by 
 
 
Table 4.1 HDAC inhibitory activity and p21 promoter assay data 
No. Compounds 
HDAC inhibitory activites IC50 (nM) p21 
promoter 
activity 
EC1000 (nM)
HDAC1 HDAC4 HDAC6 
 Trichostatin A 23 34 65 20.0 
Ky-2 cyclo(-L-Asu(NHOH)-Aib-L-Phe-D-Pro-) 18 17 230 18.0 
Ky-301 cyclo(-L-Asu(NHOH)-A2mc6c-L-Phe-D-Pro-) 10 6.4 130 8.0 
Ky-302 cyclo(-L-Asu(NHOH)-A3mc6c-L-Phe-D-Pro-) 15 14 160 2.9 
Ky-303 cyclo(-L-Asu(NHOH)-A4mc6c-L-Phe-D-Pro-) 11 12 170 4.3 
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HDAC6 compared to HDAC1 and HDAC4 and their selectivity was 10 times better 
(HDAC6/HDAC1 = 10). In the cellular activity, compound Ky-302 showed the best activity 
than Ky-301 and Ky-303, which 6-fold increased than Ky-2 and Trichostatin A. All of the 
cyclic tetrapeptides were excellent in p21 promoter-inducing activity. This was probably 
because of the presence of an aliphatic ring (Ac6c) of hydrophobicity which increased interacts 
with the rim of HDACs active pocket. Also cell permeability was enhanced in this case, which 
was reflected in their p21 activity data. The variation of HPLC retention time, which can be 
used as a parameter for hydrophobicity, could be correlated with p21 promoter-inducing 
activity. 
4.2.3 Cell growth inhibitory assay 
The compounds were tested for antiproliferative in vitro by MTT assay against MCF-7 (human 
breast cancer), Hela (human cervix cancer), 7721 (human liver cancer) and K-562 (human 
leukemia) cell lines. Three HDAC inhibitors were added to culture medium at the 
concentrations of 20, 40, 60, 80, 100 nM. The IC50 was shown in Table 4.2. All compounds 
showed good antitumor activities, which inhibited cell proliferation at nanomolar concentration. 
All these three compounds had selectivity for the four human cancer cell lines, futher, showed 
better sensitivity on MCF-7 than the other cell lines. The compound Ky-302 showed a stronger 
activity than the other two for Hela and K-562 cell lines. The result coincided with the data from  
p21 promoter assay activity experiment. 
 
Table 4.2 Cell growth inhibitory assay data  
Compounds 
IC50 (μM) 
Hela MCF-7 7721 K-562 
Ky-301 0.295 0.030 0.213 > 3.5 
Ky-302 0.048 0.026 0.297 0.044 
Ky-303 0.232 0.043 0.262 > 3.5 
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4.2.4 Morphological reversion  
The inhibitors were found to induce dramatic changes in cellular shape under light microscopy. 
After the MCF-7 cell and 7721 cell were treated by the synthesized compounds with 
concentration of 100 nM for 24 hours, which were supposed to be changed into flattened, 
rounded and spindle shapes, and the cellular borders became obviously bigger and gaps among 
cells (Fig. 4.2). 
 
 
   
 
Fig. 4.3 CD spectra of cyclic tetrapeptides.  
     
(a)                                                                                 (b) 
 
Fig. 4.2 Morphological reversion of (a) MCF-7 and (b)7721 cell lines (×400). 
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4.2.5 Conformational studies by CD and NMR 
We carried out circular dichroism (CD) spectrum study of compounds Ky-301, Ky-302 and 
Ky-303, in solvent of 0.1 mM methanol (Fig. 4.3). The CD spectrum of  three compounds were 
similar to Chlamydocin and Ky-2’s (cyclo(-L-Asu(NHOH)- Aib-L-Phe-D-Pro-) up to 260 
nm.[19] Three compounds showed two negative ellipticity at 210 nm and 245 nm regions, a 
positive ellipticity at 230 nm regions with small but reproducible difference. This fact showed 
that three compounds have similar conformations with Ky-2’s. 
We have carried out NMR (CDCl3) studies for conformation of these inhibitors by MOE 
calculations (Fig. 4.4). Solution conformations of Ky-301, Ky-302 and Ky-303 were studied by 
using 1H NMR in CDCl3. Complete assignments were made by using COSY and NOESY 
spectra. The JNH-HCα values were obtained from NMR charts and by that we estimated dihedral 
angle “θ,” using the Karplus graph. Dihedral angles θ and φ, and NOE data are shown in Table 
4.3. The energy-minimized structures of three compounds were calculated by MOE. The 
structure of Ky-302 is a little different from other two compounds at zinc binging group. 
 
  
 
 
Fig. 4.4 MOE of energy-minimized structures of compounds by NMR calculation. NOE (Å) (green line), 
Dihedral angle (φ) (red line). Ky-301(top left), Ky-302(top right), Ky-303(below left) and 
Superimposition of three compounds (below right). Ky-301and  Ky-303(stick), Ky-302(ball and stick) 
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4.2.6 Docking and molecular dynamics simulation for HDAC inhibitors towards HDACs 
To understand the binding modes between these cyclic tetrapeptides and different HDACs, 
docking studies were conducted with AutoDock 4.0 program.[24,25] AutoDock docking protocol 
and scoring function have been successful applied in the study of  interpretation of the 
inhibitory activity of several HDAC ligands.[26,27] Three enzymes, a bacterial HDAC-like 
protein (HDLP)  resembling a class I enzyme,[28] shows a 35.2% sequence identity to human 
HDAC1, a bacterial HDAC-like amidohydrolase (HDAH),[29] which has high sequential and 
functional homology to human class II HDACs and HDAC8[30] were used. The active site of 
HDAC protein was covered by a grid box size of 70×70×70 points with a spacing of 0.375 Å 
between the grid points. For cyclic tetrapeptides, all single bonds except the amide bonds and 
cyclic bonds were treated as active torsional bonds. For each inhibitor, one hundred and fifty 
independent dockings, i.e. 150 runs, were performed using genetic algorithm searches. A 
maximum number of 250 000 000 energy evaluations and a maximum number of 5000 
generations were implemented during each genetic algorithm run. A mutation rate of 0.02 and a 
crossover rate of 0.8 were used. The crossover mode was arithmetic. Default nonbonded zinc 
parameters in Autodock 4.0 were employed. Results differing by less than 2.0 Å in positional 
root-meaning- square deviation (RMSD) were clustered together and represented by the result 
with the most favorable free energy of binding. The RMSD value is an all heavy atom 
Table 4.3 NOE, coupling constant and dihedral angles data of compounds from NMR. 
 
Ky-301 Ky-302 Ky-303 
AA NOE 
JNH-HCα 
(Hz) 
θ° φ° NOE JNH-HCα 
(Hz) 
θ° φ° NOE JNH-HCα 
(Hz) 
θ° φ° 
L-Asu 
L-Asu 
(NH-HCα) 
(NH-HCβ) 
7.2 148 -152 
L-Asu 
(NH-HCα) 
(NH-HCβ) 
9.2 170 -130 
L-Asu 
(NH-HCα) 
6.8 142 -158 
Anmc6c -- -- -- -- -- -- -- -- 
A4mc6c 
(NH-HCβ) 
-- -- -- 
L-Phe 
L-Phe 
(NH-HCα) 
(NH-HCβ) 
10 180 -120 
L-Phe 
(NH-HCα) 
(NH-HCβ) 
10 180 -120 
L-Phe 
(NH-HCα) 
(HN-HCβ) 
10 180 -120 
D-Pro -- -- -- -- -- -- -- -- -- -- -- -- 
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comparison between the docked structure and the initial structure. The LigPlot program[31] was 
also employed to analyze the docking results focusing on hydrogen bonds and hydrophobic 
interactions.  
As expected, the results showed that three compounds (Ky-301, Ky-302 and Ky-303) bound to 
the active site of HDAC8 (Fig. 4.5), HDLP (Fig. 4.6) and HDAH (Fig. 4.7), the aliphatic chain 
was occupying the long, narrow channel, hydroxamic group was at the bottom of this channel, 
and the large cap domain interacted with external surface of these enzymes. And all compounds 
shared similar interaction mode with three enzymes. Fig. 4.8 shows superimposition of three 
compounds in surfaces of the active site regions with HDAC8, HDLP and HDAH, respectively. 
In HDLP-inhibitors complexes, the aromatic ring of Phe and aliphatic ring of Anmc6c are bent 
to Try194 and Phe139, respectively. But, in HDAH-inhibitors complexes, the aromatic ring is 
vertical to Phe206. This study further supports the fact that, compared to class IIb HDAC, the 
inhibitors are favorable interactions with the surface binding to class I HDACs, hence showed 
high activity. 
For each enzyme, one enzyme-inhibitor complex was chosen to analyze the hydrogen bonds 
and hydrophobic interactions between HDACs and cyclic tetrapeptides (Fig. 4.9, Fig. 4.10 and 
Fig. 4.11). It showed that the hydroxy oxygen of tetrapeptide coordinated to zinc ion, it was the 
precondition of these HDAC inhibitors for their inhibitory activities. These compounds 
established hydrophobic interactions with some amino acid residues, such as Phe139, Lys222, 
Lys265, Phe196, Gln190, Ala195 of HDLP, Ile98, Phe150, Pro208, Asp98 of HDAH and 
Phe187, Gly186, Tyr80, Met254 of HDAC8, the hydrophobic effects were also crucial for 
stabilizing the complexes.  
 
       
   HDAC8-Ky301                               HDAC8-Ky302                               HDAC8-Ky303 
Fig. 4.5 Top view of the surfaces of the active site regions of HDAC8-inhibitors complexes for docking.
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HDAH-Ky301                                 HDAH-Ky302                                   HDAH-Ky303 
Fig. 4.7 Top view of the surfaces of the active site regions of HDAH-inhibitors complexes for docking. 
         
HDLP-Ky301                                    HDLP-Ky302                                   HDLP-Ky303 
Fig. 4.6 Top view of the surfaces of the active site regions of HDLP-inhibitors complexes for docking. 
     
     HDAC8-inhibitors complex             HDLP-inhibitors complex               HDAH-inhibitors complex  
Fig. 4.8 Superimposition in surfaces of the active site regions. 
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Fig. 4.10 Hydrophobic interactions and hydrogen bonds at binding site HDLP-Ky302 complex. 
 
 
Fig. 4.9 Hydrophobic interactions and hydrogen bonds at binding site of HDAC8-Ky301 complex. 
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In the HDAC8-Ky301 complex, the zinc ion that lay at the end of the hydrophobic tunnel was 
bound to two carboxylate oxygens of Asp158, Asp 247, respectively and the nitrogen atom of 
His160, the other two coordination sites were occupied by the carbonyl and hydroxyl oxygens 
of the  hydroxamate of zinc bing group of Ky-301. The average distances between zinc and the 
nearby atoms during the last 500 ps in current MD simulations are shown in Table 4.4. The 
calculational result of HDLP-Ky302 complex showed that zinc coordinates with seven atoms, 
including two carboxylate oxygens of Asp166 and Asp256, respectively, a nitrogen atom of 
His168, and  carbonyl and hydroxyl oxygens of the  hydroxamate of zinc bing group of Ky-302. 
However, in HDAH –Ky303 complex, the zinc ion  was bound to only two carboxylate oxygens 
of Asp178, a nitrogen atom of His180 and hydroxyl oxygens of zinc bing group of Ky-302. The 
results showed that the stability of HDAC8-Ky301 and HDLP-Ky302 complexes are stronger 
than HDAH –Ky303 complex. In the HDAC8-Ky301 complex and HDLP-Ky302 complex, the 
 
 
Fig. 4.11  Hydrophobic interactions and hydrogen bonds at binding site HDAH-Ky303 complex. 
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inhibitor bound to zinc atom in heptahedron geometry. But, in HDAH –Ky303 complex, it is in 
pentahedron geometry. The results showed that the stability for inhibitors binding to classI 
HDACs are stronger than classIIb HDAC. 
 
Table 4.4 Average zinc coordination distances for compounds  with enzymes in the MD simulations. 
Complex Atom1 Atom 2 Distance (Å) 
HDAC8 – Ky301 Zn2+ Ky-301:OH 1.76 
  Ky-301:CO 2.45 
  Asp 158:OD1 2.70 
  Asp 158:OD2 2.53 
  Asp 247:OD1 2.59 
  Asp 247:OD2 2.55 
  His 160:ND1 2.72 
HDLP – Ky302 Zn2+ Ky-302:OH 1.88 
  Ky-302:CO 2.66 
  Asp 166:OD1 2.58 
  Asp 166:OD2 2.46 
  Asp 256:OD1 2.64 
  Asp 256:OD2 2.50 
  His 168:ND1 2.63 
HDAH –Ky303 Zn2+ Ky-303:OH 1.93 
  Ky-303:CO 3.11 
  Asp 178:OD1 2.46 
  Asp 178:OD2 2.52 
  His 180:ND1 2.62 
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4.3 Summary 
We have successfully synthesized several Chlamydocin–hydroxamic acid analogues as HDAC 
inhibitors. We replaced Aib in 2-position of the Chlamydocin framework by several 
non-natural amino acid containing aliphatic rings with different methyl substitution position. 
HDAC inhibitory activity of inhibitors was evaluated in vitro and in vivo and it was found that 
the inhibitors were excellent potent toward HDAC enzymes within nanomolar range. The 
results indicated that append aliphatic ring of Chlamydocin can increase the inhibitory activity 
of HDACs. 
4.4 Experimental  
General: Unless otherwise noted, all solvents and reagents were reagent grade and used 
without purification. All compounds were routinely checked by thin layer chromatography 
(TLC) or high performance liquid chromatography (HPLC). Analytical HPLC were performed 
on a Hitachi instrument equipped with a chromolith performance RP-18e column (4.6 × 100 
mm, Merck). The mobile phases used were A: H2O and 0.1% TFA, B: CH3CN with 0.1% TFA 
using a solvent gradient of A to B over 15 min with detection at 220 nm with a flow rate of 2 
mL/min. TLC was performed on aluminium-backed silica gel plates (Merck DC-Alufolien 
Kieselgel 60 F254) with spots visualized by UV light and heat. Flash chromatography was 
performed using silica gel 60 (230-400) eluting with solvents as indicated. Fast atom 
bombardment mass spectra (FAB-MS) and high resolution fast atom bombardment mass 
spectra (HR-FAB-MS) were measured on a JEOL JMS-SX 102A instrument. NMR spectra 
were recorded on a VarianINO VA400 MHz spectrometer. All NMR spectra were measured in 
CDCl3 solutions with reference to TMS. All 1H shifts are given in parts per millions (s = singlet; 
d = doublet; t = triplet; m = multiplet). Peptide were coupled using standard solution-phase 
chemistry with dicyclohexylcarbodiimide (DCC), N-Hydroxybenzotriazole (HOBt). Peptide 
cyclization was mediated by N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl- 
methylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU). The cell lines 
for bioactive assay were all from Shanghai Institute of Biochemistry and Cell Biology, SIBS, 
CAS. The PRPMI 1640 for cell culture was purchased from Gibco, and MTT was from 
Hy-Clone. 
‐ 87 ‐ 
 
4.4.1 Synthesis of cyclo(-L-Asu(NHOH)-(±)A2mc6c-L-Phe-D-Pro-) 
4.4.1.1 Synthesis of Z-(±)A2mc6c-OH (MW=291.34): 
To a suspension of (±) 2-methyl-cyclohexanecarboxylic amino acid (1.57 g, 10.0 mmol) in 
acetone (10 mL) and water (10 mL) were added Z-Osu (2.7 g, 11.0 mmol) and Na2CO3 (2.1 g, 
20.0 mmol). After stirring for overnight, acetone was removed by evaporation; residue 
dissolved in ethyl acetate, and adjusted pH 2-3 with HCl, and then washed with brine. After 
drying over MgSO4 and concentrating, product was purified by crystallization in ether and 
petroleum ether (1:9 v/v) to yield Z-(±)A2mc6c-OH (1.68 g, 5.8 mmol, 59%), HPLC: r.t. 5.94 
min. 
4.4.1.2 Synthesis of Z-(±)A2mc6c-L-Phe-D-Pro-OtBu (MW = 591.74): 
The dipeptide was coupling in the same manner as 3.8.3 described to obtain 
H-L-Phe-D-Pro-OtBu (1.05 g, 3.3 mmol). To a cooled solution of H- L-Phe-D-Pro-OtBu (1.05 
g, 3.3 mmol) and Z-(±)A2mc6c-OH (962 mg, 3.3 mmol) in DMF (6 mL) were successively 
added DCC (817 mg, 4.0 mmol), HOBt·H2O (506 mg, 5.0 mmol). After stirring for overnight, 
DMF was removed by evaporation; residue dissolved in ethyl acetate, and then successively 
washed with 10% citric acid solution, 4% sodium bicarbonate solution and brine. After drying 
over MgSO4 and concentrating, the resulting oily substance was purified by silica gel 
chromatography using a mixture of chloroform and methanol (99:1 v/v) to obtain Z-(±) 
A2mc6c-L-Phe-D-Pro-OtBu(1.24 g, 2.1 mmol, 63%). TLC: Rf, 0.8 (CHCl3/MeOH=9/1). 
HPLC: double peaks 9.00 min, 42%; 9.34 min, 51%. 
4.4.1.3 Synthesis of Boc-L-Asu(OBzl)-(±)A2mc6c-L-Phe-D-Pro-OtBu (MW =763.02 ): 
The tripeptide Z-(±)A2mc6c-L-Phe-D-Pro-OtBu(1.24 g, 2.1 mmol) was subjected to catalytic 
hydrogenation with Pd-C (105 mg) in acetic acid (4 mL). After overnight, the reaction was 
checked by TLC (CHCl3/MeOH/CH3COOH=90/10/2), the catalyst was filtered and reaction 
solution was removed by evaporation. The free amine was taken into ethyl acetate (30 mL) by 
the aid of 2M Na2CO3 solution (10 mL). After dried over anhydrous Na2CO3 ethyl acetate 
solution was evaporated to obtain H-(±)A2mc6c-L-Phe-D-Pro-OtBu (868 mg, 1.9 mmol, 91%). 
To a cooled solution of H-(±)A2mc6c-L-Phe-D-Pro-OtBu (868 mg, 1.9 mmol) and 
Boc-L-Asu(OBzl)-OH (721 mg, 1.9 mmol) in DMF (4 mL) were successively added DCC (470 
mg, 2.3 mmol), HOBt·H2O (291 mg, 1.9 mmol). After stirring for overnight, DMF was 
‐ 88 ‐ 
 
removed by evaporation; residue dissolved in ethyl acetate, and then successively washed with 
10% citric acid solution, 4% sodium bicarbonate solution and brine. After drying over MgSO4 
and concentrating, the resulting oily substance was purified by silica gel chromatography using 
a mixture of chloroform and methanol (99:1 v/v) to obtain Boc-L-Asu(OBzl)-(±)A2mc6c- 
L-Phe-D-Pro-OtBu(1.05 mg, 1.3 mmol, 69%). TLC: Rf, 0.8 (CHCl3/MeOH=9/1). HPLC: 
double peaks r.t. 10.36 min, 28%; 10.74 min, 53%. 
4.4.1.4 cyclo(-L-Asu(OBzl)-(±)A2mc6c-L-Phe-D-Pro-) (MW = 644.80): 
The protected tetrapeptide Boc-L-Asu(OBzl)-(±)A2mc6c-L-Phe-D-Pro-OtBu (1.05 mg, 1.3 
mmol) was dissolved in TFA (4 mL) at 0 0C and kept for 3 hours. After evaporation of TFA, the 
residue was solidified using ether and petroleum ether to yield TFA salt of the linear 
tetrapeptide TFA· H-L-Asu(OBzl)-(±)A2mc6c-L-Phe-D-Pro-OH (800 mg, 1.2 mmol, 100%). 
To DMF (150 mL), TFA·H-L-Asu(OBzl)-A2mc6c-L-Phe-D-Pro-OH (800 mg, 1.2 mmol), 
HATU (685 mg, 1.8 mmol), and DIEA (0.53 mL, 3.0 mmol) were added in separate five 
portions in every 30 minutes with stirring at room temperature for the cyclization reaction. 
After completion of the reaction for 1 hour, DMF was evaporated under vacuum; the residue 
was dissolved in ethyl acetate and washed with 10% citric acid solution, 4% sodium 
bicarbonate solution and brine, respectively. It was then dried over anhydrous MgSO4 and 
filtered.  After evaporation of ethyl acetate, the residue was purified by silica gel 
chromatography using a mixture of chloroform and methanol (99:1v/v) to yield 
cyclo(-L-Asu(OBzl)-(±)A2mc6c-L- Phe-D-Pro-) (503 mg, 0.8 mmol,  65%). HPLC: double 
peaks r.t. 8.90 min, 29%; 9.22 min, 67%.  
4.4.1.5 cyclo(-L-Asu(NHOH)-(±)A2mc6c-L-Phe-D-Pro-) (MW=569.69): 
Compound cyclo(-L-Asu(OBzl)-(±)A2mc6c-L-Phe-D-Pro-) (503 mg, 0.8 mmol) was dissolved 
in methanol (3 mL) and Pd-C (40 mg) was added. The mixture was stirred under H2 for 4 hours. 
After filtration of Pd-C, methanol was evaporated to yield cyclo(-L-Asu-A2mc6c-L-Phe-D- 
Pro-)  (432 mg, 0.8 mmol, 100%). The product was dissolved in DMF (3 mL) at 0 0C, and 
O-Benzylhydroxylamine hydrochloride (HCl·NH2-OBzl)(187 mg, 1.2 mmol), HOBt·H2O (119 
mg, 0.8 mmol), triethylamine (0.17 mL, 1.2 mmol) and DCC (241 mg, 1.2 mmol) were added. 
The mixture was stirred for overnight. After completion of the reaction, DMF was evaporated 
under vacuum; the residue was dissolved in ethyl acetate and washed with 10% citric acid 
solution, 4% sodium bicarbonate solution and brine, respectively. It was then dried over 
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anhydrous MgSO4 and filtered.  After evaporation of ethyl acetate, cyclo(-L-Asu(NHOBzl) 
-(±)A2mc6c-L-Phe-D-Pro-) (403 mg, 0.6 mmol, 78% ) was obtained. The product 
cyclo(-L-Asu(NHOBzl)-(±)A2mc6c-L-Phe-D-Pro-) (403 mg, 0.6 mmol) was dissolved in 
acetic acid (6 mL) and Pd-BaSO4 (200 mg) was added. The mixture was stirred under H2 for 24 
hours. After filtration of Pd-BaSO4, acetic acid was evaporated and crystallized with ether to 
yield cyclo(-L-Asu(NHOH)-(±)A2mc6c-L-Phe-D-Pro-) (259 mg, 0.4 mmol, 76%). TLC: Rf 
0.62 (CHCl3/ MeOH/CH3COOH=90/10/2). HPLC: double peaks r.t. 6.98 min, 42%; 7.36 min, 
49%. HR-FAB-MS [M+H]+ 570.3306 for C30H43N5O6 (calcd  569.3213). 1H NMR(400 MHz, 
CDCl3): δH (ppm): 0.78(d, J=7.2 Hz, 3H), 1.05(d, J=6 Hz, 1H), 1.24-1.40(m, 8H), 1.60-1.86(m, 
9H), 2.04(s, 1H), 2.14(s, 2H), 2.29(d, J=7.2 Hz, 1H), 3.19(m, 1H), 3.24(m, 1H), 3.47(s, 1H), 
3.50(m, 1H), 3.84(m, 1H), 3.98(m,1H), 4.32(m, 1H), 4.73(m, 1H), 5.20(t, J=9.2, 8.0 Hz, 1H), 
6.41(s, 1H), 6.46(s, 1H), 7.18(d, J=7.2 Hz, 1H), 7.20-7.28(m, 5H), 7.53(d, J=10, 1H). 13C NMR 
(400 MHz , CDCl3)  δC (ppm): 14.21, 18.68, 21.05, 24.57, 24.86, 25.07, 25.13, 27.28, 27.41, 
28.77, 29.32, 32.76, 36.07, 46.98, 52.88, 53.22, 54.91, 57.97, 65.04, 65.83, 125.85, 128.74, 
128.74, 129.23, 129.26, 137.09, 171.36, 173.26, 175.22, 175.86. 
4.4.2 Synthesis of  cyclo(-L-Asu(NHOH)-L-A3mc6c-L-Phe-D-Pro-) 
4.4.2.1 Synthesis of Z-L-A3mc6c-OH (MW=291.34): 
To a suspension of 3-methyl-cyclohexanecarboxylic amino acid (1.2 g, 7.7 mmol) in acetone (8 
mL) and water (8 mL) were added Z-Osu (2.1 g, 8.5 mmol) and Na2CO3 (1.6 g, 15.4 mmol). 
After stirring for overnight, acetone was removed by evaporation; residue dissolved in ethyl 
acetate, and adjusted pH 2-3 with citric acid solution, and then washed with saturated saline. 
After drying over MgSO4 and concentrating, product was purified by crystallization in ether 
and petroleum ether (1:2 v/v) to yield (2.2 g, 6.0 mmol, 78%), HPLC: r.t. 5.83 min. 
4.4.2.2 Synthesis of Z-L-A3mc6c-L-Phe-D-Pro-OtBu (MW = 591.74): 
The dipeptide was coupling in the same manner as 3.8.3 described to obtain 
H-L-Phe-D-Pro-OtBu(1.0 g, 3.0 mmol). To a cooled solution of H- L-Phe-D-Pro-OtBu (1.0 g, 
3.0 mmol) and Z-L-A3mc6c-OH (870 mg, 3.0 mmol) in DMF (6 mL) were successively added 
DCC (790 mg, 3.6 mmol), HOBt·H2O (460 mg, 3.0 mmol). After stirring for overnight, DMF 
was removed by evaporation; residue dissolved in ethyl acetate, and then successively washed 
with 10% citric acid solution, 4% sodium bicarbonate solution and brine. After drying over 
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MgSO4 and concentrating, the resulting oily substance was purified by silica gel 
chromatography using a mixture of chloroform and methanol (99:1 v/v) to obtain Z- 
A3mc6c-L-Phe-D-Pro-OtBu(1.32 g, 2.2 mmol, 74%). TLC: Rf 0.8 (CHCl3/MeOH=9/1). HPLC: 
r.t. 9.57 min, 90%. 
4.4.2.3 Synthesis of Boc-L-Asu(OBzl)-L-A3mc6c-L-Phe-D-Pro-OtBu (MW =763.02 ): 
The tripeptide Z-L-A3mc6c-L-Phe-D-Pro-OtBu(1.32 g, 2.2 mmol) was subjected to catalytic 
hydrogenation with Pd-C (111 mg) in acetic acid (5 mL). After overnight, the reaction was 
checked by TLC (CHCl3/MeOH/CH3COOH=90/10/2), the catalyst was filtered and reaction 
solution was removed by evaporation. The free amine was taken into ethyl acetate (30 mL) by 
the aid of 2M Na2CO3 solution (10 mL). After dried over anhydrous Na2CO3 ethyl acetate 
solution was evaporated to obtain H-L-A3mc6c-L-Phe-D-Pro-OtBu (917 mg, 2.0 mmol, 91%). 
To a cooled solution of H-L-A3mc6c-L-Phe-D-Pro-OtBu  (917 mg, 2.0 mmol) and Boc-L- 
Asu(OBzl)-OH (757 mg, 2.0 mmol) in DMF (4 mL) were successively added DCC (495 mg, 
2.4 mmol), HOBt·H2O (306 mg, 2.0 mmol). After stirring for overnight, DMF was removed by 
evaporation; residue dissolved in ethyl acetate, and then successively washed with 10% citric 
acid solution, 4% sodium bicarbonate solution and brine. After drying over MgSO4 and 
concentrating, the resulting oily substance was purified by silica gel chromatography using a 
mixture of chloroform and methanol (99:1 v/v) to obtain Boc-L-Asu(OBzl)-A3mc6c-L-Phe- 
D-Pro-OtBu(1.1 g, 1.4 mmol, 72%). TLC: Rf 0.8 (CHCl3/MeOH=9/1). HPLC: r.t. 10.96 min, 
95%. 
4.4.2.4 cyclo(-L-Asu(OBzl)-L-A3mc6c-L-Phe-D-Pro-) (MW = 644.80): 
The protected tetrapeptide Boc-L-Asu(OBzl)-L-A3mc6c-L-Phe-D-Pro-OtBu(1.1 mg, 1.4 mmol) 
was dissolved in TFA (5 mL) at 0 0C and kept for 3 hours. After evaporation of TFA, the residue 
was solidified using ether and petroleum ether to yield TFA salt of the linear tetrapeptide 
TFA· H-L-Asu(OBzl)-L-A3mc6c-L-Phe-D-Pro-OH (960 mg, 1.4 mmol, 100%). To DMF (150 
mL), TFA·H-L-Asu(OBzl)-L-A3mc6c-L-Phe-D-Pro-OH (960 mg, 1.4 mmol), HATU (822 mg, 
2.1 mmol), and DIEA (0.63 mL, 3.6 mmol) were added in separate five portions in every 30 
minutes with stirring at room temperature for the cyclization reaction. After completion of the 
reaction for 1 hour, DMF was evaporated under vacuum; the residue was dissolved in ethyl 
acetate and washed with 10% citric acid solution, 4% sodium bicarbonate solution and brine, 
respectively. It was then dried over anhydrous MgSO4 and filtered.  After evaporation of ethyl 
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acetate, the residue was purified by silica gel chromatography using a mixture of chloroform 
and methanol (99:1v/v) to yield cyclo(-L-Asu(OBzl)-L-A3mc6c-L-Phe-D-Pro-) (659 mg, 1.0 
mmol, 77%). HPLC: r.t. 10.04 min, 96%.  
4.4.2.5 cyclo(-L-Asu(NHOH)-L-A3mc6c-L-Phe-D-Pro-) (MW=569.69): 
Compound cyclo(-L-Asu(OBzl)-L-A3mc6c-L-Phe-D-Pro-) (659 mg, 1.0 mmol) was dissolved 
in methanol (5 mL) and Pd-C (50 mg) was added. The mixture was stirred under H2 for 
overnight. After filtration of Pd-C, methanol was evaporated to yield cyclo(-L-Asu-L-A3mc6c- 
L-Phe-D-Pro-)  (560 mg, 1.0 mmol, 100%). The product was dissolved in DMF (3 mL) at 0 0C, 
and O-Benzylhydroxylamine hydrochloride (HCl NH2-OBzl) (239 mg, 1.5 mmol), HOBt·H2O 
(153 mg, 1.0 mmol), triethylamine (0.22 mL, 1.5 mmol) and DCC (310 mg, 1.5 mmol) were 
added. The mixture was stirred for overnight. After completion of the reaction, DMF was 
evaporated under vacuum; the residue was dissolved in ethyl acetate and washed with 10% 
citric acid solution, 4% sodium bicarbonate solution and brine, respectively. It was then dried 
over anhydrous MgSO4 and filtered.  After evaporation of ethyl acetate, cyclo(-L-Asu(NHOBzl) 
–L-A3mc6c-L-Phe-D-Pro-) (613 mg, 0.93 mmol, 93% ) was obtained. The product 
cyclo(-L-Asu(NHOBzl)-L-A3mc6c-L-Phe-D-Pro-) (613 mg, 0.93 mmol) was dissolved in 
acetic acid (9 mL) and Pd-BaSO4 (135 mg) was added. The mixture was stirred under H2 for 24 
hours. After filtration of Pd-BaSO4, acetic acid was evaporated and crystallized with ether to 
yield cyclo(-Asu(NHOH)-L-A3mc6c-L-Phe-D-Pro-) (406 mg, 0.7 mmol, 79%). TLC: Rf 0.67 
(CHCl3/ MeOH/CH3COOH=90/10/2). HPLC: r.t. 8.15 min. HR-FAB-MS [M+H]+ 570.3257 
for C30H43N5O6 (calcd  569.3213). 1H NMR(400 MHz, CDCl3): δH (ppm): 0.88(dd, J=4.0, 6.0 
Hz, 4H), 1.16(m, 3H), 1.19-1.30(m, 6H), 1.48-1.72(m, 10H), 2.04(s, 1H), 2.13(m, 2H), 2.30(d, 
J=8.4 Hz, 1H), 2.95(m, 1H), 3.21(m, 1H), 3.47(m, 1H), 3.98(m, 1H), 4.18(m, 1H), 4.68(t, J=6.0 
Hz, 1H), 5.12(m, 1H), 6.38(s, 1H), 6.46(s, 1H), 7.18(d, J=9.2 Hz, 1H), 7.21-7.32(m, 5H), 
7.49(d, J=10 Hz, 1H). 13C NMR (400 MHz , CDCl3) δC (ppm): 22.50, 24.78, 24.99, 25.15, 
28.16, 29.04, 29.41, 29.60, 32.69, 33.17, 34.11, 36.07, 41.56, 42.83, 47.11, 53.22, 54.57, 57.85, 
62.48, 62.63, 126.94, 128.72, 128.78, 129.25, 129.32, 137.09, 171.22, 172.48, 173.33, 174.36. 
4.4.3 Synthesis of  cyclo(-L-Asu(NHOH)-A4mc6c-L-Phe-D-Pro-) 
4.4.3.1 Synthesis of Z-A4mc6c-OH (MW=291.34): 
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To a suspension of 4-methyl-cyclohexanecarboxylic amino acid (9.7 g, 61 mmol) in acetone 
(60 mL) and water (60 mL) were added Z-Osu (16.7 g, 67.1 mmol) and Na2CO3 (12.9 g, 122 
mmol). After stirring for overnight, acetone was removed by evaporation; residue dissolved in 
ethyl acetate, and adjusted pH 2-3 with citric acid solution, and then washed with saturated 
saline. After drying over MgSO4 and concentrating, product was purified by crystallization in 
ether and petroleum ether (1:2 v/v) to yield (10.4 g, 35.7 mmol, 59%), HPLC: r.t. 3.94 min. 
4.4.3.2 Synthesis of Z-A4mc6c-L-Phe-D-Pro-OtBu (MW = 591.74): 
The dipeptide was coupling in the same manner as 3.8.3 described to obtain 
H-L-Phe-D-Pro-OtBu (1.05 g, 3.3 mmol). To a cooled solution of H-L-Phe-D-Pro-OtBu (1.05 g, 
3.3 mmol) and Z-A4mc6c-OH (971 mg, 3.0 mmol) in DMF (6 mL) were successively added 
DCC (743 mg, 3.3 mmol), HOBt·H2O (460 mg, 3.0 mmol). After stirring for overnight, DMF 
was removed by evaporation; residue dissolved in ethyl acetate, and then successively washed 
with 10% citric acid solution, 4% sodium bicarbonate solution and brine. After drying over 
MgSO4 and concentrating, the resulting oily substance was purified by silica gel 
chromatography using a mixture of chloroform and methanol (99:1 v/v) to obtain 
Z-A4mc6c-L-Phe-D-Pro-OtBu(480 mg, 0.8 mmol, 63%). TLC: Rf 0.8 (CHCl3/MeOH=9/1). 
HPLC: r.t. 9.32 min, 58%. 
4.4.3.3 Synthesis of Boc-L-Asu(OBzl)-A4mc6c-L-Phe-D-Pro-OtBu (MW =763.02 ): 
The tripeptide Z-A4mc6c-L-Phe-D-Pro-OtBu(480 mg, 0.8 mmol) was subjected to catalytic 
hydrogenation with Pd-C (41 mg) in acetic acid (2 mL). After overnight, The reaction was 
checked by TLC (CHCl3/MeOH/CH3COOH=90/10/2), the catalyst was filtered and reaction 
solution was removed by evaporation. The free amine was taken into ethyl acetate (20 mL) by 
the aid of 2M Na2CO3 solution (5 mL). After dried over anhydrous Na2CO3 ethyl acetate 
solution was evaporated to obtain H-A4mc6c-L-Phe-D-Pro-OtBu (244 mg, 0.5 mmol, 66%). To 
a cooled solution of H-A4mc6c-L-Phe-D-Pro-OtBu (244 mg, 0.5 mmol) and 
Boc-L-Asu(OBzl)-OH (210 mg, 0.5 mmol) in DMF (3 mL) were successively added DCC (132 
mg, 0.6 mmol), HOBt·H2O (82 mg, 0.5 mmol). After stirring for overnight, DMF was removed 
by evaporation; residue dissolved in ethyl acetate, and then successively washed with 10% 
citric acid solution, 4% sodium bicarbonate solution and brine. After drying over MgSO4 and 
concentrating, the resulting oily substance was purified by silica gel chromatography using a 
mixture of chloroform and methanol (99:1 v/v) to obtain Boc-L-Asu(OBzl)-A4mc6c-L-Phe-D- 
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Pro-OtBu(320 mg, 0.4 mmol, 76%). TLC: Rf 0.8 (CHCl3/MeOH=9/1). HPLC: r.t. 10.77 min, 
80%. 
4.4.3.4 cyclo(-L-Asu(OBzl)-A4mc6c-L-Phe-D-Pro-) (MW = 644.80): 
The protected tetrapeptide Boc-L-Asu(OBzl)-A4mc6c-L-Phe-D-Pro-OtBu (320 mg, 0.4 mmol) 
was dissolved in TFA (3 mL) at 0 0C and kept for 3 hours. After evaporation of TFA, the residue 
was solidified using ether and petroleum ether to yield TFA salt of the linear tetrapeptide 
TFA· H-L-Asu(OBzl)-A4mc6c-L-Phe-D-Pro-OH (260 mg, 0.4 mmol, 100%). To DMF (50 
mL), TFA·H-L-Asu(OBzl)-A4mc6c-L-Phe-D-Pro-OH (260 mg, 0.4 mmol), HATU (228 mg, 
0.6 mmol), and DIEA (0.18 mL, 1.0 mmol) were added in separate five portions in every 30 
minutes with stirring at room temperature for the cyclization reaction. After completion of the 
reaction for 1 hour, DMF was evaporated under vacuum; the residue was dissolved in ethyl 
acetate and washed with 10% citric acid solution, 4% sodium bicarbonate solution and brine, 
respectively. It was then dried over anhydrous MgSO4 and filtered.  After evaporation of ethyl 
acetate, the residue was purified by silica gel chromatography using a mixture of chloroform 
and methanol (99:1v/v) to yield cyclo(-L-Asu(OBzl)-A4mc6c-L-Phe-D-Pro-) (145 mg, 0.2 
mmol, 56%). HPLC:  r.t. 10.09 min, 100%.  
4.4.3.5 cyclo(-L-Asu(NHOH)-A4mc6c-L-Phe-D-Pro-) (MW=569.69): 
Compound cyclo(-L-Asu(OBzl)-A4mc6c-L-Phe-D-Pro-) (145 mg, 0.2 mmol) was dissolved in 
methanol (3 mL) and Pd-C (11 mg) was added. The mixture was stirred under H2 for 4 hours. 
After filtration of Pd-C, methanol was evaporated to yield cyclo(-L-Asu-A4mc6c-L-Phe-D- 
Pro-)  (122 mg, 0.2 mmol, 100%). The product was dissolved in DMF (3 mL) at 00C, and 
O-Benzylhydroxylamine hydrochloride (HCl·NH2-OBzl)(53 mg, 0.3 mmol), HOBt·H2O (34 
mg, 0.2 mmol), triethylamine (48 μL, 0.3 mmol) and DCC (68 mg, 0.3 mmol) were added. The 
mixture was stirred for overnight. After completion of the reaction, DMF was evaporated under 
vacuum; the residue was dissolved in ethyl acetate and washed with 10% citric acid solution, 
4% sodium bicarbonate solution and brine, respectively. It was then dried over anhydrous 
MgSO4 and filtered.  After evaporation of ethyl acetate, cyclo(-L-Asu(NHOBzl) 
–A4mc6c-L-Phe-D-Pro-) (133 mg, 0.2 mmol, 91% ) was obtained. The product 
cyclo(-L-Asu(NHOBzl)-A4mc6c-L-Phe-D-Pro-) (133 mg, 0.2 mmol) was dissolved in acetic 
acid (2 mL) and Pd-BaSO4 (30 mg) was added. The mixture was stirred under H2 for 24 hours. 
After filtration of Pd-BaSO4, acetic acid was evaporated and crystallized with ether to yield 
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cyclo(-L-Asu(NHOH)-A4mc6c-L-Phe-D-Pro-) (61 mg, 0.1 mmol, 54%). TLC: Rf 0.65 
(CHCl3/MeOH/CH3COOH=90/10/2). HPLC: r.t. 7.60 min, 47%. HR-FAB-MS [M+H]+ 
570.3262 for C30H43N5O6 (calcd  569.3213). 1H NMR (400 MHz, CDCl3): δH (ppm): 0.77(d, 
J=12 Hz, 1H), 0.84(d, J=5.6 Hz, 3H), 1.25-1.30(m, 12H), 1.61-1.74(m, 6H), 2.05(s, 1H), 
2.13-2.29(m, 4H), 2.94(d, J=5.2 Hz, 1H), 2.97(d, J=5.6 Hz, 1H), 3.29(m, 1H), 3.97(m, 1H), 
4.23(m, 1H), 4.68(t, J=6.0 Hz, 1H), 5.15(dd, J=9.2, 6.4 Hz, 1H), 6.46(s, 1H), 6.67(s, 1H), 
7.19(d, J=6.8 Hz, 1H), 7.21-7.28(m, 5H), 7.53(d, J=10 Hz, 1H).  13C NMR (400 MHz , CDCl3) 
δC (ppm): 21.63, 24.77, 24.94, 25.05, 25.26, 28.39, 28.70,  29.18, 31.25, 32.56, 32.75, 34.04, 
36.26, 35.78, 36.04, 47.03, 53.16, 54.70, 57.82, 61.95, 126.89, 128.71, 128.71, 129.22, 129.22, 
137.08, 173.21, 174.31, 174.39, 174.48. 
4.4.4 HDACs preparation and enzyme activity assay 
In a 100-mm dish, 293T cells (1-2 × 106) were grown for 24 hours and transiently transfected 
with 10 g each of the vector pcDNA3-HDAC1 for human HDAC1, pcDNA3-HDAC4 for 
human HDAC4, or pcDNA3-mHDA2/HDAC6 for mouse HDAC6, using the Lipofect AMINE 
2000 reagent (Invitrogen). After successive cultivation in DMEM for 24 hours, the cells were 
washed with PBS and lysed by sonication in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 
120 mM NaCl, 5 mM EDTA, and 0.5% NP40. The soluble fraction collected by micro 
 
 
Fig. 4.10 The method of enzyme activity assay 
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centrifugation was precleared by incubation with protein A/G plus agarose beads (Santa Cruz 
Biotechnologies, Inc.). After the cleared supernatant had been incubated for 1 hour at 4˚C with 
4 g of an anti-FLAG M2 antibody (Sigma-Aldrich Inc.) for HDAC1, HDAC4 and HDAC6, the 
agarose beads were washed three times with lysis buffer and once with histone deacetylase 
buffer consisting of 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 10% glycerol. The bound 
proteins were released from the immune complex by incubation for 1 hour at 4˚C with 40 g of 
the FLAG peptide (Sigma-Aldrich Inc.) in histone deacetylase buffer (200 mL). The 
supernatant was collected by centrifugation. For the enzyme assay, 10 L of the enzyme 
fraction was added to 1 L of fluorescent substrate (2 mM Ac-KGLGK(Ac)-MCA) and 9 L of 
histone deacetylase buffer, and the mixture was incubated at 37˚C for 30 minutes. The reaction 
was stopped by the addition of 30 L of tripsin (20 mg/mL) and incubated at 37˚C for 15 
minutes. The released amino methyl coumarin (AMC) was measured using a fluorescence plate 
reader. The 50% inhibitory concentrations (IC50) were determined as the means with SD 
calculated from at least three independent dose response curves (Fig. 4.10). 
4.4.5 The p21 promoter assay 
A luciferase reporter plasmid (pGW-FL) was constructed by cloning the 2.4 kb genomic 
fragment containing the transcription start site into HindIII and SmaI sites of the pGL3-Basic 
plasmid (Promega Co., Madison, WI). Mv1Lu (mink lung epitherial cell line) cells were 
transfected with the pGW-FL and a phagemid expressing neomycin/kanamycin resistance gene 
(pBK-CMV, Stratagene, La Jolla, CA) with the Lipofectamine reagent (Life Technology, 
Rockville, MD USA). After the transfected cells had been selected by 400 µg/mL Geneticin 
(G418, Life Technology), colonies formed were isolated. One of the clones was selected and 
named MFLL-9. MFLL-9 expressed a low level of luciferase, of which activity was enhanced 
 
 
Fig. 4.11 The p21 promoter assay 
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by TSA in a dose-dependent manner. MFLL-9 cells (1 × 105) cultured in a 96-well multi-well 
plate for 6 hours were incubated for 18 hours in the medium containing various concentrations 
of drugs. The luciferase activity of each cell lysate was measured with a LucLite luciferase 
Reporter Gene Assay Kit (Packard Instrument Co., Meriden, CT) and recorded with a 
Luminescencer-JNR luminometer (ATTO, Tokyo, Japan). Data were normalized to the protein 
concentration in cell lysates. Concentrations at which a drug induces the luciferase activity 
10-fold higher than the basal level are presented as the 1000% effective concentration 1000% 
(EC1000). The human wild-type p21 promoter luciferase fusion plasmid, WWP-Luc, was a kind 
gift from Dr. B. Vogelstein (Fig. 4.11). 
4.4.6 Cell growth inhibition assay 
The MTT colorimetric assay was used to determine growth inhibition (Fig. 4.12). HeLa, 7721, 
K-562 and MCF-7 were all cultured in a humidified atmosphere of 5% CO2 in air, with RPMI 
1640 media, containing 10% fatal bovine serum. The cell lines were diluted to 5~9×104 
cells/mL with the corresponding media and were plated in 96-well microplates. After adhere 
overnight, three HDACs inhibitors were added to culture medium at the concentrations of 20, 
40, 60, 80, 100 nM and then the cells were incubated for 48 hours.  Then 200 μL MTT (0.5 
mg/mL) reagent diluted in serum free media was added to each well and the cells were 
incubated for an additional 4 hours. Thereafter, the resulted dark blue crystal (formazan) was 
dissolved in 200 μL DMSO, and an optical density was measured on a microplate 
spectrophotometer at 570 nm. All experiments were performed in triplicate and repeated at least 
three times. Data are presented as mean ± standard deviation of three independent experiments. 
The IC50 values were caculated by nonlinear regression analysis using SPSS 17.0 software. 
 
 
 
Fig. 4.12  Cell growth inhibition assay (MCF-7, Hela, K-562 and 7721 cell lines) 
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4.4.7 Morphological reversion assay 
Method crystal violet staining was used to observe the changes in cell morphology (Fig. 
4.13).[20] MCF-7 cells and 7721 cells were plated into 96-well microplates at 2×104 cells/mL 
and allowed to adhere overnight. Inhibitors were added to culture medium at the concentration 
of 100 nM (Ky-301, Ky-302 and Ky-303) and incubated for 24 hours. Cells were then washed 
once with PBS, and fixed in 4% buffered formalin for 1 hour at room temperature. The fixed 
cells were then washed once further with PBS and stained with 1% Crystal Violet in methanol 
for 5 minutes. Excess stain was removed by washing with tap water. After the microtiter plate 
was being air-dried at 370C, MCF-7 cells and 7721 cells were taken Photographs using an 
inverted microscope. 
 
4.4.8 Circular dichroism measurement 
 CD spectra were recorded on a JASCO J-820 spectropolarimeter (Tokyo, Japan) using a quartz 
cell of 1 cm light path length at room temperature. Peptide solutions (0.1 mM) were prepared in 
methanol and CD spectra were recorded in terms of molar ellipticity, []M (deg  cm2  dmol-1). 
 4.4.9 Molecular dynamics simulation 
All the molecular mechanics and dynamics calculations were carried out with the AMBER9 
package. The standard AMBER ff99 force field[44] was used as the parameters for the protein 
and water atoms, and the general AMBER force field (GAFF)[45] and AM1-BCC charges[46] 
were used for the ligands. Zinc was modeled using the Stote nonbonded model (q = +2e-, r = 1.7 
 
 
Fig. 4.13   Morphological reversion assay 
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Å, ε = 0.67 kcal/mol).[47] Each initial structure for the simulation was prepared from the docked 
conformations of HDAC8-ligand complexes. The local hydrogen bonding network around the 
histidine residues was checked. Histidine residue 180 was assigned as HIE (histidine with 
hydrogen on its epsilon nitrogen), and other histidine residues as HID (histidine with hydrogen 
on its delta nitrogen). The force field parameters of cyclic tetrapeptides were prepared with the 
Antechamber module[48] of AMBER 9 package. Hydrogen atoms were added to the 
crystallographic protein with the AMBER LEaP module. Sodium counterions were added to 
neutralize the system. The system was then solvated with an octahedral box of TIP3P water 
molecules.[49] The minimum distance from the surface of the protein to the faces of the box was 
10 Å. The particle mesh Ewald (PME) method[50] was used to treat long-range electrostatic 
interactions. The cutoff distance for the long-range electrostatic and the van der Waals energy 
terms were set at 12.0 Å. All covalent bonds to hydrogen atoms were constrained using the 
SHAKE algorithm.[51] 
Energy minimization was achieved via three steps. At first, movement was allowed only for the 
water molecules and ions. Next, the ligand and the receptor residues were all allowed to move 
and the water molecules, together with ions, were constrained. Finally, all atoms were permitted 
to move freely. With each step, energy minimization was executed by the steepest descent 
method for the first 5000 steps and the conjugated gradient method for the subsequent 2500 
steps.  
Periodic boundary conditions were used. The time steps were 2 ps during the production 
dynamics. The temperature was maintained by rescaling the velocities using the Berendsen 
weak-coupling algorithm,[52] with a time constant of 2 ps for the heat bath.  
After the system was heated to 300 K from the initial temperature of 0 K using the NVT 
ensemble in 120.0 ps, molecular dynamics were performed at a constant temperature of 300 K. 
After a 50 ps position-restrained dynamics, each simulation was proceeded 2 ns under periodic 
boundary conditions with NPT ensemble at 1 atm and at 300 K.  The convergence of energy, 
temperatures, and pressures of the systems, and the atomic root-mean-square deviation of the 
enzyme and the inhibitor (RMSD), were used to verify the stability of the systems. Trajectories 
were analyzed using the PTRAJ modules.[53]  
In the present MD simulations, the overall structure of all complexes appeared to be 
equilibrated after 1.5 ns. Hence, atom coordinates were collected at the interval of 5 ps for the 
last 500 ps to analyze the structure in detail. The series of snapshots between 1.5 and 2.0 ns of 
the equilibrium phase was used for free energy calculations and structure evaluation.  
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Chapter 5  
Molecular Design of Cyclic Tetrapeptide HDAC Inhibitors by 
Replacement of L-Phe in Chlamydocin Framework 
5.1 Introduction 
High HDACs activity due to HAT mutation or abnormal recruitment of HDACs is associated 
with a number of malignant diseases, so HDAC inhibitors are a promising class of anticancer 
agents due to their efficacy against cancer cell line.[1,2] Therefore, design and synthesis of 
HDACs inhibitors represent exciting opportunity for the development of therapeutics for 
treatment of cancers. So far a number of natural and synthetic compounds have been reported as 
HDACs inhibitors, and several of them are already in clinical trials.[3] Among these the 
naturally occurring cyclic tetrapeptides, Chlamydocin which is isolated from fungus 
Diheterosporia Chlamdosphoria containing Aib, L-Phe, D-Pro, and 2-amino-8-oxo-9,10- 
epoxydecanoic acid (Aoe) shows a highly HDAC inhibition with an IC50 of 1.3 nM in vitro.[4] 
L-Aoe provides an epoxyketone moiety in the side chain which irreversible inhibits HDACs. 
To expect reversible and potent HDAC inhibitors, some Chlamydocin analogs with various 
functionalities have been reported.[5,6] Some potent HDAC inhibitors were reported with a 
benzyl cap group in surface recognition domain, such as TSA, SAHA and Trapoxin etc (Fig. 
5.1). Therefore, it is importance that HDAC inhibitors of cyclic tetrapeptide contain L-Phe 
residue in scaffold.[7,8] To improve the hydrophobic interaction of the cap groups with HDACs, 
we focused on the benzene ring of L-Phe in Chlamydocin framework. 
The discrepancy of inhibitory activity is 30-fold for TSA-HDLP comparing to SAHA-HDLP, 
though the catalytic mechanism for hydroxamic acid group of SAHA and TSA interacting with 
the zinc ion are the same manner.[9] To compare the structure to discover SAHA lack of methyl 
and double bond to TSA, the aromatic ring bears weak electron density and the saturated link of 
SAHA makes loose interactivity with around amino acid of tubular hydrophobic pocket.  
FK228 is a natural product and showes potent in vivo antitumor activity.[10-13] There is no 
visible functional group in FK228 that interacts with the zinc ion in the HDAC binding pocket. 
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Nishino and coworkers pointed out that the zinc-binding site is the sulfhydral functional group 
and FK228 is converted to its active form (RedFK228) by cellular reducing activity.  
To find out specific inhibitors, we designed and synthesized four novel cyclic tetrapeptides with 
methyl L-Phe in their macrocyclic frameworks, in which the thiol function was protected as 
disulfide hybrid (compound 1 cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-), compound 2 
cyclo(-L-Am7(S2Py)-Aib-L-Phe(2-Me)-D-Pro-), compound 3 cyclo(-L-Am7(S2Py)-Aib-L- 
Phe(4-Me)-D-Pro-), compound 4 cyclo(-L-Am7(S2Py)-Aib-L-Phe(3,5-2Me)-D-Pro-) as show 
in Fig. 5.2). We also synthesized cyclic tetrapeptide containing hydroxamic acid which has 
been reported as a comparison (cyclo(-L-Asu(NHOH)-Aib-L-Phe(4-Me)- D-Pro-), compound 
5 ). 
Conformational analysis of HDAC inhibitors is very helpful for comprehending the 
structure-activity relationship (SAR) behavior and designing new drug candidates. Molecular 
dynamics (MD) simulation is a very useful technique for exploring the structure and the 
dynamic behavior of molecules of biochemical interest, a recent MD simulation study of 
HDLP-inhibitors has given us the details of binding mode of HDLP with hydroxamic acid 
inhibitors.[14] Free energy calculation methods can provide quantitative measurements of 
protein-ligand or protein-protein interactions.[15-17] A promising approach, molecular 
mechanics-Poisson Boltzmann surface area (MM-PBSA) has been used for evaluating the 
 
 
Fig. 5.1 Several HDACs inhibitors. 
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binding free energy of macromolecules and their complexes.[18-22] To explore the interaction 
mechanisms of HDACs with cyclic tetrapeptide inhibitors containing sulfur, docking and MD 
simulations are conducted for HDAC8 with the compounds above. MM-PBSA method is also 
used to estimate the binding free energy of each HDAC8-ligand complex. Cyclic tetrapeptides 
are the most structurally complex HDAC inhibitors, but the details of interaction between 
cyclic tetrapeptides and HDACs are only partly known, up to now only two contributions 
analyzing the binding contacts between HDLP and the cyclic tetrapeptide were published.[23,24]  
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Fig. 5.2 Design of HDAC inhibitors of cyclic tetrapeptides with L-Phe(n-Me). 
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5.2 Results and discussion 
5.2.1 Chemistry 
In order to synthesize potent HDAC inhibitors which have the similar cyclic framework as 
Chlamydocin, we prepared non-natural amino acids Boc-L-methyphenylalanines according to 
the literature.[25,26] The synthesis strategy was described in scheme 3.1. 
The cyclic tetrapeptides were prepared according to general conventional solution phase 
method. Synthesis routes of target compounds 1, 2 and 4 are shown in Scheme 5.1, and 
compound 3  and 5 is showed in Scheme 5.2. 
 
Synthesis of compounds 1, 2 and 4: benzyl-protected D-Pro was reacted with Boc-protected 
Phe (or Phe(2-Me) or Phe(3,5-2Me)) to give protected dipeptide. Boc protection was then 
removed using 4N HCl/DXN and again coupled with Boc-Aib. The N-terminal of the tripeptide 
was deprotected by 4N HCl/DXN and coupled with Boc-L-Ab7 to yieled linear tetrapeptide. 
After the C-terminal benzyl protection was removed by catalytic hydrogenation, the N-terminal 
Boc protection was removed by treatment with trifluoroacetic acid (TFA). Cyclization reaction 
was carried out by the aid of HATU in DMF (2 mM) with minimum amount of DIEA (2.5 eq). 
The yield of cyclic tetrapeptides was 50%-60% after purification by silica gel chromatography. 
The cyclic tetrapeptide containing L-Ab7 was reacted with potassium thioacetate to convert the 
 
 
Scheme 5.1 Synthetic strategy of cyclic tetrapeptides. 
L-AA: L-Phe, L-Phe(2-Me), L-Phe(3,5-2Me) 
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bromide to thioacetate ester. Further treatment with methylamine in the presence of 
2,2′-dipyridyl disulphide gave the targeted cyclic tetrapeptides. 
The compounds 3 and 5 was prepared according to general Scheme 5.2, starting from Z-Pro 
tert-butyl ester. After the removal of Z-protection by catalytic hydrogenation, free amine was 
extracted and used for condensation with Z-L-Phe(4-Me) and Z-Aib using DCC/HOBt orderly. 
Boc-L-2-amino-7-bromoheptanoic acid (L-Ab7) was incorporated to prepare the linear 
tetrapeptide (Boc-L-Ab7-Aib-L-Phe(4-Me)-D-Pro-OtBu). After removal of C-terminal and 
N-terminal protections by treating with TFA. Then liner tetrapeptede was cyclized and 
modified according to the same way as above.  
All the synthesized compounds 1-4 were characterized by 1H and 13C NMR and HR-FAB-MS. 
The purity of the compounds were determined by HPLC analysis and showed purity above 
97%. 
 
5.2.2 Cell growth inhibitory assay 
The compounds were tested for antiproliferative in vitro by MTT assay against MCF-7 (human 
breast cancer), Hela (human cervix cancer) and 7721 (human liver cancer) cell lines. The IC50  
 
 
Scheme 5.2 Synthetic strategy of cyclic tetrapeptides. 
Reagents: (a) H2, Pd/C, MeOH; (b) Cl·NH2-OBzl, DCC/HOBt, DMF; (c) Pd-BaSO4, CH3COOH.  
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Fig. 5.3 Effect of HDACs inhibitors on proliferation. (a) Hela cell for compounds 1-4, (b) MCF-7 cell for 
compounds 1-4, (c) 7721 cell for compounds 1-4, (d)  Hela, MCF-7 and 7721 cells for compound 5. 
Table 5.1  Cell growth inhibition for compounds 1-5 
Compounds 
IC50 (μM) 
Hela MCF-7 7721 
1 
0.81 3.59 11.85 
2 
0.52 3.02 13.14 
3 0.66 5.45 10.98 
4 0.49 3.13 12.35 
5 0.062 0.043 0.071 
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value is shown in Table 5.1. All compounds showed good antitumor activities, which inhibited 
cell proliferation at a low concentration. The compounds 1-4 exhibited selectivity for the three 
human cancer cell lines, showing better sensitivity on Hela than the other two cell lines with 
IC50, but no obvious difference for one cell lines. The inhibition activity of compound 5 was 
stronger 10-100 fold than compounds 1-4 with IC50, but there was no selectivity in three cell 
lines. The activity of Compounds 1-4 were almost the same. 
5.2.3 Morphological reversion  
Compounds were added to culture medium of MCF-7 cells at the concentration of 10 μM 
(compounds 1-4) and 100 nM (compound 5) and MCF-7 cells were incubated. Cells were 
stained with 1% crystal violet. The inhibitors were found to induce dramatic changes in cellular 
shape under light microscopy. As the MCF-7 cells was treated by compounds 1-5 for 24 hours, 
cells progressively assumed flattened, rounded, and spindle shapes, with clear cellular borders 
and obvious gaps between cells (Fig. 5.4).  
 
5.2.4 Enzyme inhibition and biological activity 
Compound 1 was assayed for HDAC inhibitory activity using HDAC1, HDAC4 and HDAC6 
prepared from 293T cells, and showed potent HDACs inhibitory activity, with the IC50 of 3.9 
nM (HDAC1), 1.8 nM (HDAC4) and 40 nM (HDAC6), respectively (Table 5.2). The 
compound 1 was poorly inhibited by HDAC6 compared to HDAC1 and HDAC4 and the 
selectivity was better (HDAC6/HDAC4= 22.2). In the cellular activity, the cell permeability of 
compound 1 showed the better activity than TSA with 4-fold increased, which was reflected in 
their p21 promoter assay data.  
 
 
Fig. 5.4 Morphological reversion of MCF-7 cells (×400). 
‐ 108 ‐ 
 
 
5.2.5 Conformation studies by CD and NMR  
The interesting HDAC activity data of compounds 1-5 forced us to study their conformations. 
We have carried out circular dichroism (CD) spectral studies of compounds 1-5 (Fig. 5.5) and 
conformation by NMR (CDCl3) with MOE calculations for compound 2 (Fig. 5.6). CD spectra 
of compounds were carried out in methanol as solvent with peptide concentration of 0.1 mM. 
The CD spectrum of the synthesized compoundes were similar to reference compound 1 at 
190-260 nm. These compounds had two negative ellipticity at 210 nm and 245 nm, and a weak 
positive ellipticity at 230 nm. Compound 4 had a sharp ellipticity because of containing two 
methyl groups (L-Phe(3,5-2Me)). These similarities on CD spectra suggested that the peptide  
backbone of these compounds had also similar structures. This explained the fact that the 
change of methyl positions in L-Phe(n-Me) can not affect their conformations.  
 
 
 
Fig. 5.5 CD spectra of compounds 1-5. 
Table 5.2 HDAC inhibitory activity and p21 promoter activity data for TSA and compound 1. 
Compounds IC50 (nM) HDAC1/ HDAC6/ p21 promoter assay
 HDAC1 HDAC4 HDAC6 HDAC4a HDAC4a EC1000 (nM) 
TSA 1.9 2.0 2.8 1.0 1.4 190 
1 3.9 1.8 40.0 2.1 22.2 45 
aSelectivity toward HDAC4 
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The solution conformation of compound 2 was studied using 1H NMR in CDCl3. Complete 
assignments were made using COSY and NOESY spectra. The JNH-HCα values were obtained 
from NMR charts and by that we estimated dihedral angle “θ”(180°) using the Karplus graph. 
The structures of compound 2 having minimum energy configuration was generated by using 
MOE program and also using the φ values (-120°) obtained from NMR (Table 5.3). The 
energy-minimized structures of compound 2 are shown in Fig.5.6. Compounds 1-5 have similar 
energy-minimized structures. 
 
 
 
  
 
Fig. 5.6 MOE of compound 2 by NMR calculation. Superimposition of compounds 1-5(right). 
Table 5.3 NOE, coupling constant and dihedral angles data from NMR charts of compound 2. 
residues NOE JNH-HCα θ φ 
L-Am7 L-Am7(NH-HCα) 10 Hz 1800 -1200 
Aib L-Aib(NH-HCβ) ---- ---- ---- 
L-Phe(2-Me) 
L-Phe(2-Me)(NH-HCα) 
L-Phe(2-Me)(NH-HCβ) 
L-Phe(2-Me)(NH)-Aib(HCβ) 
10 Hz 1800 -1200 
D-Pro ---- ---- ---- ---- 
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5.2.6 Docking and molecular simulation for the HDAC inhibitors towards HDAC8  
5.2.6.1 Docking studies 
The results of dock modeling for compounds 1, 2, 3 and 4 into HDAC8 are shown in Fig. 5.7, 
all compounds bound in the active site of HDAC8 with a similar pattern to TSA, SAHA and 
MS344.[27] The aliphatic chain was occupying the long, narrow channel, the sulfhydryl group 
was at the bottom of this channel, and the large cap domain interacted with the external surface 
of the enzyme. The hydrogen bonds and hydrophobic interactions between HDAC8 and 
compound 1-4 are shown in Fig. 5.8. It showed that the sulfur atom of each compound 
established a hydrogen bond with the O(H) atom of Tyr306, this hydrogen bond was very 
important for keeping the binding of them to HDAC8. These compounds established 
hydrophobic interactions with some amino acid residues, such as Phe152, His180, Phe207 and 
Met274, etc., the hydrophobic effects were also crucial for stabilizing the complexes. In 
docking studies, the inhibitors bound to zinc atom of HDAC8 in pentahedron geometry. 
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Fig. 5.7 Top view of the surfaces of the active site of the (a) HDAC8-TSA, HDAC8-SAHA and 
HDAC8-MS344 from X-ray crystal structures; (b) HDAC8-Compound 1-4 for docking. 
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5.2.6.2 Molecular dynamics simulation 
 
Fig. 5.8 The hydrogen bonds and hydrophobic interactions between HDAC8 and compounds 
1-4 for docking.  
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Molecular dynamics simulations were performed on four complexes of HDAC8 for 2 ns, 
respectively. All complexes converged and were stable as indicated by monitoring energetic 
and structural properties. The potential energy and root mean square deviations (RMSD) 
remained stable during the last 1000 ps of the simulation for the four systems. The RMSD 
between the Cα, C, and N atoms of the structures obtained during the trajectories and the initial 
structures are shown in Fig.5.9 for the four systems. Root-mean-squared-fluctuation (RMSF) of 
the Cα, C, N atoms for these complexes were analyzed, it showed that the four structures shared 
similar RMSF distribution (Fig.5.10), and the conformational changes of the amino acid 
residues in the active site were all very small, especially in the bottom of the channel (His142, 
His143, Asp176, Asp178 and Asp267) (Fig. 5.11), indicated that the binding between HDAC8 
and these compounds have lead directly to the rigidity of the complex. In the HDAC8-ligand 
X-ray structures, the zinc ion that lay at the end of the hydrophobic tunnel was bound to 
carboxylate oxygens of Asp178, Asp 267 and the nitrogen atom of His180, the other two  
 
 
Fig. 5.10 Root mean square fluctuation (RMSF) for all residues. RMSF averaged during the last 500 ps in 
the MD simulations. 
 
 
Fig. 5.9 Root mean square deviation (RMSD) of the Cα, C, and N atoms of the systems in the MD 
simulations with respect to the starting structure. 
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coordination sites were occupied by the carbonyl and hydroxyl oxygens of the inhibitors’ 
hydroxamate. The average distances between zinc and the nearby atoms during the last 500 ps 
in current MD simulations are shown in Table 5.4, it showed that zinc coordinates with five 
atoms, including one or two carboxylate oxygens of Asp178 and Asp267, a nitrogen atom of 
His180, and sulfur atom of the inhibitor, resulting in a pentahedral geometry. The coordination 
number of zinc in current MD simulations was equal to HDAC8-inhibitor crystal structures, but 
the atoms that coordinated to zinc were not the same, it revealed that all carboxylate oxygens of 
Asp178 and Asp267 and nitrogen atom of His180 can coordinate to the zinc ion. The sulfur 
atom occupied one coordination site, and this may be the precondition of these 
sulfur-containing HDAC inhibitors for their inhibitory activities. 
 
Table 5.4 Average zinc coordination distances for compound 1-4 with HDAC8 during the last 500 ps in the 
MD simulations 
Complex Atom1 Atom 2 Distance (Å) 
HDAC8 - compound 1 Zn2+ His 142:NE2 5.16 
  His 143:NE2 5.22 
  Asp 178:OD1 3.60 
  Asp 178:OD2 2.59 
  His 180:ND1 2.84 
  His 180:O 5.14 
 
 
Fig. 5.11 RMSF for the residues in the active site during the last 500 ps in the MD simulations. 
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  Asp 267:OD1 2.73 
  Asp 267:OD2 2.62 
  Compound 1:S 2.84 
HDAC8 - compound 2 Zn2+ His 142:NE2 3.36 
  His 143:NE2 3.44 
  Asp 178:OD1 2.67 
  Asp 178:OD2 2.61 
  His 180:ND1 2.75 
  His 180:O 5.15 
  Asp 267:OD1 3.98 
  Asp 267:OD2 2.61 
  Compound 2:S 2.85 
HDAC8 - compound 3 Zn2+ His 142:NE2 3.92 
  His 143:NE2 3.38 
  Asp 178:OD1 2.72 
  Asp 178:OD2 2.58 
  His 180:ND1 2.83 
  His 180:O 3.09 
  Asp 267:OD1 4.33 
  Asp 267:OD2 2.68 
  Compound 3:S 2.81 
HDAC8- compound 4 Zn2+ His 142:NE2 4.36 
  His 143:NE2 3.51 
  Asp 178:OD1 2.77 
  Asp 178:OD2 2.60 
  His 180:ND1 3.09 
  His 180:O 5.37 
  Asp 267:OD1 2.65 
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  Asp 267:OD2 2.73 
  Compound 4:S 2.81 
 
Hydrogen bonds between the ligand and protein played an essential role in stabilizing the 
complexes. These hydrogen bonds formed by the inhibitors in binding active pocket of HDAC8 
were investigated. As shown in Table 5.5, the sulfur atoms of all compounds created strong 
hydrogen bond with the Tyr306 residue of HDAC8, it may be crucial for stabilizing the 
complex. Oxygen atoms in each compound also created hydrogen bonds with HDAC8, it can be 
seen that metal binding and surface recognition domain of cyclic tetrapeptides can create 
hydrogen bonds with HDAC8, and this may be the reason that cyclic tetrapeptides have high 
HDACs inhibitory activities. The carboxylate moieties of Asp176 and Asp183 formed 
hydrogen bonds with the ND1 atoms of His142 and His143, respectively. These two hydrogen 
bonds were also formed through corresponding amino acid residues in HDLP-inhibitor 
complexes, so they may be important in stabilizing the binding of HDAC8-inhibitor. 
 
Table 5.5 Hydrogen bonds between the compounds and HDAC8 active site of MD simulation 
Inhibitor Donor Acceptor H Acceptor 
MD simulation 
Occupied
(%) 
Distance 
(Å) 
Angle 
(Degree) 
Compound 1 Compound 1:S Tyr306:HH Tyr306:OH 99.60 2.969 13.95 
 Compound 1:O2 His180:HE2 His180:NE2 99.80 2.895 18.90 
 Asp176:OD2 His142:HD1 His142:ND1 98.80 2.804 27.18 
 Asp183:OD2 His143:HD1 His143:ND1 95.81 2.917 21.03 
Compound 2 Compound 2:S Tyr306:HH Tyr306:OH 100.00 2.942 14.76 
 Compound 2:O2 His180:HE2 His180:NE2 63.24 3.012 23.04 
 Compound 2:O3 Phe208:H Phe208:N 3.59 3.131 46.78 
 Asp176:OD2 His142:HD1 His142:ND1 99.80 2.747 30.46 
 Asp183:OD2 His143:HD1 His143:ND1 88.71 2.856 22.05 
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Compound 3 Compound 3:S Tyr306:HH Tyr306:OH 98.20 2.922 11.99 
 Compound 3:O2 His180:HE2 His180:NE2 65.47 2.995 38.38 
 Compound 3:O3 Phe208:H Phe208:N 65.07 3.027 38.74 
 Asp176:OD2 His142:HD1 His142:ND1 92.02 2.911 32.69 
 Asp183:OD2 His143:HD1 His143:ND1 99.00 2.922 16.59 
Compound 4 Compound 4:S Tyr306:HH Tyr306:OH 100.00 2.945 11.08 
 Compound 4:O2 His180:HE2 His180:NE2 99.60 2.889 22.17 
 Asp176:OD2 His142:HD1 His142:ND1 99.60 2.737 30.63 
 Asp183:OD2 His143:HD1 His143:ND1 29.34 2.978 45.24 
 
5.2.6.3 Free energy calculation  
Free energy of inhibitor binding in HDAC8 was analyzed by Molecular Mechanics-Poisson 
Boltzmann Surface Area (MM-PBSA) method[28-38] integrated in AMBER9. As shown in 
Table 5.6, to all complexes, intermolecular van der Waals (ΔEvdw int ) and electrostatics (ΔEele int ) 
interactions provide major favorable contributions to the binding, nonpolar salvation terms 
 
 
Table 5.6 Binding free energies (kcal/mol) from MM-PBSA analysis of the HDAC8-ligand complexes 
Contribution HDAC8-1 HDAC8-2 HDAC8-3 HDAC8-4 
ΔEele int  -87.32 -81.38 -84.27 -90.86 
ΔEvdw int  -24.03 -29.28 -27.56 -22.27 
ΔE int -111.35 -110.67 -111.83 -111.13 
ΔGnonpol sol  -4.80 -5.30 -5.98 -4.95 
ΔGele sol  108.28 106.08 109.03 107.19 
ΔG sol 103.48 100.78 103.05 102.24 
ΔG ele 20.96 24.70 24.76 17.33 
ΔG b -7.87 -7.89 -8.78 -8.89 
 
‐ 117 ‐ 
 
(ΔG nonpol  sol ) contribute also favorably, whereas polar solvation terms (ΔGele sol ) oppose binding. The 
electrostatic interactions between water molecules and the inhibitors are stronger than that 
between HDAC8 and inhibitors, so the total electrostatic interactions (ΔG ele) are unfavorable for 
binding. Hydrophobic interactions (ΔGnonpol sol ) contribute almost half of the total binding energy  
(ΔG b), this is expected since the surface recognition domains of the inhibitors are hydrophobic, 
and the surface of HDAC8 active site is constituted by some hydrophobic amino acid residues, 
such as Phe, Met and Leu, it can generate strong van der Waals and hydrophobic interactions 
with these inhibitors. The slightly change of hydrophobicity of surface recognition domain 
seems no obvious effect.  
5.3 Summary 
We have successfully synthesized several sulfur-containing cyclic tetrapeptides as HDAC 
inhibitors, and all of them showed potent anticancer activities toward cancer cell lines. The 
studies of MD simulation indicated that both surface recognition and metal binding domains of 
them were critical for their inhibitory activities. The hydrophobic interactions between HDAC8 
and cyclic tetrapeptides were great important for stabilizing the complexes, but slightly change 
of hydrophobicity in surface recognition domain by introducing methylene group on the 
aromatic ring at L-Phe position seemed no obvious change for their anticancer activities. Based 
on the details of interaction between cyclic tetrapeptides and HDAC8, we can design some new 
cyclic tetrapeptides with different surface recognition and metal binding domains as potent 
HDAC inhibitors. 
5.4 Experimental 
General: Unless otherwise noted, all solvents and reagents were reagent grade and used 
without purification. All compounds were routinely checked by thin layer chromatography 
(TLC) or high performance liquid chromatography (HPLC). Analytical HPLC were performed 
on a Hitachi or Agilent 1100 instrument equipped with a chromolith performance RP-18e 
column (4.6 × 100 mm, Merck). The mobile phases used were A: H2O and 0.1% TFA, B: 
CH3CN with 0.1% TFA using a solvent gradient of 10% A to 100% B over 15 min with 
detection at 220 nm with a flow rate of 2 mL/min. TLC was performed on aluminium-backed 
silica gel plates (Merck DC-Alufolien Kieselgel 60 F254) with spots visualized by UV light and 
heat. Flash chromatography was performed using silica gel 60 (230-400) eluting with solvents 
as indicated. Fast atom bombardment mass spectra (FAB-MS) and high resolution fast atom 
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bombardment mass spectra (HR-FAB-MS) were measured on a JEOL JMS-SX 102A. NMR 
spectra were recorded on a VarianINO VA400 MHz spectrometer. All NMR spectra were 
measured in CDCl3 solutions with reference to TMS. All 1H shifts are given in parts per 
millions (s = singlet; d = doublet; t = triplet; m = multiplet). Peptide was coupled using standard 
solution-phase chemistry with dicyclohexylcarbodiimide (DCC), N-Hydroxybenzotriazole 
(HOBt). Peptide cyclization was mediated by N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b] 
pyridin-1-yl-methylene]-N-methyl- methanaminium hexafluorophosphate N-oxide (HATU). 
The cell lines for bioactive assay were all from Shanghai Institute of Biochemistry and Cell 
Biology, SIBS, CAS. The PRPMI 1640 for cell culture was purchased from Gibco, and MTT 
was from Hy-Clone. 
5.4.1 Synthesis of cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) 
5.4.1.1 Synthesis of Boc-D-Pro-OBzl (MW = 305.35): 
Boc-D-Pro-OH (18.87 g, 87 mmol) was dissolved into DMF (450 mL). To the solution was 
added benzyl bromide (12.4 mL, 104.4 mmol) and triethyl amine (14.6 mL, 104.4 mmol). After 
stirring for overnight at room temperature, the solvent was removed by evaporation. Finally 
crude product was purified by silica gel chromatography using a mixture of chloroform and 
methanol (99/1 v/v) to yield pure Boc-D-Pro-OBzl (24.1 g, 79.1 mmol, 91%), HPLC: r.t. 8.68 
min. 
5.4.1.2 Synthesis of Boc-L-Phe-D-Pro-OBzl (MW = 452.54): 
Boc-D-Pro-OBzl (24.1 g, 79.1 mmol) was dissolved in TFA (115 mL) and left standing on ice 
for 1 hour. After the reaction solution was concentrated by evaporation, ether was added to the 
residue and solidified to obtain white solid of TFA·H-D-Pro-OBzl (24.9 g, 78 mmol, 98.6%), 
HPLC: r.t. 4.3 min. While cooling on ice, HOBt·H2O (0.47 g, 3.48 mmol), DCC (0.72 g, 3.48 
mmol)and triethyl amine (0.41 mL, 2.9 mmol) were added to DMF (7 mL) containing 
Boc-L-Phe-OH(0.79 g, 2.9 mmol)and TFA·H-D-Pro-OBzl (2.01 g, 2.9 mmol). After stirring 
for overnight, DMF was removed by evaporation; residue dissolved in ethyl acetate, and then 
successively washed with an aqueous 10% citric acid solution, an aqueous 4% sodium 
bicarbonate solution, and brine. After drying over MgSO4 and concentrating, the resulting oily 
substance was purified by silica gel chromatography using a mixture of chloroform and 
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methanol (99:1 v/v) to obtain Boc-L-Phe-D-Pro-OBzl (1.27 g, 2.8 mmol, 97%) as oily 
compound. TLC: Rf 0.86 (CHCl3 / MeOH=9/1), HPLC: r.t.8.9 min.   
5.4.1.3 Synthesis of Boc-Aib-L-Phe-D-Pro-OBzl (MW = 537.65): 
The dipeptide Boc-L-Phe-D-Pro-OBzl (1.27 g, 2.8 mmol) was dissolved in dioxane (7 mL) and 
added 4N HCl/dioxane (7mL). After 2 hours at room temperature, the reaction solution was 
removed by evaporation, ether was added to the residue and solidified to obtain white solid of 
HCl·H-L-Phe-D-Pro-OBzl (1.09 g, 2.8 mmol, 100%), HPLC: r.t. 5.73 min. To a cooled 
solution of HClH-Phe-D-Pro-OBzl (1.09 g, 2.8 mmol) and Boc-Aib-OH (680 mg, 3.36 mmol) 
in DMF (6 mL) were added HOBt·H2O (470 mg, 3.36 mmol), HBTU (1.49 g, 3.92 mmol), 
DIEA (0.97 mL, 5.6 mmol). After stirring for overnight, check with TLC (CHCl3/MeOH=9/1), 
DMF was removed by evaporation; residue dissolved in ethyl acetate, and then successively 
washed with an aqueous 10% citric acid solution, an aqueous 4% sodium bicarbonate solution 
and brine. After drying over MgSO4 and concentrating, the resulting oily substance was 
purified by silica gel chromatography using a mixture of chloroform and methanol (99:1 v/v) to 
obtain Boc-Aib-L-Phe-D-Pro-OBzl (1.27 g, 2.37 mmol, 84%) as oily compound. TLC: Rf 0.84 
(CHCl3/MeOH =9/1), HPLC: r.t. 8.82 min.   
5.4.1.4 Synthesis of Boc-L-Ab7-Aib-L-Phe-D-Pro-OBzl (MW = 543.73): 
The tripeptide Boc-Aib-L-Phe-D-Pro-OBzl (1.27 g, 2.37 mmol) was dissolved in dioxane (6 
mL) and added 4N HCl/dioxane (6 mL). After 2 hours at room temperature, the reaction 
solution was removed by evaporation, ether was added to the residue and solidified to obtain 
white solid of HCl·H-Aib-L-Phe-D-Pro-OBzl (1.12 g, 2.37 mmol, 100%), HPLC: r.t. 6.10 min. 
While cooling on ice, HOBt·H2O (0.38 g, 4.6 mmol), DCC (0.59 g, 4.6 mmol) and triethyl 
amine (0.33 mL, 2.37 mmol) were added to DMF (6 mL) containing HCl·H-Aib-L-Phe- 
D-Pro-OBzl (1.12 g, 2.37 mmol) and Boc-L-Ab7-OH (1.38 g, 3.55 mmol) . After stirring for 
overnight, DMF was removed by evaporation; residue dissolved in ethyl acetate, and then 
successively washed with 10% citric acid solution, 4% sodium bicarbonate solution and brine. 
After drying over MgSO4 and concentrating, the resulting oily substance was purified by silica 
gel chromatography using a mixture of chloroform and methanol (99:1 v/v) to obtain 
Boc-L-Ab7-Aib-L-Phe-D-Pro-OBzl (662 mg, 0.9 mmol, 38%) as oily compound. TLC: Rf 0.9 
(CHCl3/ MeOH=9/1), HPLC: r.t.10.17 min.   
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5.4.1.5 Synthesis of cyclo(-L-Ab7-Aib-L-Phe-D-Pro-) (MW = 535.47): 
Boc-L-Ab7-Aib-L-Phe-D-Pro-OBzl (662 mg, 0.9 mmol) was dissolved in methanol (5 mL) and 
subjected to catalytic hydrogenation in presence of the catalyst Pd-C (60 mg). After 8 hours, the 
catalyst was filtered and reaction solution was removed by evaporation. The residue 
Boc-L-Ab7-Aib-L-Phe-D-Pro-OH (574 mg, 0.89 mmol, 99%, HPLC: r.t. 7.85 min) was 
obtained. Boc-L-Ab7-Aib-L-Phe-D-Pro-OH (574 mg, 0.89 mmol) was dissolved in TFA (3 
mL) and left standing on ice for 1 hour. After evaporation of TFA, the residue was solidified by 
trituration with ether and petroleum ether to yield TFA·H-L-Ab7-Aib-L-Phe-D-Pro-OH (608 
mg, 0.89 mmol, 100%), HPLC: r.t. 5.40 min. To a volume of DMF (100 mL) TFA·H-L-Ab7- 
Aib-L-Phe-D-Pro-OH (608 mg, 0.89 mmol), HATU (500 mg, 1.32 mmol) and DIEA (0.38 mL, 
2.19 mmol) were added in five aliquots with 30 min time interval, while the solution was stirred 
vigorously. After the final addition the reaction mixture was allowed to stir for an additional 
hour. Completion of the reaction was monitored by HPLC. DMF was removed by evaporation. 
The crude cyclic tetrapeptide was dissolved in ethyl acetate and was successively washed with 
10% citric acid, 4% sodium bicarbonate and brine. Finally the ethyl acetate solution was dried 
over anhydrous MgSO4 and filtered. After evaporation of ethyl acetate, the residue was purified 
by silica gel chromatography using a mixture of chloroform and methanol (99:1 v/v) to yield 
cyclo(-L-Ab7-Aib-L-Phe-D-Pro-) (220 mg, 0.4 mmol, 46%) as white foam. HPLC: r.t. 7.98 
min. 
5.4.1.6 Synthesis of cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) (MW = 597.79): 
Potassium thioacetate (80 mg, 0.62 mmol) was added to DMF (2 mL) containing cyclic 
tetrapeptide cyclo(-L-Ab7-Aib-L-Phe-D-Pro-) (220 mg, 0.4 mmol) and this was reacted for 4 
hours. The reaction solution was concentrated, dissolved in ethyl acetate, and was successively 
washed with aqueous 10% citric acid solution and brine. After drying over MgSO4 and 
concentrating the solvent yielded the thioester, cyclo(-L-Am7(acetyl)-Aib-L-Phe-D-Pro-) (184 
mg, 0.35 mmol, 85%), TLC: Rf 0.84, HPLC: r.t. 7.83 min. Subsequent treatment of thioester 
with MeNH2 / methanol (0.20 mL, 1.7 mmol) in the presence of 2,2’-dipyridyl disulfide (120 
mg, 0.45 mmol) gave product cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-), which was purified by 
silica gel chromatography (99:1 v/v) and obtained as white foam (180 mg, 0.3 mmol, 87%). The 
yield: 10.4%, TLC: Rf 0.83, HPLC:  r.t. 8.33 min. HR-FAB-MS [M+H]+ 598.2478 for 
C30H40O4N5S2 (calcd 598.2522). 1H NMR(400 MHz, CDCl3): δ 1.27(m, 2H), 1.34(s, 3H), 
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1.42(m, 2H), 1.61(m, 1H), 1.71(m, 1H), 1.77(s, 3H), 1.88(m, 1H), 2.168(m, 1H), 2.249(m, 1H), 
2.775(t, 2H), 2.963(m,1H), 3.226(m, 2H), 4.19(m, 1H), 4.66(d, J=6Hz, 2H), 5.17(m, 1H), 
6.06(s, 1H), 7.11(m, 1H), 7.21(d, J=4Hz, 1H), 7.25(m, 5H), 7.51(d, J=10Hz, 1H), 7.66(m, 1H), 
7.73(d, J=8 Hz, 1H), 8.47(d, J=5 Hz, 1H). 13C NMR(400 MHz, CDCl3): δ 23.57, 24.75, 25.02, 
25.09, 26.47, 28.06, 28.61, 28.83, 35.82, 38.66, 46.99, 53.43, 54.3, 57.78, 58.81, 119.62, 
120.55, 126.72, 128.62, 128.62, 129.04, 129.04, 137.01, 137.04, 149.6, 160.54, 171.85, 172.84, 
174.33, 175.63. 
5.4.2 Synthesis of cyclo(-L-Am7(S2Py)-Aib-L-Phe(2-Me)-D-Pro-) 
5.4.2.1 Synthesis of Boc-L-Phe(2-Me)-D-Pro-OBzl (MW = 466.57): 
While cooling on ice, HOBt·H2O (1.84 g, 12 mmol), DCC (2.47 g, 12 mmol) and triethyl amine 
(1.4 mL, 10 mmol) were added to DMF (20 mL) containing Boc-L-Phe(2-Me)-OH (3.35 g, 12 
mmol)and TFA·H-D-Pro-OBzl (3.19 g, 10 mmol). After stirring for overnight, DMF was 
removed by evaporation; residue dissolved in ethyl acetate, and then successively washed with 
an aqueous 10% citric acid solution, an aqueous 4% sodium bicarbonate solution, and brine. 
After drying over MgSO4 and concentrating, the resulting oily substance was purified by silica 
gel chromatography using a mixture of chloroform and methanol (99:1 v/v) to obtain 
Boc-L-Phe(2-Me)-D-Pro-OBzl (3.45 g, 7.4 mmol, 73.9%) as oily compound. TLC: Rf 0.85 
(CHCl3/MeOH =9/1), HPLC: r.t. 11.1 min. 
5.4.2.2 Synthesis of Boc-Aib-L-Phe(2-Me)-D-Pro-OBzl (MW = 551.67): 
The dipeptide Boc-L-Phe(2-Me)-D-Pro-OBzl (3.45 g, 7.4 mmol) was dissolved in TFA(15 mL). 
After 1 hour in ice bath, the reaction solution was removed by evaporation, ether was added to 
the residue and solidified to obtain white solid of TFA·H-L-Phe(2-Me)-D-Pro-OBzl (4.3 g, 7.4 
mmol, 100%). To a cooled solution of TFAH-Phe(2-Me)-D-Pro-OBzl (4.3 g, 7.4 mmol) and 
Boc-Aib-OH (1.8 g, 8.7 mmol) in DMF (30 mL) were added HOBt (1.36 g, 8.7 mmol), HBTU 
(4.2 g, 11.1 mmol),  DIEA (3.6mL, 20.7 mmol). After stirring for overnight, check with TLC 
(CHCl3/MeOH=9/1), DMF was removed by evaporation; residue dissolved in ethyl acetate, and 
then successively washed with 10% citric acid solution, 4% sodium bicarbonate solution and 
brine. After drying over MgSO4 and concentrating, the resulting oily substance was purified by 
silica gel chromatography using a mixture of chloroform and methanol (99:1 v/v) to obtain 
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Boc-Aib-L-Phe(2-Me)-D-Pro-OBzl (2.28 g, 4.1 mmol, 55.9%) as oily compound. TLC: Rf 
0.85 (CHCl3/MeOH=9/1), HPLC: r.t. 10.8 min.   
5.4.2.3 Synthesis of Boc-L-Ab7-Aib-L-Phe(2-Me)-D-Pro-OBzl (MW = 757.75): 
The tripeptide Boc-Aib-L-Phe(2-Me)-D-Pro-OBzl (2.28 g, 4.13 mmol) was dissolved in TFA 
(8 mL). After 1 hour in ice bath, the reaction solution was removed by evaporation, ether was 
added to the residue and solidified to obtain white solid of TFA·H-Aib-L-Phe(2-Me)- 
D-Pro-OBzl (2.4 g, 4.13 mmol, 100%). While cooling on ice, HOBt·H2O (632 mg, 4.13 mmol), 
DCC (1.0 g, 5.0 mmol)and triethyl amine (0.64 mL, 4.5 mmol) were added to DMF (5 mL) 
containing TFA·H-Aib-L-Phe(2-Me)-D-Pro-OBzl (2.4 g, 4.1 mmol)and Boc-L-Ab7-OH (1.5 g, 
4.5 mmol). After stirring for overnight, DMF was removed by evaporation; residue dissolved in 
ethyl acetate, and then successively washed with 10% citric acid solution, 4% sodium 
bicarbonate solution, and brine. After drying over MgSO4 and concentrating, the resulting oily 
substance was purified by silica gel chromatography using a mixture of chloroform and 
methanol (99:1 v/v) to obtain Boc-L-Ab7-Aib-L-Phe(2-Me)-D-Pro-OBzl (1.97 g, 2.6 mmol, 
63%) as oily compound. TLC: Rf 0.8 (CHCl3/MeOH=9/1), HPLC: r.t. 10.9 min.   
5.4.2.4 Synthesis of cyclo(-L-Ab7-Aib-L-Phe(2-Me)-D-Pro-) (MW = 549.50): 
Boc-L-Ab7-Aib-L-Phe(2-Me)-D-Pro-OBzl (1.97 g, 2.6 mmol) was dissolved in methanol (13 
mL) and subjected to catalytic hydrogenation in presence of the catalyst Pd-C (130 mg). After 6 
hours, the reaction was checked by TLC (CHCl3/MeOH/ CH3COOH=90/10/2), the catalyst was 
filtered and reaction solution was removed by evaporation. The residue Boc-L-Ab7-Aib-L- 
Phe(2-Me)-D-Pro-OH (1.53 g, 2.3 mmol, 88%) was obtained. Boc-L-Ab7-Aib-L-Phe(2-Me)- 
D-Pro-OH (1.53 g, 2.3 mmol) was dissolved in TFA (5 mL) and left standing on ice for 1 hour. 
After evaporation of TFA, the residue was solidified by trituration with ether and petroleum 
ether to yield TFA·H-L-Ab7-Aib-L-Phe(2-Me)-D-Pro-OH (1.6 g, 2.3 mmol, 100%). To a 
volume of DMF (230 mL) TFA·H-L-Ab7-Aib-L-Phe-D-Pro-OH (1.6 g, 2.3 mmol ), HATU 
(1.31 mg, 3.4 mmol) and DIEA (1.0 mL, 5.7 mmol) were added in five aliquots with 30 min 
time interval, while the solution was stirred vigorously. After the final addition the reaction 
mixture was allowed to stir for an additional hour. Completion of the reaction was monitored by 
HPLC. DMF was removed by evaporation. The crude cyclic tetrapeptide was dissolved in ethyl 
acetate and was successively washed with 10% citric acid, 4% sodium bicarbonate and brine. 
Finally the ethyl acetate solution was dried over anhydrous MgSO4 and filtered. After 
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evaporation of ethyl acetate, the residue was purified by silica gel chromatography using a 
mixture of chloroform and methanol (99:1 v/v) to yield cyclo(-L-Ab7-Aib-L-Phe(2-Me)-D- 
Pro-) (493 mg, 0.9 mmol, 39%) as white foam. HPLC: r.t. 8.08 min. 
5.4.2.5 Synthesis of cyclo(-L-Am7(S2Py)-Aib-L-Phe(2-Me)-D-Pro-) (MW=611.82) 
Potassium thioacetate (145 mg, 1.28 mmol) was added to DMF (4 mL) containing cyclic 
tetrapeptide cyclo(-L-Ab7-Aib-L-Phe(2-Me)-D-Pro-) (493 mg, 0.9 mmol) and this was reacted 
for 4 hours. The reaction solution was concentrated, dissolved in ethyl acetate, and was 
successively washed with 10% citric acid solution, 4% sodium bicarbonate and brine. After 
drying over MgSO4 and concentrating the solvent yielded the thioester, cyclo(-L-Am7(acetyl)- 
Aib-L-Phe(2Me)-D-Pro-) (451 mg, 0.8 mmol, 92%). Subsequent treatment of thioester with 
MeNH2 / methanol (0.45 mL, 4.1 mmol) in the presence of 2,2’-dipyridyl disulfide (364 mg, 1.7 
mmol) gave product cyclo(-L-Am7(S2Py)-Aib-L-Phe(2-Me)-D-Pro-), which was purified by 
silica gel chromatography (99:1 v/v) and obtained as white foam (449 mg, 0.7 mmol, 88%), The 
yield: 7.3%, HPLC:  r.t. 8.42 min. HR-FAB-MS [M+H]+ 612.2722 for C31H42O4N5S2 (calcd 
612.2679). 1H NMR(400 MHz, CDCl3) : δ 1.08(m, 1H), 1.32(m, 1H), 1.34(s, 3H), 1.37(m, 3H), 
1.60(m, 1H), 1.66(s, 3H), 1.70(m, 2H), 1.77(s, 2H), 1.93(m, 2H), 2.31(m, 1H), 2.39(s, 3H), 
2.78(t, 1H), 2.962(m, 1H), 3.231(m, 1H), 3.439(m, 1H), 3.848(m, 1H), 4.176(m, 1H), 4.676(m, 
1H), 5.19(m, 1H), 6.012(s, 1H), 7.113(m, 1H), 7.133(m, 1H), 7.263(s, 4H), 7.517(d, J=10Hz, 
1H), 7.651(m, 1H), 7.71(m, 1H), 8.46(dd, J=4Hz,1H). 13C NMR (400 MHz , CDCl3): δ 19.72, 
23.70, 24.86, 25.08, 26.46, 28.17, 28.72, 29.35, 33.02, 34.08, 38.72, 46.97, 52.35, 54.44, 57.87, 
58.87, 119.69, 120.20, 126.20, 126.91, 129.43, 130.55, 135.35, 136.60, 137.15, 149.71, 160.62, 
171.97, 173.03, 174.53, 175.80.  
5.4.3 Synthesis of cyclo(-L-Am7(S2Py)-Aib-L-Phe(4-Me)-D-Pro-) 
5.4.3.1 Synthesis of Z-D-Pro-OtBu (MW = 305.37): 
Z-D-Pro-OH (4.9 g, 20 mmol) was dissolved into t-butyl alcohol (50 mL). To the solution was 
added (Boc)2O (8.72 g, 40 mmol) and 4-methylaminopyridine (733 mg, 6 mmol). After 2 hours 
reaction at room temperature, the solution was concentrated. Finally crude product was purified 
by silica gel chromatography using a mixture of ethyl acetate and hexane (1/8 v/v) to yield pure 
Z-D-Pro-OtBu (5.8 g, 19.2 mmol, 96%), HPLC: r.t. 8.08 min. 
5.4.3.2 Synthesis of Z-L-Phe(4-Me)-D-Pro-OtBu (MW = 452.54): 
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Z- D-Pro-OtBu (1.83 g, 6 mmol) was dissolved in acetic acid (12 mL) and subjected to catalytic 
hydrogenation in presence of the catalyst Pd-C (300 mg). After 18 hours, the reaction was 
checked by TLC (CHCl3/MeOH/CH3COOH=90/10/2), the catalyst was filtered and reaction 
solution was removed by evaporation. The residue was dissolved in ethyl acetate (30 mL), 
washed with 2 M Na2CO3 solution (10 mL), ethyl acetate was evaporated to get H- D-Pro-OtBu 
(2.13 g, 4.7 mmol, 78%), TLC: Rf 0.6.While cooling on ice, DCC (1.17 g, 5.64 mmol) and 
HOBt·H2O (640 mg, 4.7 mmol) were added to DMF (10 mL) containing Z-L-Phe(4-Me)-OH 
(720 mg, 4.7 mmol) and H-D-Pro-OtBu (2.13 g, 4.7 mmol). After stirring for 15 hours, DMF 
was removed by evaporation; residue dissolved in ethyl acetate, and then successively washed 
with 10% citric acid solution, 4% sodium bicarbonate solution and brine. After drying over 
MgSO4 and concentrating, the resulting oily substance was purified by silica gel 
chromatography using a mixture of chloroform and methanol (99:1 v/v) to obtain 
Z-L-Phe(4-Me)-D-Pro-OtBu (2.15 g, 4.6 mmol, 98%) as oily compound. TLC: Rf, 0.9 
(CHCl3/MeOH= 9/1), HPLC: r.t. 8.92 min. 
5.4.3.3 Synthesis of Z-Aib-L-Phe(4-Me)-D-Pro-OtBu (MW = 551.67): 
Z-L-Phe(4-Me)-D-Pro-OtBu (2.15 g, 4.6 mmol) was dissolved in acetic acid (10 mL) and 
subjected to catalytic hydrogenation in presence of the catalyst Pd-C (360 mg). After 18 hours, 
the reaction was checked by TLC (CHCl3/MeOH/CH3COOH= 90/10 /2), the catalyst was 
filtered and reaction solution was removed by evaporation. The residue was dissolved in ethyl 
acetate (30 mL), washed with 2 M Na2CO3 solution (10 mL), ethyl acetate was evaporated to 
get H- L-Phe(4-Me)-D-Pro-OtBu (2.04 g, 3.7 mmol, 82.5%). To a cooled solution of H- 
L-Phe(4-Me)-D-Pro-OtBu (1.23 g, 3.7 mmol) and Z-Aib-OH (880 mg, 3.7 mmol) in DMF (8 
mL) were successively added DCC (950 mg, 4.4 mmol), HOBt.H2O (500 mg, 3.7 mmol). After 
stirring for 15 hours, DMF was removed by evaporation; residue dissolved in ethyl acetate, and 
then successively washed with an aqueous 10% citric acid solution, an aqueous 4% sodium 
bicarbonate solution and brine. After drying over MgSO4 and concentrating, the resulting oily 
substance was purified by silica gel chromatography using a mixture of chloroform and 
methanol (99:1 v/v) to obtain Z-Aib-L-Phe(4-Me)-D-Pro-OtBu(2.04 g, 3.7 mmol, 100%). TLC: 
Rf 0.86 (CHCl3/MeOH=9/1) , HPLC: r.t. 8.61 min. 
5.4.3.4 Synthesis of Boc-L-Ab7-Aib-L-Phe(4-Me)-D-Pro-OtBu (MW = 723.74): 
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The tripeptide Z-Aib-L-Phe(4-Me)-D-Pro-OtBu(2.04 g, 3.7 mmol) was subjected to catalytic 
hydrogenation with Pd-C (300 mg) in acetic acid (8 mL). After 18 hours, the reaction was 
checked by TLC (CHCl3/MeOH/CH3COOH=90/10/2), the catalyst was filtered and reaction 
solution was removed by evaporation. The free amine was taken into ethyl acetate (30 mL) by 
the aid of 2M Na2CO3 solution (10 mL). After dried over anhydrous Na2CO3 ethyl acetate 
solution was evaporated to obtain H-Aib-L-Phe(4-Me)-D-Pro-OtBu (690 mg, 1.8 mmol, 50%), 
HPLC: r.t. 5.54 min. To a cooled solution of H-Aib-L-Phe(4-Me)-D-Pro-OtBu (690 mg, 1.8 
mmol) and Boc-L-Ab7-OH (650 mg, 2.1 mmol) in DMF (4 mL) were successively added DCC 
(440 mg, 2.1 mmol), HOBt·H2O (240 mg, 1.8 mmol). After stirring for 15 hours, DMF was 
removed by evaporation; residue dissolved in ethyl acetate, and then successively washed with 
10% citric acid solution, 4% sodium bicarbonate solution and brine. After drying over MgSO4 
and concentrating, the resulting oily substance was purified by silica gel chromatography using 
a mixture of chloroform and methanol (99:1 v/v) to obtain Boc-L-Ab7-Aib-L-Phe(4-Me) 
-D-Pro-OtBu(941 mg, 1.3 mmol, 75%). TLC: Rf 0.84 (CHCl3/MeOH=9/1), HPLC: r.t. 9.48 
min. 
5.4.3.5 Synthesis of cyclo(-L-Ab7-Aib-L-Phe(4-Me)-D-Pro-)  (MW = 549.50): 
Boc-L-Ab7-Aib-L-Phe(4-Me)-D-Pro-OtBu (941 mg, 1.3 mmol) was dissolved in TFA (4 mL) 
and left standing on ice for 3 hours. After evaporation of TFA, the residue was solidified by 
trituration with ether to yield TFA·H-L-Ab7-Aib-L-Phe(4-Me)-D-Pro-OH (800 mg, 1.1 mmol, 
85%), HPLC: r.t. 5.63 min. To a volume of DMF (110 mL) TFA·H-L-Ab7-Aib-L-Phe(4-Me)- 
D-Pro-OH (800 mg, 1.1 mmol), HATU (630 mg, 1.65 mmol) and DIEA (0.46 mL, 2.64 mmol) 
were added in five aliquots with 30 min time interval, while the solution was stirred vigorously. 
After the final addition the reaction mixture was allowed to stir for an additional hour. 
Completion of the reaction was monitored by HPLC. DMF was removed by evaporation. The 
crude cyclic tetrapeptide was dissolved in ethyl acetate and was successively washed with 10% 
citric acid, 4% sodium bicarbonate and brine. Finally the ethyl acetate solution was dried over 
anhydrous MgSO4 and filtered. After evaporation of ethyl acetate, the residue was purified by 
silica gel chromatography using a mixture of chloroform and methanol (99:1 v/v) to yield 
cyclo(-L-Ab7-Aib-L-Phe(4-Me)-D-Pro-) (385 mg, 0.7 mmol, 65%) as white foam. TLC: Rf 
0.75 (CHCl3/MeOH=9/1), HPLC: r.t. 7.90 min. 
5.4.3.6 Synthesis of cyclo(-L-Am7(S2Py)-Aib-L-Phe(4-Me)-D-Pro-)(MW = 611.82) 
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Potassium thioacetate (120 mg, 1.05 mmol) was added to DMF (2 mL) containing cyclic 
tetrapeptide cyclo(-L-Ab7-Aib-L-Phe(4-Me)-D-Pro-) (385 mg, 0.7 mmol) and this was reacted 
for 4 hours. The reaction solution was concentrated, dissolved in ethyl acetate, and was 
successively washed with 10% citric acid solution, 4% sodium bicarbonate and brine. After 
drying over MgSO4 and concentrating the solvent yielded the thioester, cyclo(-L-Am7(acetyl)- 
Aib-L-Phe(4-Me)-D-Pro-) (324 mg, 0.6 mmol, 85%), HPLC: r.t. 7.74 min. Subsequent 
treatment of thioester with MeNH2/methanol (0.32 mL, 3 mmol) in the presence of 
2,2’-dipyridyl disulfide (200 mg, 0.9 mmol) gave product, which was purified by silica gel 
chromatography and obtained as white foam cyclo(-L-Am7(S2Py)-Aib-L-Phe(4-Me)- D-Pro-) 
(281 mg, 0.46 mmol, 76%). The yield: 9.2%, TLC: Rf 0.77, HPLC: r.t. 8.86 min. HR-FAB-MS 
[M+H]+ 612.2680 for C31H42O4N5S2 (calcd 612.2679). 1H NMR (400 MHz; CDCl3): δ 0.86(m, 
1H), 1.28(m, 3H),1.34(s, 3H), 1.42(m, 2H), 1.70(m, 3H), 1.78(s, 3H), 1.80(m, 2H), 2.17(m, 1H), 
2.26(s, 3H), 2.33(m,1H), 2.78(t, 1H), 2.88(m, 1H), 3.17(m, 1H), 3.27(m, 2H), 4.17(m, 1H), 
4.66(d, J=6Hz,1H), 5.15(m, 1H), 5.96(s, 1H), 6.84(s, 3H), 7.09(m, 2H), 7.27(s, 1H), 7.49(d, 
J=10Hz,1H), 7.66(t, 1H), 7.72(d, J=8Hz, 1H), 8.46(d, J=4Hz, 1H).  13C NMR (400 MHz, 
CDCl3):  δ 21.05, 23.57, 24.76, 25.04, 25.1, 26.53, 28.08, 28.62, 28.79, 35.37, 38.67, 47.00, 
53.49, 54.26, 57.78, 58.84, 119.61, 120.54, 128.88, 128.88, 129.30, 129.30, 133.89, 136.21, 
136.99, 149.62, 160.56, 171.85,172.90, 174.29, 175.63.  
5.4.4 Synthesis of cyclo(-L-Am7(S2Py)-Aib-L-Phe(3,5-2Me)-D-Pro-) 
5.4.4.1 Synthesis of Boc-L-Phe(3,5-2Me)-D-Pro-OBzl (MW = 480.60): 
While cooling on ice, HOBt·H2O (1.23 g, 8.0 mmol), DCC (1.98 g, 9.6 mmol) and triethyl 
amine (1.23 mL, 8.8 mmol) were added to DMF (16 mL) containing Boc-L-Phe(3,5-2Me)-OH 
(2.45 g, 8.3 mmol) and TFA·H-D-Pro-OBzl (1.93 g, 8.0 mmol). After stirring for overnight, 
DMF was removed by evaporation; residue dissolved in ethyl acetate, and then successively 
washed with an aqueous 10% citric acid solution, an aqueous 4% sodium bicarbonate solution, 
and brine. After drying over MgSO4 and concentrating, the resulting oily substance was 
purified by silica gel chromatography using a mixture of chloroform and methanol (99:1 v/v) to 
obtain Boc-L-Phe(3,5-2Me)-D-Pro-OBzl (3.83 g, 8.0 mmol, 99%) as oily compound. TLC: Rf 
0.85 (CHCl3/MeOH =9/1), HPLC: r.t. 9.27 min, 98%. 
5.4.4.2 Synthesis of Boc-Aib-L-Phe(3,5-2Me)-D-Pro-OtBu (MW = 565.70): 
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The dipeptide Boc-L-Phe(3,5-2Me)-D-Pro-OBzl (3.83 g, 8.0 mmol) was dissolved in dioxane 
(15 mL) and added 4N HCl/dioxane (15mL). After 2 hours at room temperature, the reaction 
solution was removed by evaporation, ether was added to the residue and solidified to obtain 
white solid of HCl·H-L-Phe(3,5-2Me)-D-Pro-OBzl (3.33 g, 8.0 mmol, 100%, HPLC: r.t. 5.91 
min, 96%). To a cooled solution of HCl·H-L-Phe(3,5-2Me)-D-Pro-OBzl (3.33 g, 8.0 mmol) 
and Boc-Aib-OH (1.90 g, 8.0 mmol) in DMF (16 mL) were added HOBt·H2O (1.23 g, 8.0 
mmol), HBTU(3.03 g, 8.0 mmol),  DIEA (1.73 mL, 12.0 mmol). After stirring for overnight, 
check with TLC (CHCl3/ MeOH=9/1), DMF was removed by evaporation; residue dissolved in 
ethyl acetate, and then successively washed with 10% citric acid solution, 4% sodium 
bicarbonate solution and brine. After drying over MgSO4 and concentrating, the resulting oily 
substance was purified by silica gel chromatography using a mixture of chloroform and 
methanol (99:1 v/v) to obtain Boc-Aib-L-Phe(3,5-2Me)-D-Pro-OBzl (1.93 g, 3.4 mmol, 43%) 
as oily compound. TLC: Rf 0.85 (CHCl3/MeOH=9/1), HPLC: r.t. 8.86 min, 89%.   
5.4.4.3 Synthesis of Boc-L-Ab7-Aib-L-Phe(3,5-2Me)-D-Pro-OtBu (MW =771.78): 
The tripeptide Boc-Aib-L-Phe(3,5-2Me)-D-Pro-OBzl (1.93 g, 3.4 mmol) was was dissolved in 
dioxane (7 mL) and added 4N HCl/dioxane (7 mL). After 2 hours at room temperature, the 
reaction solution was removed by evaporation, ether was added to the residue and solidified to 
obtain white solid of HCl·H-Aib-L-Phe(3,5-2Me)-D-Pro-OBzl (1.71 g, 3.4 mmol, 100%, 
HPLC: r.t. 6.05 min, 95%). While cooling on ice, HOBt·H2O (521 mg, 3.4 mmol), DCC (1.03 g, 
5.0 mmol)and triethyl amine (0.74 mL, 5.1 mmol) were added to DMF (7 mL) containing 
HCl·H-Aib-L-Phe(3,5-2Me)-D-Pro-OBzl (1.93 g, 3.4 mmol) and Boc-L-Ab7-OH (1.13 g, 3.4 
mmol). After stirring for overnight, DMF was removed by evaporation; residue dissolved in 
ethyl acetate, and then successively washed with 10% citric acid solution, 4% sodium 
bicarbonate solution, and brine. After drying over MgSO4 and concentrating, the resulting oily 
substance was purified by silica gel chromatography using a mixture of chloroform and 
methanol (99:1 v/v) to obtain Boc-L-Ab7-Aib-L-Phe(3,5-2Me)-D-Pro-OBzl (1.48 g, 1.9 mmol, 
58%) as oily compound. TLC: Rf 0.8 (CHCl3/MeOH=9/1), HPLC: r.t. 9.56 min, 93%.   
5.4.4.4 Synthesis of cyclo(-L-Ab7-Aib-L-Phe(3,5-2Me)-D-Pro-)  (MW = 563.53): 
Boc-L-Ab7-Aib-L-Phe(3,5-2Me)-D-Pro-OBzl (1.48 g, 1.9 mmol) was dissolved in methanol (4 
mL) and subjected to catalytic hydrogenation in presence of the catalyst Pd-C (100 mg). After 
10 hours, the reaction was checked by TLC (CHCl3/MeOH/ CH3COOH=90/10/2), the catalyst 
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was filtered and reaction solution was removed by evaporation. The residue Boc-L-Ab7-Aib-L- 
Phe(3,5-2Me)-D-Pro-OH (1.30 g, 1.9 mmol, 100%) was obtained. Boc-L-Ab7-Aib-L- 
Phe(3,5-2Me)-D-Pro-OH (1.30 g, 1.9 mmol) was dissolved in TFA (4 mL) and left standing on 
ice for 1 hour. After evaporation of TFA, the residue was solidified by trituration with ether and 
petroleum ether to yield TFA·H-L-Ab7-Aib-L-Phe(3,5-2Me)-D- Pro-OH (1.22 g, 1.9 mmol, 
100%). To a volume of DMF (200 mL) TFA·H-L-Ab7-Aib- Phe(3,5-2Me)-D-Pro-OH (1.22 g, 
1.9 mmol ), HATU (1.08 mg, 2.9 mmol) and DIEA (0.83 mL, 4.75 mmol) were added in five 
aliquots with 30 min time interval, while the solution was stirred vigorously. After the final 
addition the reaction mixture was allowed to stir for an additional hour. Completion of the 
reaction was monitored by HPLC. DMF was removed by evaporation. The crude cyclic 
tetrapeptide was dissolved in ethyl acetate and was successively washed with 10% citric acid, 
4% sodium bicarbonate and brine. Finally the ethyl acetate solution was dried over anhydrous 
MgSO4 and filtered. After evaporation of ethyl acetate, the residue was purified by silica gel 
chromatography using a mixture of chloroform and methanol (99:1 v/v) to yield 
cyclo(-L-Ab7-Aib-L- Phe(3,5-2Me)-D-Pro-) (533 mg, 1.0 mmol, 53%) as white foam. TLC: Rf 
0.9 (CHCl3 /MeOH=9/1), HPLC: r.t. 8.23 min, 97%.   
5.4.4.5 Synthesis of cyclo(-L-Am7(S2Py)-Aib-L-Phe(3,5-2Me)-D-Pro-)(MW= 611.82): 
Potassium thioacetate (145 mg, 1.28 mmol) was added to DMF (4 mL) containing cyclic 
tetrapeptide cyclo(-L-Ab7-Aib-L-Phe(2-Me)-D-Pro-) (493 mg, 0.9 mmol) and this was reacted 
for 4 hours. The reaction solution was concentrated, dissolved in ethyl acetate, and was 
successively washed with 10% citric acid solution, 4% sodium bicarbonate and brine. After 
drying over MgSO4 and concentrating the solvent yielded the thioester, cyclo(-L-Am7(acetyl)- 
Aib-L-Phe(3,5-2Me)-D-Pro-) (481 mg, 0.9 mmol, 94%, HPLC: r.t. 8.10 min, 98%). Subsequent 
treatment of thioester with 9N MeNH2 in 40% methanol (0.50 mL, 4.5 mmol) in the presence of 
2,2’-dipyridyl disulfide (311 mg, 1.4 mmol) gave product cyclo(-L-Am7(S2Py)-Aib-L- 
Phe(3,5-2Me)-D-Pro-), which was purified by silica gel chromatography (99:1 v/v) and 
obtained as white foam (204 mg, 0.3 mmol, 38%). The yield: 6.9%. TLC: Rf 0.8, HPLC:  r.t. 
8.11 min, 98%. HR-FAB-MS: [M+H]+ 626.2814 for C32H44O4N5S2 (calcd 626.2835). 1H 
NMR(400 MHz, CDCl3) δ: 0.80(m, 1H), 1.28(m, 2H), 1.34(s, 3H), 1.42(m, 2H), 1.60(m, 1H), 
1.69(m, 3H), 1.77(s, 3H), 2.17(m, 1H), 2.30(s, 6H), 2.33(m, 1H), 2.78(t, 2H), 2.90(m, 1H), 
3.22(m, 2H), 3.87(m, 1H), 4.17(m, 1H), 4.65(s, 1H), 5.14(m, 1H), 5.92(s, 1H), 6.84(s, 3H), 
7.09(m, 1H), 7.27(s, 2H), 7.49(d, J=10.4Hz, 1H), 7.66(t, 1H), 7.72(d, J=8Hz, 1H), 8.46(d, 
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J=4Hz, 1H). 13C NMR (400 MHz , CDCl3)  δ: 21.26, 21.26, 23.57, 24.76, 25.05, 25.09, 26.53, 
28.07, 28.62, 28.79, 35.64, 38.68, 47.01, 53.40, 54.25, 57.79, 58.84, 119.62,120.53, 126.82, 
128.82, 128.33, 136.9, 136.97, 137.99, 137.99, 149.61, 160.57, 171.84, 172.91, 174.29, 175.57. 
5.4.5 Synthesis of cyclo(-L-Asu(NHOH)-Aib-L-Phe(4-Me)-D-Pro-) 
5.4.5.1 Synthesis of Boc-Asu(OBzl)-Aib-L-Phe(4-Me)-D-Pro-OtBu (MW = 750.96): 
The tripeptide was coupling in the same manner as 4.4.3 described to obtain H-Aib-L- 
Phe(4-Me)-D-Pro-OtBu (610 mg, 1.4 mmol), To a cooled solution of the free amine (610 mg, 
1.4 mmol), Boc-L-Asu(OBzl)-OH (660 mg, 1.7 mmol) and HOBt·H2O (200 mg, 1.4 mmol) in 
DMF (3 mL), DCC (370 mg, 1.7 mmol) was added and stirred for overnight at room 
temperature. DMF was removed by evaporation; residue dissolved in ethyl acetate, and then 
successively washed with an aqueous 10% citric acid solution, an aqueous 4% sodium 
bicarbonate solution and brine. After drying over MgSO4 and concentrating, the resulting oily 
substance was purified by silica gel chromatography using a mixture of chloroform and 
methanol (99:1 v/v) to obtain Boc-Asu(OBzl)-Aib-L-Phe(4-Me)-D-Pro-OtBu (940 mg, 1.2 
mmol, 83%). TLC: Rf 0.75 (CHCl3/MeOH=9/1) , HPLC: r.t. 10.05 min. 
5.4.5.2 Synthesis of cyclo(-Asu(NHOH)-Aib-L-Phe(4-Me)-D-Pro-) (MW = 604.74): 
The protected tetrapeptide (901 mg, 1.2 mmol) was dissolved in TFA (3 mL) at 0 0C and kept 
for 3 hours. After evaporation of TFA, the residue was solidified using ether and petroleum 
ether to yield TFA salt of the linear tetrapeptide TFA·H-Asu(OBzl)-Aib-L-Phe(4-Me)- 
D-Pro-OH (796 mg, 1.1 mmol, 90%), TLC: Rf 0.5, HPLC: r.t. 6.50 min. To DMF (100 mL), 
TFA·H-Asu(OBzl)-Aib-L-Phe(4-Me)-D-Pro-OH (796 mg, 1.1 mmol), HATU (630 mg, 1.7 
mmol), and DIEA (0.45 mL, 2.7  mmol) were added in separate five portions in every 30 min 
with stirring at room temperature for the cyclization reaction. After completion of the reaction, 
DMF was evaporated under vacuum; the residue was dissolved in ethyl acetate and washed 
with 10% citric acid solution, 4% sodium bicarbonate solution and brine, respectively. It was 
then dried over anhydrous MgSO4 and filtered.  After evaporation of ethyl acetate, the residue 
was purified by silica gel chromatography using a mixture of chloroform and methanol 
(99:1v/v) to yield cyclo(-Asu(OBzl)-Aib-L-Phe(4-Me)-D-Pro-) (540 mg, 0.9 mmol,  81%). 
HPLC, r.t. 8.70 min. Compound cyclo(-Asu(OBzl)-Aib-L-Phe(4-Me)-D-Pro-) (540 mg, 0.9 
mmol) was dissolved in methanol (4 mL) and Pd-C (50 mg) was added. The mixture was stirred 
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under H2 for 5 hours. After filtration of Pd-C, methanol was evaporated to yield 
cyclo(-Asu-Aib- L-Phe(4-Me)-D-Pro-)  (421 mg, 0.8 mmol, 92%) TLC: Rf 0.72, HPLC: r.t. 
5.91 min. The product was dissolved in DMF (2 mL) at 0 0C, and O-Benzylhydroxylamine 
hydrochloride (HCl NH2-OBzl) (196 mg, 1.2 mmol), HOBt (111 mg, 0.8 mmol), triethylamine 
(0.18 mL, 1.2 mmol) and DCC (260 mg, 1.2 mmol) were added. The mixture was stirred for 24 
hours. After completion of the reaction, DMF was evaporated under vacuum; the residue was 
dissolved in ethyl acetate and washed with 10% citric acid solution, 4% sodium bicarbonate 
solution and brine, respectively. It was then dried over anhydrous MgSO4 and filtered.  After 
evaporation of ethyl acetate, cyclo(-Asu(NHOBzl)-Aib-L-Phe(4-Me)-D-Pro-) (400 mg, 0.6 
mmol, 78%, TLC: Rf 0.82, HPLC: r.t. 6.90 min ) was obtained. The product (400 mg, 0.6 
mmol) was dissolved in acetic acid (6 mL) and Pd-BaSO4 (200 mg) was added. The mixture 
was stirred under H2 for 24 hours. After filtration of Pd-BaSO4, acetic acid was evaporated and 
crystallized with ether to yield cyclo(-L-Asu(NHOH)-Aib-L-Phe(4-Me)-D-Pro-) (255 mg, 0.4 
mmol, 65%), TLC: Rf 0.7(CHCl3/MeOH=9/1), HPLC: 5.07 min, 98%. The yield: 19.2%. 
ESI-MS：[M+H]+530.3012 for C27H40O6N5(calcd 530.2979). 1H NMR(400 MHz, CDCl3 ) δ: 
1.21(m, 2H), 1.33(m, 8H), 1.61(s, 3H), 1.77(m, 6H), 2.15(m, 2H), 2.29(s, 4H), 2.89(m, 1H), 
3.20(m, 2H), 3.85(m, 1H), 4.31(m, 1H), 4.70(d, J=6.4Hz, 1H), 5.13(d, J=5.4, 1H), 7.10(m, 5H), 
7.29(s, 1H), 7.66(d, J=10, 1H). 13C NMR (400 MHz , CDCl3) δ: 19.20, 23.68, 24.74, 24.82, 
24.93, 25.06, 25.97, 28.34, 28.86, 32.64, 35.54, 46.76, 53.34, 54.48, 57.74, 58.56, 128.86, 
128.86, 129.30, 129.30, 133.77, 136.21, 171.21, 172.21, 173.10, 174.63, 175.53. 
5.4.6 Circular dichroism measurement 
 CD spectra were recorded on a JASCO J-810 spectropolarimeter (Tokyo, Japan) using a quartz 
cell of 1 cm light path length at room temperature. Peptide solutions (0.1 mM) were prepared in 
methanol and CD spectra were recorded in terms of molar ellipticity, []M (deg  cm2  dmol-1). 
 5.4.7 Cell growth inhibition assay 
The MTT colorimetric assay was used to determine growth inhibition. HeLa, 7721 and MCF-7 
were all cultured in a humidified atmosphere of 5% CO2 in air, with RPMI 1640 media, 
containing 10% fatal bovine serum. The cell lines were diluted to 5~9×104 cells/mL with the 
corresponding media and were plated in 96-well microplates. After adhere overnight, HDACs 
inhibitors 1-4 were added to culture medium at the concentrations of 2, 4, 6, 8, 10 μM and then 
the cells were incubated for 48 hours. The concentrations of compound 5 were 20, 40, 60, 80, 
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100 nM. Then 200 μL MTT (0.5 mg/mL) reagent diluted in serum free media was added to each 
well and the cells were incubated for an additional 4 hours. Thereafter, the resulted dark blue 
crystal (formazan) was dissolved in 200 μL DMSO, and a optical density was measured on a 
microplate spectrophotometer at 570 nm. All experiments were performed in triplicate and 
repeated at least three times. Data are presented as mean ± standard deviation of three 
independent experiments. The IC50 values were caculated by nonlinear regression analysis 
using SPSS 17.0 software. 
5.4.8 Morphological reversion assay 
Method crystal violet staining was used to observe the changes in cell morphology. MCF-7 cells 
were plated into 96-well microplates at 2×104 cells/mL and allowed to adhere overnight. 
Inhibitors were added to culture medium at the concentration of 10 μM (compounds 1-4) and 
100 nM (compounds 5) and incubated for 24 hours. Cells were then washed once with PBS, and 
fixed in 4% buffered formalin for 1 hour at room temperature. The fixed cells were then washed 
once further with PBS and stained with 1% crystal violet in methanol for 5 minutes. Excess 
stain was removed by washing with tap water. After the microtiter plate was being air-dried at 
370C, MCF-7 cells were taken photographs using an inverted microscope. 
5.4.9 Computational methodology for the HDAC inhibitors towards HDAC8 
5.4.9.1 Docking calculation 
Docking studies were conducted with AutoDock 4.0 program[39,40] using a Lamarckian genetic 
algorithm. AutoDock docking protocol and scoring function have been successful applied in the 
interpretation of the inhibitory activity of several HDAC inhibitors.[41] Initial structure for the 
HDAC8 modeled from the atom coordinates of the X-ray crystal structure (PDB code: 1T69). 
The active site of HDAC8 was covered by a grid box size of 70×70×70 points with a spacing of 
0.375 Å between the grid points. For the cyclic tetrapeptides, all single bonds except the amide 
bonds and cyclic bonds were treated as active torsional bonds. For each inhibitor, two hundred 
independent dockings, i.e. 200 runs, were performed using genetic algorithm searches. A 
maximum number of 250 000 000 energy evaluations and a maximum number of 10 000 
generations were implemented during each genetic algorithm run. The default nonbonded zinc 
parameters in Autodock 4.0 were employed. The LigPlot program[42] was also employed to 
analyze the docking results focusing on hydrogen bonds and hydrophobic interactions. 
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5.4.9.2 Molecular dynamics simulation 
All the molecular mechanics and dynamics calculations were carried out with the AMBER9[43] 
package. The standard AMBER ff99 force field[44] was used as the parameters for the protein 
and water atoms, and the general AMBER force field (GAFF)[45] and AM1-BCC charges[46] 
were used for the ligands. Zinc was modeled using the Stote nonbonded model (q = +2e- , r = 
1.7 Å, ε = 0.67 kcal/mol).[47] Each initial structure for the simulation was prepared from the 
docked conformations of HDAC8-ligand complexes. The local hydrogen bonding network 
around the histidine residues was checked. Histidine residue 180 was assigned as HIE (histidine 
with hydrogen on its epsilon nitrogen), and other histidine residues as HID (histidine with 
hydrogen on its delta nitrogen). The force field parameters of cyclic tetrapeptides were prepared 
with the Antechamber module[48] of AMBER 9 package. Hydrogen atoms were added to the 
crystallographic protein with the AMBER LEaP module. Sodium counterions were added to 
neutralize the system. The system was then solvated with an octahedral box of TIP3P water 
molecules.[49] The minimum distance from the surface of the protein to the faces of the box was 
10 Å. The particle mesh Ewald (PME) method[50] was used to treat long-range electrostatic 
interactions. The cutoff distance for the long-range electrostatic and the van der Waals energy 
terms were set at 12.0 Å. All covalent bonds to hydrogen atoms were constrained using the 
SHAKE algorithm.[51] 
Energy minimization was achieved in three steps. At first, movement was allowed only for the 
water molecules and ions. Next, the ligand and the receptor residues were all allowed to move 
and the water molecules, together with ions, were constrained. Finally, all atoms were permitted 
to move freely. In each step, energy minimization was executed by the steepest descent method 
for the first 5000 steps and the conjugated gradient method for the subsequent 2500 steps.  
Periodic boundary conditions were used. The time steps were 2 ps during the production 
dynamics. The temperature was maintained by rescaling the velocities using the Berendsen 
weak-coupling algorithm,[52] with a time constant of 2 ps for the heat bath.  
After the system was heated to 300 K from the initial temperature of 0 K using the NVT 
ensemble in 120.0 ps, molecular dynamics were performed at a constant temperature of 300 K. 
After a 50 ps position-restrained dynamics, each simulation was proceeded 2 ns under periodic 
boundary conditions with NPT ensemble at 1 atm and at 300 K. The convergence of energy, 
temperatures, and pressures of the systems, and the atomic root-mean-square deviation of the 
enzyme and the inhibitor (RMSD), were used to verify the stability of the systems. Trajectories 
were analyzed using the PTRAJ modules.[53]  
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In the present MD simulations, the overall structure of all complexes appeared to be 
equilibrated after 1.5 ns. Hence, atom coordinates were collected at the interval of 5 ps for the 
last 500 ps to analyze the structure in detail. The series of snapshots between 1.5 and 2.0 ns of 
the equilibrium phase was used for free energy calculations and structure evaluation.  
5.4.9.3 Free energy calculations  
For MM-PBSA methodology, snapshots were taken at 5 ps time intervals from the 
corresponding 500 ps MD trajectories. The explicit water molecules were removed from the 
snapshots. The energy components were calculated using very large cut off (999 Å). The 
binding free energy, ΔGbind, was estimated as follows: 
ΔGb =ΔEMM + ΔGsol - TΔS (1) 
where ΔEMM is the molecular mechanics energy and is given by ΔEMM = ΔEele int  + ΔEvdw int  (2) 
where ΔEele int and ΔEvdw int represent the HDAC8-ligand electrostatic and van der Waals interactions , 
respectively. 
The solvation free energy (ΔGsol) was estimated as the sum of electrostatic solvation free energy 
(ΔGele sol ) and nonpolar solvation free energy (ΔGnonpol sol ): 
ΔGsol =ΔGele sol  + ΔGnonpol sol  (3) 
where ΔGele sol  was calculated using the generalized Born (GB) model of Onufriev et al.[54] and the 
ΔGnonpol sol  was determined with a function of the solvent-accessible surface- area: [55] 
nonpol 
sol  =γ·A + b  
where A is the solvent-accessible surface area estimated with the LCPO method[56] and the 
parameters γ= 0.0072 kcal/ (mol Å2) and b = 0.0 kcal/mol. 
The change of solute entropy upon complexation, TΔSconf, was not estimated in this work. It 
seems that entropy does not contribute much to the relative binding free energy of the ligands 
with similar to the same protein, and in some studies there were good agreements between the 
experimental and calculated relative binding energy.   
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Chapter 6  
Molecular Design of Cyclic Tetrapeptide HDAC Inhibitors by 
Replacement of L-Phe in Chlamydocin Framework 
6.1 Introduction  
Reversible acetylation and deacetylation of the ε-amino groups of lysines by histone acetyl 
transferase (HAT) and histone deacetylase (HDAC) enzymes play a crucial role in the 
regulation of gene expression by altering the chromatin architecture and controlling DNA to 
transcriptional regulators.[1-5] HAT and HDAC inhibitors have been studied as potential 
therapeutics for treatment of cancers.[6-8] In histone deacetylase inhibitors, a wide variety of 
structurally unrelated natural and synthetic cyclopeptides play an important role with reversible 
or irreversible zinc bind group as effective anticancer activities agents. for example, 
Chlamydocin,[9] Trapoxin,[10] Cyl-1,[11] Cyl-2,[12] HC-toxins,[13] Apicidin[14,15], depsipeptide 
FK228,[16-18] and their analogues CHAPs, SCOPs and so on.[19-28] The conformational features 
of compounds have been established by X-ray and NMR spectroscopic studies and by 
comparison of their biological activity with that of simplified synthetic analogues. 
Chlamydocin is a cyclic tetrapeptide containing an epoxyketone moiety in the zinc bind group 
which makes it irreversible inhibit HDACs and an aromatic ring moiety (L-Phe) in cyclic 
framework which provides specific hydrophobic interaction with the rim of HDAC enzymes.  
Chlamydocin  inhibits HDAC activity in vitro with an IC50 value of 1.3 nM. Though the activity 
is major due to the epoxyketone moiety, there are evidences which support that the cyclic 
tetrapeptide framework also has a significant structural role.[28]  Whereas, HC-Toxins are also 
cyclic tetrapeptide that do not contain aromatic ring in macrocyclic framework which yet are 
potent inhibitors of HDACs (Fig.6.1). 
Recently, current HDAC inhibitors in clinical trials are regarded as broad spectrum HDACs 
inhibitors with moderate anticancer effect. Therefore, it is desirable clinically to develop 
specific anticancer drugs that are effective for a particular HDAC over expressed in cancer.[29] It 
is less homologous that the amino acid residues of  HDAC isoforms bind to inhibitor at rim of 
active site. So, the modification of the cap group allows to have a significant impact upon 
isoform selectivity.[30] Therefore, one of various approaches is to modify the cap group of 
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the HDAC inhibitors. To investigate the interaction of aliphatic cap group with the surface of 
HDAC enzymes, we designed and synthesized cyclic tetrapeptide that replaced L-Phe by 
chlorine-contain aliphatic amino acid (Ac5 or Ac6) in their capping group, and replaced the 
epoxyketone moiety of Chlamydocin with hydroxamic acid group to synthesize potent 
reversible and selective HDAC inhibitors (Ky-335 cyclo(-L- Asu(NHOH)-Aib-L-Ac5-D-Pro-) 
and Ky-336 cyclo(-L-Asu(NHOH)-Aib-L-Ac6-D-Pro-) (Fig.6.2). On the other hand, we 
designed the side chain of chlorine-contain cyclic tetrapeptide Acn in framework to be modified 
by oxygen or sulfur with chelating zinc ion of HDAC active pocket bottom. 
cyclo(-L-Ac5-Aib-L-Phe-L-Pro-) was synthesized as a intermediate prodrug (Fig.6.3). 
However, this cyclic tetrapeptide was reacted with potassium thioacetate to convert the chlorine 
to thioacetate ester, the reaction was failed. In synthesis process, we lighted on the L-Ac5 
change into L-Pro obtaining Ky-337 cyclo(-L-Asu(NHOH)-Aib-L-Pro-D-Pro-). The inhibitory 
activity of the cyclic tetrapeptides against histone deacetylase enzymes were evaluated and the 
result showed potent inhibitors. 
 
 
Fig.6.2 Design chlorine-contain HDAC inhibitors 
 
Fig. 6.1  HDACs inhibitors. 
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6.2 Results and discussion 
6.2.1 Chemistry 
Our aim is to synthesize potent HDACs inhibitors. Initially we synthesized Chlamydocin 
analogues by replacing the phenylalanine at 3-position of the cyclic framework  by 2- 
amino-5-chloro-pentanoic acid (L-Ac5-OH) and 2-amino-6-chloro-hexanoic acid (L-Ac6-OH) . 
Cyclic tetrapeptides were prepared according to general Scheme 6.1 by the conventional 
solution phase method. tert-Butyl protected D-Pro was coupled with Boc-L-Ac5 (or Ac6) to 
give the dipeptide Boc-L-Ac5-D-Pro-OtBu. The Boc group of dipeptide was deprotected by 4 N 
HCl/ dioxane and coupled with Z-Aib using DCC/HOBt·H2O orderly. The Z group of the 
resulted tripeptide Z-Aib-L-Ac5-D-Pro-OtBu was deprotected by catalytic hydrogenation. It 
was then coupled with Boc protected amino suberic acid benzyl ester (Boc-L-Asu(OBzl)) to 
give linear tetrapeptide Boc-L-Asu(OBzl)-Aib-L-Ac5-D-Pro-OtBu. The C-terminal and 
N-terminal protections of the tetrapeptide were removed by treatment with trifluoroacetic acid 
(TFA) and the resulted linear peptide was cyclized in DMF  (2 mM) with minimum amount of 
DIEA (2.5 equiv) under high dilution condition using HATU as a coupling reagent to give 
cyclo(-L-Asu(OBzl)-Aib-L-Ac5-D-Pro-) in 50-60% yield. The OBzl of side chain of cyclic 
peptide was deprotected by catalytic hydrogenation and then coupled with hydroxylamine 
hydrochloride and the resulted product was deprotected by catalytic hydrogenation to yield the 
desired compounds and finally purified using gel filtration. We replaced L-Phe residue with 
non-natural amino acids (Ac5 and Ac6) to study the effect on the HDACs inhibitory activity. 
All the synthesized compounds were characterized by 1H NMR and HR-FAB-MS. The purity 
of the compounds was determined by HPLC analysis and all the synthesized cyclic 
tetrapeptides showed purity above 97%. 
 
 
Fig. 6.3 Design chloro-containing HDAC inhibitors. 
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6.2.2 Enzyme inhibition and biological activity 
We assayed three synthesized compounds (Ky-335, Ky-336 and Ky-337) for HDACs 
inhibitory activity using HDAC1, HDAC4 and HDAC6 enzymes prepared by 293T cells. In 
addition, to know the inhibitory activity of these compounds in cell based condition, we carried 
out p21 promoter assay. The results of HDAC inhibitory activity and the p21 promoter assay of 
compounds are shown in Table 6.1. 
Inhibitory activity of TSA and Ky-2 are also shown in Table 6.1 for comparison with 
synthesized compounds. Three compounds all showed good activity against HDAC1 and 
HDAC4 in nanomolar range, but these compounds were poorly inhibited by HDAC6 and their 
selectivity was better (HDAC6/HDAC1 = 10). The compound Ky-336 showed the best activity 
in both cell free and cell based conditions than the other two compounds Ky-335 and Ky-337 
and the activity of Ky-336 was similar to TSA and Ky-2 data. The activity toward HDAC1 
slightly changed with the difference of the length of the side chain of aliphatic amino acid. 
However, the changes in activity toward HDAC4 and HDAC6 were not so remarkable. The 
result suggested that hydrophobicity of aliphatic amino acid can also increase interaction with 
rim of HDACs active pocket and aromatic ring is no need in cyclic framework. Also cell 
permeability was enhanced in this case, which was reflected in their p21 activity data.  
 
 
Scheme 6.1 Structure of   cyclo(-L-Asu(NHOH)-Aib-L-AA-D-Pro-). 
Reagents: (a) H2, Pd/C, MeOH; (b) HCl·NH2OH, BOP, DIEA, DMF. L-AA: L-Ac5; L-Ac6; L-Pro. 
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6.2.3 Conformational study 
We carried out circular dichroism (CD) spectrum study of compounds Ky-335, Ky-336 and 
Ky-337, in methanol as solvent with peptide concentration of 0.1 mM (Fig. 6.4). The CD 
spectrum of  three compounds were similar to reference Ky-2 (cyclo(-L-Asu(NHOH)-Aib- 
L-Phe-D-Pro-) at 215 nm to 260 nm. Three compounds showed a negative ellipticity at 220 nm 
and 240 nm regions, a positive ellipticity at 230 nm regions and different ellipticity at  200 nm ~ 
215 nm. Ky-336 of CD spectrum with more negative ellipticity showed good biological activity. 
This fact showed that chlorine-contain cyclic tetrapeptide (Ky-335 and Ky-336) compounds 
have similar conformations. 
 
Table 6.1   HDAC inhibitory activity and p21 promoter assay 
No. Compounds 
HDAC inhibitory activites IC50 
(nM) 
EC1000 
(nM) 
HDAC1 HDAC4 HDAC6 
P21 
promoter 
activity 
 Trichostatin A 23 34 65 20 
Ky-2 cyclo(-L-Asu(NHOH)-Aib-L-Phe-D-Pro-) 18 17 230 18 
Ky-335 cyclo(-L-Asu(NHOH)-Aib-L-Ac5-D-Pro-) 14 19 110 210 
Ky-336 cyclo(-L-Asu(NHOH)-Aib-L-Ac6-D-Pro-) 7.9 15 96 36 
Ky-337 cyclo(-L-Asu(NHOH)-Aib-L-Pro-D-Pro-) 53 60 310 210 
 
Fig.6.4 CD spectra of cyclic tetrapeptides.
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We have carried out NMR (CDCl3) studies for conformation of Ky-335 and Ky-336 by with 
MOE calculations (Ky-337 no dissolves in CDCl3). Solution conformation of Ky-335 and 
Ky-336  were studied using 1H NMR in CDCl3 (Fig. 6.5). Complete assignments were made 
using COSY and NOESY spectra. The JNH-HCα values  of Ky-335 and Ky-336 were obtained 
from NMR charts and by that we estimated dihedral angle “θ,” using the Karplus graph. 
Dihedral angles θ and φ, and NOE data are shown in Table 6.2. Two compounds have similar 
energy-minimized structures. 
 
 
 
 
Fig. 6.5 MOE of Ky-335 and Ky-336 by NMR calculation. Superimposition of compounds (below). 
Table 6.2 NOE,coupling constant and dihedral angles data from NMR. 
residues 
NOE 
JNH-HCα θ φ 
Ky-335 Ky-336 
L-Asu L-Asu(NH-HCα) 
L-Asu(NH-HCα) 
L-Asu(NH-HCβ) 
10 Hz 180° -120° 
Aib Aib(NH-HCβ) 
Aib(NH-HCβ) 
Aib(NH)-L-Asu(HCβ) 
 
---- ---- ---- 
L-Ac6 or L-Ac5 
L-Ac5(NH-HCα) 
L-Ac5(NH-HCβ)  
L-Ac6(NH-HCα) 
L-Ac6(NH-HCγ) 
10 Hz 180° -120° 
D-Pro   ---- ---- ---- 
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6.2.4 Docking for HDAC inhibitors towards HDAC8 
To understand the binding modes between HDACs and this serial of HDAC inhibitors, docking 
studies for HDAC8 and HDLP with these inhibitors were conducted with AutoDock 4.0 
program. The active sites of HDAC8 and HDLP were covered by a grid box of 70×70×70 
points with a spacing of 0.375 Å between the grid points. For all inhibitors, all the single bonds 
except the amide bonds and cyclic bonds were treated as active torsional bonds. For each 
inhibitor, 150 independent dockings were performed using genetic algorithm searches. A 
maximum number of 250 000 000 energy evaluations and a maximum number of 5 000 
generations were implemented during each genetic algorithm run. A mutation rate of 0.02 and a 
crossover rate of 0.8 were used. The default nonbonded zinc parameters in Autodock 4.0 were 
employed. Results differing by less than 2.0 Å in positional root-meaning-square deviation 
(RMSD) were clustered together. The RMSD value is an all heavy atom comparison between 
the docked structure and the initial structure. The LigPlot program was also employed to 
analyze the docking results focusing on hydrogen bonds and hydrophobic interactions. 
The docking results are shown in Fig.6.6 and Fig.6.7. It indicated that all inhibitors bound to the 
active site of HDAC8 and HDLP with a similar pattern, the surface recognition domain 
interacted with the external surface of the enzyme, and the hydroxamic acid group as metal 
binding domain was at the bottom of active pocket. In the active sites of HDAC8, zinc ion 
coordinated with the oxygen atom of carbonyl group, the while in the active site of HDLP, zinc 
ion coordinated with the oxygen atom of oxhydryl group. The average distances between zinc 
ion and the nearby atoms were tested during the last 500 ps in current MD simulations. The 
average distances  of zinc ion to oxygen atom of carbonyl group of HDAC8 were 1.84, 1.75 and 
1.86 Å, respectively, while the distances with the oxygen atom of oxhydryl group of HDLP 
were 1.73, 1.96 and 1.76 Å respectively. Chelating with zinc was essential for inhibitors in the 
HDAC inhibitory activities. In the results of docking for HDAC8-inhibitors, the hydrogen bond 
was build between Lys19 of HDAC8 and Ky-337. For HDLP-inhibitors, the chlorine atom of 
Ky-335 created a hydrogen bond with Tyr194 of HDLP. The hydrophobic interaction between 
inhibitors and HDACs were also crucial for stabilizing the binding. As shown, some amino 
acids, including Tyr80, His122, His 123, Gly131, Phe132, His160, Phe187, Phe188, Pro253 
and Met254 of HDAC8, Phe139, His168, Gln190, Ala195, Phe196, Phe198, Leu263, Ser264 
and Lys265 of HDLP, contact inhibitors via hydrophobic interactions. For each inhibitor, six or 
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seven of these amino acids of HDAC8 or HDLP were involved in establishing hydrophobic 
interactions (Fig. 6.8). 
 
 
               
                 (a) HDAH8-compounds                   (b) HDLP-compounds 
 
Fig. 6.7 Superimposition in surfaces of the active site regions for docking. Ky-335 (magenta), Ky-336 
(cyan), Ky-337 (yellow). 
   
(a) HDAC8-Ky335                       (b) HDAC8-Ky336                     (c) HDAC8-Ky337 
     
         (d) HDLP-Ky335                              (e) HDLP-Ky336                        (f) HDLP-Ky337 
 
Fig. 6.6 Top view of the surfaces of the active site for docking. 
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6.3 Summary 
In summary, in order to find novel and potent non-aromatic HDAC inhibitors, we designed and 
synthesized three cyclic tetrapeptide hydroxamic acids by changing chlorine-contain aliphatic 
amino acid at 3-position of cyclic framework. These inhibitors showed potent HDAC inhibitory 
activity in vivo and in vitro. They also showed some selectivity among the HDAC isoforms. 
The length of aliphatic chain was important, and four CH2 length was the optimum for in vivo 
activity. The Ky-335 and Ky-336 showed better HDAC inhibitory activities than Ky-337 and 
 
Fig. 6.8 The hydrogen bonds and hydrophobic interactions (above) HDAC8 and (below) HDLP for 
docking.(a) Ky-335, (b) Ky-336, (c) Ky-337.  
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the same as Ky-2 and TSA. In the cellular activity, the Ky-336 showed the best than other two 
compounds, and similar to Ky-2. These results further confirmed that modification of the cap 
group of HDAC inhibitors can lead to potent HDAC inhibitors, which may have potential as 
anticancer agents. We also carried out conformational analysis of these inhibitors by CD and 
NMR calculation methods, and conducted docking studies for HDAC8 and HDLP with these 
inhibitors with AutoDock 4.0 program. Ky-336 of CD spectrum with more negative ellipticity 
showed good biological activity. The presence of an aliphatic chain can also increase its 
interactions with the rim of HDACs active pocket. 
6.4 Experimental 
General: Unless otherwise noted, all solvents and reagents were reagent grade and used 
without purification. All compounds were routinely checked by thin layer chromatography 
(TLC) or high performance liquid chromatography (HPLC). Analytical HPLC were performed 
on a Hitachi equipped with a chromolith performance RP-18e column (4.6 × 100 mm, Merck). 
The mobile phases used were A: H2O and 0.1% TFA, B: CH3CN with 0.1% TFA using a 
solvent gradient of A to B over 15 min with detection at 220 nm with a flow rate of 2 mL/min. 
TLC was performed on aluminium-backed silica gel plates (Merck DC-Alufolien Kieselgel 60 
F254) with spots visualized by UV light and heat. Flash chromatography was performed using 
silica gel 60 (230-400) eluting with solvents as indicated. Fast atom bombardment mass spectra 
(FAB-MS) and high resolution fast atom bombardment mass spectra (HR-FAB-MS) were 
measured on a JEOL JMS-SX 102A instrument. NMR spectra were recorded on a Brucker 500 
MHz spectrometer. All NMR spectra were measured in CDCl3 solutions with reference to TMS. 
All 1H shifts are given in parts per millions (s = singlet; d = doublet; t = triplet; m = multiplet). 
Peptide were coupled using standard solution-phase chemistry with dicyclohexylcarbodiimide 
(DCC), N-Hydroxybenzotriazole (HOBt). Peptide cyclization was mediated by 
N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminiu
m hexafluorophosphate N-oxide (HATU).  
6.4.1 Synthesis of  cyclo(-L-Asu(NHOH)-Aib-L-Ac5-D-Pro-) 
6.4.1.1 Synthesis of Boc-L-Ac5-D-Pro-OtBu (MW = 404.20): 
While cooling on ice, DCC (1.2 g, 6.0 mmol) and HOBt·H2O (800  mg, 5.0 mmol) were added 
to DMF (10 mL) containing Boc-L-Ac5-OH (1.3 g, 5.0 mmol) and H-D-Pro-OtBu (855 mg, 5.0 
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mmol). After stirring for overnight, DMF was removed by evaporation; residue dissolved in 
ethyl acetate, and then successively washed with 10% citric acid solution, 4% sodium 
bicarbonate solution and brine. After drying over MgSO4 and concentrating, the resulting oily 
substance was purified by silica gel chromatography (3.4 x 20 cm) using a mixture of 
chloroform and methanol (99:1 v/v) to obtain Boc-L-Ac5-D-Pro-OtBu (1.6 g, 3.9 mmol, 79%) 
as oily compound. TLC: Rf, 0.9 (CHCl3/MeOH= 9/1) , HPLC: r.t. 7.87 min. 
6.4.1.2 Synthesis of Z-Aib-L-Ac5-D-Pro-OtBu (MW = 523.24): 
The dipeptide Boc-L-Ac5-D-Pro-OtBu (1.6 g, 3.9 mmol) was dissolved in 4N HCl/dioxane (10 
mL). After 30 minutes at 0 0C, the reaction solution was removed by evaporation, ether was 
added to the residue and solidified to obtain white solid of HCl·H-L-Ac5-D-Pro- OtBu (1.2 g,  
3.9 mmol, 100%). To a cooled solution of HClH-L-Ac5-D-Pro-OtBu (1.2 g,  3.9 mmol) and 
Z-Aib-OH (950 mg, 5.0 mmol) in DMF (10 mL) were added HOBt·H2O (770 mg, 5.0 mmol), 
DCC(1.2 g, 6.0 mmol), Et3N (0.7 mL, 5.0  mmol). After stirring for overnight, check with TLC 
(Rf 0.75, CHCl3/MeOH=9/1), DMF was removed by evaporation; residue dissolved in ethyl 
acetate, and then successively washed with 10% citric acid, 4% sodium bicarbonate and brine. 
After drying over MgSO4 and concentrating, the resulting oily substance was purified by silica 
gel chromatography(1.6 x 20 cm)  using a mixture of chloroform and methanol (99:1 v/v) to 
obtain Z-Aib-L-Ac5-D-Pro-OtBu (0.7 g, 1.3 mmol, 34%) as oily compound. TLC: Rf 0.9 
(CHCl3/MeOH =9/1), HPLC: r.t. 7.29 min.  
6.4.1.3 Synthesis of Boc-L-Asu(OBzl)-Aib-L-Ac5-D-Pro-OtBu (MW = 722.40): 
The tripeptide Z-Aib-L-Ac5-D-Pro-OtBu (0.7 g, 1.3 mmol) was subjected to catalytic 
hydrogenation with Pd-C (80 mg) in acetic acid (10 mL). After overnight, The reaction was 
checked by TLC (CHCl3/MeOH/CH3COOH=90/10/2), the catalyst was filtered and reaction 
solution was removed by evaporation. The free amine was taken into ethyl acetate (30 mL) by 
the aid of 2M Na2CO3 solution (10 mL). After dried over anhydrous Na2CO3 ethyl acetate 
solution was evaporated to obtain H-Aib-L-Ac5-D-Pro-OtBu(330 mg, 0.85 mmol, 65%). To a 
cooled solution of H-Aib-L-Ac5-D-Pro-OtBu(300 mg, 0.7 mmol) and Boc-L-Asu(OBzl)-OH 
(400 mg, 1.0 mmol) in DMF (3 mL) were successively added DCC (200 mg, 1.2 mmol), 
HOBt·H2O (200 mg, 1.0 mmol). After stirring for overnight, DMF was removed by 
evaporation; residue dissolved in ethyl acetate, and then successively washed with 10% citric 
acid solution, 4% sodium bicarbonate solution and brine. After drying over MgSO4 and 
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concentrating, the resulting oily substance was purified by silica gel chromatography using a 
mixture of chloroform and methanol (99:1 v/v) to obtain 
Boc-L-Asu(OBzl)-Aib-L-Ac5-D-Pro-OtBu (330 g, 0.45 mmol, 63%). TLC: Rf 0.8 
(CHCl3/MeOH=9/1). HPLC: r.t. 9.64 min. 
6.4.1.4 cyclo(-L-Asu(OBzl)-Aib-L-Ac5-D-Pro-) (MW = 576.27): 
The protected tetrapeptide Boc-L-Asu(OBzl)-Aib-L-Ac5-D-Pro-OtBu (330 g, 0.45 mmol) was 
dissolved in TFA (5 mL) at 00C and kept for 3 hours,and checked by TLC(Rf 0.2, CHCl3/ 
MeOH=9/1). After evaporation of TFA, the residue was solidified using ether and petroleum 
ether to yield TFA salt of the linear tetrapeptide TFA· H-Asu(OBzl)-Aib-L-Ac5-D-Pro-OH 
(267 mg, 0.4 mmol, 96%). To DMF (50 mL), TFA· H-Asu(OBzl)-Aib-L-Ac5-D-Pro-OH (267 
mg, 0.4 mmol), HATU (183 mg, 0.4 mmol), and DIEA (0.2 mL, 1.4 mmol) were added in 
separate five portions in every 30 minutes with stirring at room temperature for the cyclization 
reaction. After completion of the reaction for 1 hour, DMF was evaporated under vacuum; the 
residue was dissolved in ethyl acetate and washed with 10% citric acid solution, 4% sodium 
bicarbonate solution and brine, respectively. It was then dried over anhydrous MgSO4 and 
filtered.  After evaporation of ethyl acetate, the residue was purified by silica gel 
chromatography (1.6 x 20 cm)  using a mixture of chloroform and methanol (99:1v/v) to yield 
cyclo(-L-Asu(OBzl)-Aib-L-Ac5-D-Pro-) (130 mg, 0.2 mmol, 57%). HPLC: r.t. 8.05 min.  
6.4.1.5 cyclo(-L-Asu(NHOH)-Aib-L-Ac5-D-Pro-) (MW=501.23): 
Compound cyclo(-L-Asu(OBzl)-Aib-L-Ac5-D-Pro-)(0.13 g, 0.2 mmol)  was dissolved in 
methanol (5 mL) and Pd-C (50 mg) was added. The mixture was stirred under H2 for 6 hours. 
After filtration of Pd-C, methanol was evaporated to yield cyclo(-L-Asu-Aib-L-Ac5-D-Pro-) 
(110 mg, 2.0 mmol, 98%, HPLC:  r.t. 5.40 min). The product was dissolved in DMF (3 mL) at 0 
0C, and NH2OH·HCl (33 mg, 0.48 mmol), benzotriazole-1-yloxy-tris(dimethylamino) 
phosphonium-hexafluorophosphate (BOP, 159 mg, 0.36 mmol) and DIEA (0.19 mL, 1.08 
mmol) were added. The mixture was stirred for 30 minutes and then checked by TLC(Rf 0.13, 
CHCl3/ MeOH=9/1, FeCl3 spray). After completion of the reaction, DMF was evaporated under 
vacuum; the residue was purified by LH-20 to yield cyclo(-L-Asu(NHOH)-Aib-L-Ac5-D-Pro-) 
(52 mg, 0.1 mmol, 50%). HPLC: r.t. 4.95 min. HR-FAB MS: [M+H]+ 502.2417 Calcd. 
501.2534, C22H36ClN5O6. 1H NMR (500 MHz, CDCl3) δH: 1.20(t, 2H), 1.24(t, 2H),1.36(s, 3H), 
1.62-1.67(m, 1H), 1.77(s, 3H), 1.80-1.96(m, 2H), 2.15(m, 1H), 2.88(s, 1H), 2.95(s, 1H), 3.55(m, 
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3H), 3.72(m, 1H), 4.26(ddd, J= 7.1, 10.3, 3.3 Hz, 1H), 4.78(t, J= 7.9 Hz, 1H), 4.88(ddd, J= 7.5, 
10, 2.9 Hz, 1H), 6.48(s, 1H),  7.16(d, J=10 Hz, 1H), 7.45(d, J= 10 Hz, 1H). 
6.4.2 Synthesis of cyclo(-L-Asu(NHOH)-Aib-L-Pro-D-Pro-) 
6.4.2.1 Z-Aib-L-Pro-D-Pro-OtBu (MW = 487.27 ): 
To a cooled solution of HClH-L-Pro-D-Pro-OtBu (1.3 g,  4.8 mmol) and Z-Aib-OH (950 mg, 
5.0 mmol) in DMF (10 mL) were added HOBt·H2O (770 mg, 5.0 mmol), DCC (1.2 g, 6.0 
mmol), Et3N (0.7 mL, 5.0  mmol). After stirring for overnight, check with TLC (Rf 0.75, 
CHCl3/MeOH=9/1), DMF was removed by evaporation; residue dissolved in ethyl acetate, and 
then successively washed with 10% citric acid, 4% sodium bicarbonate and brine. After drying 
over MgSO4 and concentrating, the resulting oily substance was purified by silica gel 
chromatography (1.6 x 20 cm)  using a mixture of chloroform and methanol (99:1 v/v) to obtain 
Z-Aib-L-Pro-D-Pro-OtBu (0.68 g, 1.4 mmol, 36%) as oily compound. TLC: Rf 0.9 
(CHCl3/MeOH =9/1), HPLC: r.t. 7.09 min.  
6.4.2.2 Synthesis of Boc-L-Asu(OBzl)-Aib-L-Pro-D-Pro-OtBu (MW = 686.43): 
The tripeptide Z-Aib-L-Pro-D-Pro-OtBu (0.68 g, 1.4 mmol) was subjected to catalytic 
hydrogenation with Pd-C (80 mg) in acetic acid (10 mL). After overnight, the reaction was 
checked by TLC (CHCl3/MeOH/CH3COOH=90/10/2), the catalyst was filtered and reaction 
solution was removed by evaporation. The free amine was taken into ethyl acetate (30 mL) by 
the aid of 2M Na2CO3 solution (10 mL). After dried over anhydrous Na2CO3 ethyl acetate 
solution was evaporated to obtain H-Aib-L-Pro-D-Pro-OtBu (460 mg, 1.3 mmol, 93%). To a 
cooled solution of H-Aib-L-Pro-D-Pro-OtBu (0.46 g, 1.3 mmol) and Boc-L-Asu(OBzl)-OH 
(570 mg, 1.5 mmol) in DMF (3 mL) were successively added DCC (370 mg, 1.8 mmol), 
HOBt·H2O (230 mg, 1.5 mmol). After stirring for overnight, DMF was removed by 
evaporation; residue dissolved in ethyl acetate, and then successively washed with 10% citric 
acid solution, 4% sodium bicarbonate solution and brine. After drying over MgSO4 and 
concentrating, the resulting oily substance was purified by silica gel chromatography (1.6 x 20 
cm) using a mixture of chloroform and methanol (99:1 v/v) to obtain 
Boc-L-Asu(OBzl)-Aib-L-Pro-D-Pro- OtBu (710 g, 1.0 mmol, 78%). TLC: Rf 0.8 
(CHCl3/MeOH=9/1). HPLC: r.t. 9.39 min. 
6.4.2.3 cyclo(-L-Asu(OBzl)-Aib-L-Pro-D-Pro-) (MW = 540.29): 
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The protected tetrapeptide Boc-L-Asu(OBzl)-Aib-L-Pro-D-Pro-OtBu (710 g, 1.0 mmol) was 
dissolved in TFA (5 mL) at 00C and kept for 3 hours,and checked by TLC (Rf 0.2, CHCl3/ 
MeOH=9/1). After evaporation of TFA, the residue was solidified using ether and petroleum 
ether to yield TFA salt of the linear tetrapeptide TFA· H-Asu(OBzl)-Aib-L-Pro-D-Pro-OH 
(640 mg, 1.0 mmol, 98%). To DMF (100 mL), TFA· H-Asu(OBzl)-Aib-L-Pro-D-Pro-OH (640 
mg, 1.0 mmol), HATU (460 mg, 1.2 mmol), DIEA (0.59 mL, 3.4 mmol) were added in separate 
five portions in every 30 minutes with stirring at room temperature for the cyclization reaction. 
After completion of the reaction for 1 hour, DMF was evaporated under vacuum; the residue 
was dissolved in ethyl acetate and washed with 10% citric acid solution, 4% sodium 
bicarbonate solution and brine, respectively. It was then dried over anhydrous MgSO4 and 
filtered.  After evaporation of ethyl acetate, the residue was purified by silica gel 
chromatography (1.6 x 20 cm)  using a mixture of chloroform and methanol (99:1v/v) to yield  
cyclo(-L-Asu(OBzl)-Aib-L-Pro-D-Pro-) (270 mg, 0.5 mmol, 49%). HPLC: r.t. 8.05 min.  
6.4.2.4 cyclo(-L-Asu(NHOH)-Aib-L-Pro-D-Pro-) (MW= 465.26): 
Compound cyclo(-L-Asu(OBzl)-Aib-L-Pro-D-Pro-) (270 mg, 0.5 mmol)  was dissolved in 
methanol (5 mL) and Pd-C (25 mg) was added. The mixture was stirred under H2 for 6 hours. 
After filtration of Pd-C, methanol was evaporated to yield cyclo(-L-Asu-Aib-L-Pro-D-Pro-) 
(230 mg, 0.5 mmol, 96%, HPLC:  r.t. 5.53 min). The product was dissolved in DMF (4 mL) at 
00C, and NH2OH·HCl (470 mg, 0.7 mmol), BOP(230 mg, 0.5 mmol) and DIEA (0.27 mL, 1.5 
mmol) were added. The mixture was stirred for 30 minutes and then checked by TLC (Rf 0.13, 
CHCl3/ MeOH=9/1, spray FeCl3). After completion of the reaction, DMF was evaporated under 
vacuum; the residue was purified by LH-20 to yield cyclo(-L-Asu(NHOH)-Aib-L-Pro-D-Pro-) 
(100 mg, mmol, %). HPLC: r.t. 4.80 min. HR-FAB MS: [M+H]+ 465.2664 Calcd. 465.2587, 
C22H35N5O6.  1H NMR: The compound do not dissolve in CDCl3. 
6.4.3 Synthesis of  cyclo(-L-Asu(NHOH)-Aib-L-Ac6-D-Pro-) 
6.4.3.1 Synthesis of Boc-L-Ac6-D-Pro-OtBu (MW = 418.22): 
While cooling on ice, DCC (1.22 g, 5.0 mmol) and HOBt·H2O (770 mg, 5.0 mmol) were added 
to DMF (10 mL) containing Boc-L-Ac6-OH (1.33 g, 5.0 mmol) and H-D-Pro-OtBu (787 mg, 
4.6 mmol). After stirring for overnight, DMF was removed by evaporation; residue dissolved in 
ethyl acetate, and then successively washed with 10% citric acid solution, 4% sodium 
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bicarbonate solution and brine. After drying over MgSO4 and concentrating, the  resulting oily 
substance was purified by silica gel chromatography (3.4 x 15 cm) using a mixture of 
chloroform and methanol (99:1 v/v) to obtain Boc-L-Ac6-D-Pro-OtBu (1.51 g, 3.6 mmol, 78%) 
as oily compound. TLC: Rf, 0.9 (CHCl3/MeOH= 9/1) , HPLC: r.t. 8.18 min. 
6.4.3.2 Synthesis of Boc-Aib-L-Ac6-D-Pro-OtBu (MW = 503.28): 
The dipeptide Boc-L-Ac6-D-Pro-OtBu (1.21 g, 2.9 mmol) was dissolved in 4N HCl/dioxane 
(10 mL). After 30 minutes at 0 0C, the reaction solution was removed by evaporation, ether was 
added to the residue and solidified to obtain white solid of HCl·H-L-Ac6-D-Pro-OtBu (880 mg,  
2.4 mmol, 87%). To a cooled solution of HCl·H-L-Ac6-D-Pro-OtBu (880 mg,  2.4 mmol) and 
Boc-Aib-OH (560 mg, 2.8 mmol) in DMF (5 mL) were added HOBt·H2O (420 mg, 2.8 mmol), 
DCC (610 mg, 3.0 mmol), Et3N (0.4 mL, 2.8 mmol). After stirring for overnight, check with 
TLC (Rf 0.85, CHCl3/MeOH=9/1), DMF was removed by evaporation; residue dissolved in 
ethyl acetate, and then successively washed with 10% citric acid, 4% sodium bicarbonate and 
brine. After drying over MgSO4 and concentrating, the resulting oily substance was purified by 
silica gel chromatography (1.6 x 15 cm)  using a mixture of chloroform and methanol (99:1 v/v) 
to obtain Boc-Aib-L-Ac6-D-Pro-OtBu (880 mg, 1.7 mmol, 71%) as oily compound. TLC: Rf 
0.9 (CHCl3/MeOH =9/1), HPLC: r.t. 7.98 min.  
6.4.3.3 Synthesis of Boc-L-Asu(OBzl)-Aib-L-Ac6-D-Pro-OtBu (MW = 736.42): 
The tripeptide Boc-Aib-L-Ac6-D-Pro-OtBu (880 mg, 1.7 mmol) was dissolved in 4N 
HCl/dioxane (15 mL). After 30 minutes at 00C, the reaction solution was removed by 
evaporation, ether was added to the residue and solidified to obtain white solid of 
HCl·H-Aib-L-Ac6-D-Pro-OtBu (710 mg,  1.6 mmol, 95%). To a cooled solution of 
HCl·H-Aib-L-Ac6-D-Pro-OtBu (710 mg, 1.6 mmol) and Boc-L-Asu(OBzl)-OH (680 mg, 1.8 
mmol) in DMF (4 mL) were added HOBt·H2O (280 mg, 1.8 mmol), DCC (440 mg, 2.2 mmol), 
Et3N (0.25 mL, 1.8 mmol). After stirring for overnight, check with TLC (Rf 0.90, 
CHCl3/MeOH=9/1), DMF was removed by evaporation; residue dissolved in ethyl acetate, and 
then successively washed with 10% citric acid, 4% sodium bicarbonate and brine. After drying 
over MgSO4 and concentrating, the resulting oily substance was purified by silica gel 
chromatography(1.6 x 20 cm)  using a mixture of chloroform and methanol (99:1 v/v) to obtain 
Boc-L-Asu(OBzl)-Aib-L-Ac6-D-Pro-OtBu (960 mg, 1.3 mmol, 76%) as oily compound. TLC: 
Rf 0.9 (CHCl3/MeOH =9/1), HPLC: r.t. 9.42 min.  
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6.4.3.4 cyclo(-L-Asu(OBzl)-Aib-L-Ac6-D-Pro-) (MW = 590.29): 
The protected tetrapeptide Boc-L-Asu(OBzl)-Aib-L-Ac6-D-Pro-OtBu (960 mg, 1.3 mmol) was 
dissolved in TFA (8 mL) at 00C and kept for 3 hours,and checked by TLC (Rf 0.2, CHCl3/ 
MeOH=9/1). After evaporation of TFA, the residue was solidified using ether and petroleum 
ether to yield TFA salt of the linear tetrapeptide TFA.H-L-Asu(OBzl)-Aib-L-Ac6-D-Pro-OH 
(850 mg, 1.2 mmol, 93%). To DMF (50 mL), TFA.H-L-Asu(OBzl)-Aib-L-Ac6-D-Pro-OH 
(850 mg, 1.2 mmol), HATU (550 mg, 1.4 mmol), and DIEA (0.7 mL, 4.1 mmol) were added in 
separate five portions in every 30 minutes with stirring at room temperature for the cyclization 
reaction. After completion of the reaction for 1 hour, DMF was evaporated under vacuum; the 
residue was dissolved in ethyl acetate and washed with 10% citric acid solution, 4% sodium 
bicarbonate solution and brine, respectively. It was then dried over anhydrous MgSO4 and 
filtered.  After evaporation of ethyl acetate, the residue was purified by silica gel 
chromatography (1.6 x 20 cm)  using a mixture of chloroform and methanol (99:1v/v) to yield 
cyclo(-L-Asu(OBzl)-Aib-L-Ac6-D-Pro-) (290 mg, 0.5 mmol, 42%). HPLC: r.t. 8.32 min. 
6.4.3.5 cyclo(-L-Asu(NHOH)-Aib-L-Ac6-D-Pro-) (MW= 515.25): 
Compound cyclo(-L-Asu(OBzl)-Aib-L-Ac6-D-Pro-)(290 mg, 0.5 mmol)  was dissolved in 
methanol (10 mL) and Pd-C (25 mg) was added. The mixture was stirred under H2 for 6 hours. 
After filtration of Pd-C, methanol was evaporated to yield cyclo(-L-Asu-Aib-L-Ac6-D-Pro-) 
(230 mg, 0.5 mmol, 96%, HPLC:  r.t. 5.72 min). The product was dissolved in DMF (4 mL) at 
00C, and NH2OH·HCl (60 mg, 0.92 mmol) , BOP ( 310 mg, 0.69 mmol) and DIEA (0.36 mL, 
2.1 mmol) were added. The mixture was stirred for 30 minutes and then checked by TLC (Rf 
0.13, CHCl3/ MeOH=9/1, FeCl3 spray). After completion of the reaction, DMF was evaporated 
under vacuum; the residue was purified by LH-20 to yield cyclo(-L-Asu(NHOH)-Aib-L-Ac6- 
D-Pro-) (200 mg, 0.39 mmol, 78%). HPLC: r.t. 5.24 min. HR-FAB MS: [M+H]+ 516.2620, 
Calcd. 515.2511,  C23H38ClN5O6. 1H NMR (500 MHz, CDCl3) δH: 1.24(t, 2H), 1.36(s, 3H), 
1.43(d, J= 6.7 Hz, 1H), 1.47(d, J= 6.7, Hz, 1H), 1.49(t, 2H), 1.16-1.74(m, 6H), 1.76(s, 3H), 
1.78-1.88(m, 4H), 2.16-2.40(m, 4H), 2.88(s, 1H), 2.96(s, 1H), 3.53(m, 3H), 3.72(m, 1H), 
4.24(ddd, J= 8, 9.9, 2.4 Hz, 1H), 4.77(t, J= 7.9 Hz, 1H), 4.85(ddd, J= 7.1, 10, 2.9 Hz, 1H), 
6.40(s, 1H),  7.18(d, J=10 Hz, 1H), 7.40(d, J= 10 Hz, 1H). 
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6.4.4 HDACs preparation and enzyme activity assay 
In a 100-mm dish, 293T cells (1-2 × 106) were grown for 24 hours and transiently transfected 
with 10 g each of the vector pcDNA3-HDAC1 for human HDAC1, pcDNA3-HDAC4 for 
human HDAC4, or pcDNA3-mHDA2/HDAC6 for mouse HDAC6, using the Lipofect AMINE 
2000 reagent (Invitrogen). After successive cultivation in DMEM for 24 hours, the cells were 
washed with PBS and lysed by sonication in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 
120 mM NaCl, 5 mM EDTA, and 0.5% NP40. The soluble fraction collected by micro 
centrifugation was precleared by incubation with protein A/G plus agarose beads (Santa Cruz 
Biotechnologies, Inc.). After the cleared supernatant had been incubated for 1 hour at 4˚C with 
4 g of an anti-FLAG M2 antibody (Sigma-Aldrich Inc.) for HDAC1, HDAC4 and HDAC6, the 
agarose beads were washed three times with lysis buffer and once with histone deacetylase 
buffer consisting of 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 10% glycerol. The bound 
proteins were released from the immune complex by incubation for 1 hour at 4˚C with 40 g of 
the FLAG peptide (Sigma-Aldrich Inc.) in histone deacetylase buffer (200 mL). The 
supernatant was collected by centrifugation. For the enzyme assay, 10 L of the enzyme 
fraction was added to 1 L of fluorescent substrate (2 mM Ac-KGLGK(Ac)-MCA) and 9 L of 
histone deacetylase buffer, and the mixture was incubated at 37˚C for 30 minutes. The reaction 
was stopped by the addition of 30 L of tripsin (20 mg/mL) and incubated at 37˚C for 15 
minutes. The released amino methyl coumarin (AMC) was measured using a fluorescence plate 
reader. The 50% inhibitory concentrations (IC50) were determined as the means with SD 
calculated from at least three independent dose response curves. 
6.4.5 The p21 promoter assay 
A luciferase reporter plasmid (pGW-FL) was constructed by cloning the 2.4 kb genomic 
fragment containing the transcription start site into HindIII and SmaI sites of the pGL3-Basic 
plasmid (Promega Co., Madison, WI). Mv1Lu (mink lung epitherial cell line) cells were 
transfected with the pGW-FL and a phagemid expressing neomycin/kanamycin resistance gene 
(pBK-CMV, Stratagene, La Jolla, CA) with the Lipofectamine reagent (Life Technology, 
Rockville, MD USA). After the transfected cells had been selected by 400 µg/mL Geneticin 
(G418, Life Technology), colonies formed were isolated. One of the clones was selected and 
named MFLL-9. MFLL-9 expressed a low level of luciferase, of which activity was enhanced 
by TSA in a dose-dependent manner. MFLL-9 cells (1 × 105) cultured in a 96-well multi-well 
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plate for 6 hours were incubated for 18 hours in the medium containing various concentrations 
of drugs. The luciferase activity of each cell lysate was measured with a LucLite luciferase 
Reporter Gene Assay Kit (Packard Instrument Co., Meriden, CT) and recorded with a 
Luminescencer-JNR luminometer (ATTO, Tokyo, Japan). Data were normalized to the protein 
concentration in cell lysates. Concentrations at which a drug induces the luciferase activity 
10-fold higher than the basal level are presented as the 1000% effective concentration 1000% 
(EC1000). The human wild-type p21 promoter luciferase fusion plasmid, WWP-Luc, was a kind 
gift from Dr. B. Vogelstein. 
6.4.6 Circular dichroism measurement 
 CD spectra were recorded on a JASCO J-820 spectropolarimeter (Tokyo, Japan) using a quartz 
cell of 1 cm light path length at room temperature. Peptide solutions (0.1 mM) were prepared in 
methanol and CD spectra were recorded in terms of molar ellipticity, []M (deg  cm2  dmol-1). 
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Chapter 7  
Cyclic Tetrapeptide HDAC Inhibitors: a Potent Anticancer 
Prodrug  
Currently, histone deacetylase (HDACs) have been considered as a promising target in 
anticancer drug development, and many studies suggests that HDAC inhibitors can reactivate 
gene expression and inhibit the growth and survival of tumor cells, and HDAC inhibitors are 
emerging as a new class of anticancer agents. A number of structurally diverse classes of 
HDAC inhibitors (natural and synthetic) are known to interact with a zinc atom of HDACs and 
to induce the acetylation of histone and non-histone protein. Among them, SAHA, depsipeptide 
(FK228), sodium phenyl-butyrate, alproic acid, PXD101, LAQ824, MS-275, CI-994 and 
pyroxamide are already in phase I or II clinical trials in cancer patients. Suberoylanilide 
hydroxamic acid (SAHA, Zolinza) which contains a hydroxamic acid functional group for bind 
to the active site Zn2+ of HDACs, recently approved by the U.S. Food and Drug Administration 
(FDA) for the treatment of cutaneous T cell lymphoma (CTCL) in patients with progressive, 
persistent, or recurrent disease On October 6, 2006. On November 5, 2009, Romidepsin 
(FK228, Istodax) was also approved by the FDA for the treatment of CTCL. Romidepsin was 
isolated in a culture of Chromobacterium violaceum from a soil sample and found to have little 
to no antibacterial activity, but was potently cytotoxic against several human cancer cell lines, 
with no effect on normal cells; studies on mice later found it to have antitumor activity in vivo as 
well. Romidepsin acts as a prodrug with the disulfide bond undergoing reduction within the cell 
to release a zinc-binding thiol. The thiol reversibly interacts with a zinc atom in the binding 
pocket of Zn2+-dependent HDACs. HDAC inhibitors are potential treatments for cancer 
through the ability to restore normal expression of genes, which may result in cell cycle arrest, 
differentiation, and apoptosis. 
In this dissertation, the primary objective was to design and synthesize of cyclic tetrapeptide 
based HDAC inhibitors. The strategy was to modify the cap group of cyclic tetrapeptide by 
changing non-natural amino acids in different residue positions of cyclic tetrapeptide scaffold. 
As the area surrounding the opening to the binding pocket has less homology between HDAC 
isoforms compared to the active site, the modification of the cap group allows to have a 
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significant impact upon isoform selectivity.  
In Chapter 2 of this thesis, to explore the molecular details of interactions between HDACs and 
cyclic tetrapeptides, and analyzed selective inhibition, we constructed 3D model of human 
HDAC1 structure using human HDAC8 as template and performed docking and molecule 
dynamics simulation studies between HDAC1, HDAC8 and Apicidin comparing the binding 
modes of Apicidin-HDAC1 and Apicidin-HDAC8 complexes. The zinc-chelated conformation 
of HDAC1 model and Apicidin was rightly the lowest binding energy conformation (∆Gbinding= 
-9.67 kcal/mol), and the ethyl ketone moiety was primary foundation in coordinating with Zn2+ 
in a distance of 1.78 Å and establishing hydrogen bond with the O(H) of Tyr303. This hydrogen 
bond was very important for stabilizing the binding of ligands to HDAC1. The tetrapeptide core 
extended its hydrophobic interactions thanks to the N-O-methyl-Trp side chain. Apicidin is 
known as isoform-selective inhibitor for class I HDACs, with IC50 value of 1 nM for HDAC1 
while > IC50 1000 nM for HDAC8. In molecule dynamics simulations of complexes of Apicidin 
binding to HDAC1 and HDAC8, the hydrogen bond existence maps showed that, Apicidin 
mainly created two hydrogen bonds with Tyr303 while none in Apicidin-HDAC8. Comparing 
with Apicidin-HDAC1, there were few residues forming hydrophobic interactions and less 
hydrogen bonds in Apicidin-HDAC8, which mean less stabilities and lower inhibitory activity. 
In Chapter 3 of this thesis, a variety of non-natural amino acids for the use of synthesis potent 
HDACs inhibitors of cyclic tetrapeptide were synthesized. 
In Chapter 4 of this thesis, a series of Chlamydocin analogues based cyclic tetrapeptide 
hydroxamic acid HDAC inhibitors were designed by changing Aib using containing aliphatic 
ring non-natural amino acids. The three methyl substitutional positions of aliphatic ring were 
accomplished, and found that 3-methyl position was the optimum for cyclic tetrapeptide with 
n-methyl-amino-cyclohexane-carboxylic acid (Anmc6c) at 2-position. These inhibitors showed 
potent HDAC inhibitory activity in vivo and in vitro. They also showed some selectivity among 
the HDAC isoforms (HDAC6/HDAC1 = 10). Compound Ky-302 showed the best activity than 
Ky-301 and Ky-303 in the cellular activity, which 6-fold increased than Ky-2 and Trichostatin 
A. We carried out molecular docking studies on Chlamydocin–hydroxamic acid analogues and 
HDLP, HDAC8 and HDAH, respectively. HDAC8-Ky301 and HDLP-Ky302 complexes had 
chelate zinc coordinates with seven atoms, but the zinc ion of HDAH –Ky303 complex  was 
bound to five atoms. The results showed that the stability and activity of HDAC8-Ky301 and 
HDLP-Ky302 complexes were stronger than HDAH –Ky303 complex. This study further 
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supports the fact that, compared to class IIb HDAC, the inhibitors are favorable interactions 
with the surface binding to class I HDACs, hence showed high activity. 
In Chapter 5 of this thesis, author designed and synthesized HDACs inhibitors of replacing 
L-Phe by L-Phe(n-Me) and bearing L-2-amino-7-(2-pyridyl)-disulphidyl heptanoyl (L-Am7 
(S2Py)) in Chlamydocin scaffold, which equiped thiol function protected by disulfide hybrid. 
The aim is to change exiguous hydrophobicity to know that it plays an important role in cap 
group interaction with rim of active pocket. All compounds showed better sensitivity on Hela 
than MCF-7 and 7721 cell lines, but no obvious difference for the same one cell lines. The 
activity of Compounds 1-4 were almost the same. We performed docking and molecular 
dynamics simulation towards HDAC8. The results showed that the sulfur atom of each 
compound established a hydrogen bond with the O(H) atom of Tyr306, and this hydrogen bond 
was very important for keeping the binding of them to HDAC8. These compounds established 
hydrophobic interactions with some amino acid residues, such as Phe152, His180, Phe207 and 
Met274, etc., the hydrophobic effects were also crucial for stabilizing the complexes. 
In Chapter 6 of this thesis, HDAC inhibitors of cyclic tetrapeptide of phenylalanine residue 
replaced by two aliphatic amino acids containing chlorine (Ac5 and Ac6) in Chlamydocin 
framework were designed and synthesized. All compounds showed good activity against 
HDAC1 and HDAC4 in nanomolar range, but were poorly inhibited to HDAC6 and their 
selectivity was better (HDAC6/HDAC1=10). The compound Ky-336 showed the best activity 
in both cell free and cell based conditions than the other two compounds Ky-335 and Ky-337 
and the activity of Ky-336 was similar to TSA and Ky-2 data. The result suggested that 
hydrophobicity of aliphatic amino acid can  also increase interaction with rim of HDACs active 
pocket and aromatic ring was no need in cyclic framework. Also cell permeability was 
enhanced in this case, which was reflected in their p21 activity data.  
In conclusion, in order to find novel and potent HDAC inhibitors, we designed and synthesized 
a series of Chlamydocin-based cyclic tetrapeptide. These inhibitors showed potent HDAC 
inhibitory activity in vivo and in vitro. They also showed some selectivity among the HDAC 
isoforms. These results further confirmed the hypothesis that modification of the cap group of 
HDAC inhibitors can lead to potent HDAC inhibitors, which may become potential as 
anticancer agents. We carried out conformational analysis of these inhibitors by NMR and CD 
studies. We also performed docking and molecular dynamics simulation for these inhibitors 
and analyzed the binding interactions between HDACs and these inhibitors at active pocket. 
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